

GenCore version 5.1.3
Copyright (c) 1993 - 2002 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 20, 2002, 11:35:32; Search time 21 seconds
(without alignments)
2485.761 Million cell updates/sec

Title: US-09-759-207-2
Perfect score: 2842
Sequence: 1 MLRSKPALPPLMLLLGP.....LPATSYSPFVIRNAKVAACI 543
Scoring table: BL0SUM62
Gapop 10.0, Gapext 0.5

Searched: 283224 seqs, 96134422 residues

Total number of hits satisfying chosen parameters: 283224

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	897.5	31.6	480	JC7506	heparanase protein
2	416	14.6	521	T45608	hypothetical prote
3	169.5	6.0	190	T01953	hypothetical prote
4	112.5	4.0	356	F64383	hypothetical prote
5	111.5	3.9	575	T12094	beta-fructofuranos
6	111	3.9	670	T10666	hypothetical prote
7	111	3.9	688	S32961	hypothetical prote
8	111	3.9	2298	T49648	hypothetical prote
9	109.5	3.9	879	E91031	probable outer mem
10	108.5	3.8	411	S74760	hypothetical prote
11	107.5	3.8	500	D87541	beta-xylosidase [i
12	106	3.7	879	F85875	probable fibrinol
13	105	3.7	670	T38446	microtubule associ
14	104.5	3.7	788	S00652	phosphoribosylamin
15	104	3.7	432	F70411	adenylosuccinate s
16	104	3.7	2013	A11489	probable peptidogl
17	103.5	3.6	587	S36231	beta-fructofuranos
18	103.5	3.6	676	A71153	transcription anti
19	103.5	3.6	687	F85188	retrotransposon li
20	103	3.6	796	D97065	transketolase [imp
21	101	3.6	594	A82913	hypothetical prote
22	101	3.6	644	A97268	methionyl-tRNA syn
23	100.5	3.5	805	C86525	DNA gyrase subunit
24	100.5	3.5	805	H72098	DNA gyrase, chain
25	100.5	3.5	989	A82140	toxin secretion AB
26	99.5	3.5	510	H69893	conserved hypotet
27	99.5	3.5	837	A31842	endo-1,4-beta-xyla
28	99	3.5	897	G02529	dynein heavy chain
29	99	3.5	4644	A38905	dynein heavy chain

30	98.5	3.5	596	2	T04506	hypothetical prote
31	98.5	3.5	629	2	C64180	hypothetical prote
32	98.5	3.5	654	2	T14202	NADH2 dehydrogenase
33	98.5	3.5	699	2	F95146	DNA topoisomerase
34	98.5	3.5	701	2	D98014	DNA topoisomerase
35	98.5	3.5	746	2	T46821	sideophore recept
36	98.5	3.5	746	2	A95420	Rhizobactin r
37	98.5	3.5	1012	2	JC5925	hypothetical prote
38	98	3.4	465	2	T19113	hypothetical prote
39	98	3.4	716	1	C60008	RNA-directed RNA p
40	98	3.4	760	2	T34414	hypothetical prote
41	98	3.4	817	2	H75035	probable membrane
42	97.5	3.4	454	2	T20829	probable serine ca
43	97.5	3.4	511	2	S61166	probable membrane
44	97.5	3.4	604	2	E75119	hypothetical prote
45	97.5	3.4	804	2	G71546	probable DNA gyras

ALIGNMENTS

RESULT 1

JC7506
heparanase protein 2a - human
C:Species: Homo sapiens (man)
C:Date: 17-Nov-2000 #sequence_revision 17-Nov-2000 #text_change 01-Dec-2000
C:Accession: JC7506
R:McKenzie, E.; Tyson, K.; Stamps, A.; Smith, P.; Turner, P.; Barry, R.; Hancock, Biochem. Biophys. Res. Commun. 276, 1170-1177, 2000
A:Title: Cloning and expression profiling of Hpa2, a novel mammalian heparanase fa
A:Reference number: JC7506
A:Accession: JC7506
A:Molecule type: mRNA
A:Residues: 1-480 <MCK>
A:Cross-references: GB:AF282865
C:Comment: This protein, a intracellular membrane-bound enzyme, has biological and therapies.
C:Genetics:
A:Gene: hpa2a
A:Map position: 10q23-10q24
C:Keywords: heparin binding; membrane bound

Query Match	31.6%	Score 897.5	DB 2	Length 480
Best Local Similarity	36.0%	Pred. 2.6e-59		
Matches 202	Conservative 74	Mismatches 146	Indels 139	Gaps 9
Oy	20	PLGPIISGAL-----PRPA-----QAQYVDLDFTOEPLILVSPS	55	
Db	18	PACIAPGALYIALLLHLSLSSQAGDRRLPYDRAAGLKEKTLILLDVSTKNPRTVMEN	77	
Oy	56	FLSVITDANLADPRFLILILGSPKLTARGLSPAYLRFPGTKTDFLIF----	111	
Db	78	FLSLQDPSIITHD-GWLDLFSKRLVTLARGLSPAFELRGGRTRDFLOQNLRNPAKSR-	135	
Oy	112	FEERSWOSQVODICKYISIPDVEEKLRLMPYOEQLLREHYOKFKNSTYSSSYD	171	
Db	136	-----GGPGPD-----YLUKNE-----	148	
Oy	172	VLYTRANSGDLIFGLNALFTADLQNNSSNAQLLDYCSSKGYNISWELGNEPNSFLK	231	
Db	149	-----DEPNNTKT	156	
Oy	232	KADIFINSQLEDGYIOLHKLRK-STFNNAKLYGPDVGOPRRKTAAMLSFLKAGGEVI	290	
Db	157	MHGKRAVNSQLCKDYIOLKSLQPIRIYSRASLYGPNLGRPKKNVIALDGFMYKAGSTV	216	
Oy	291	DSVTWHYVYLNCRATREDFLNPDLVDFISSVQAVFQVVESTPRGKKVWLGESYACG	350	
Db	217	DAVTQHCYIDRNVKVKVDFLTKTRLDLSDQIRIKQKVVNTYTGKIMLEGVVTSAG	276	
Oy	351	GAPLSDFFPAAGFMILDKILSARMKIEYVNRQVFFGAGNHYLDENEDPLPDYILSLIF	410	
Db	277	GTNNLSDSYAAAGFLWNLTLGLMLANQIDIVIRHSFDDHGYNHLVDQNNFPLPDYILSLY	336	

```

OY 411 KLVGTVLMASVQSGRR-----KLVYLHCTNTDNPYKESDGLTVYAINLHNT 461
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 337 KRLIGPVLAVHAGLQRRPRGRVIRDKLRIYAHCHNNHNNHVRSGITLFIINLRSR 396

OY 462 KYLRLPYPSNKOVDKLLRPLGPHGLLSVOLNGLTLKMWDDOTLPLMEKPLRPGSS 521
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 397 KKKLKGTLRDKLVHQLDLPDGOEGLSKSVOLNGLPVMDDGTLPKLPRLRAGRT 456

OY 522 LGLPFSYSPFVIRNAKVAAC 542
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 457 LVIPVTMGFFVVKNNVALAC 477

RESULT 2
T45608
hypothetical protein F13G24.30 - Arabidopsis thaliana
C:Species: Arabidopsis thaliana (mouse-ear cross)
C:Date: 04-Feb-2000 #sequence_revision 04-Feb-2000 #text_change 04-Feb-2000
C:Accession: T45608
R:Bevan, M.; Van Der Schueren, J.; Chuang, Y.J.; Voel, M.; Robben, J.; Volckaert, G.; Ba
submitted to the Protein Sequence Database, December 1999
A:Reference number: 223009
A:Accession: T45608
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-521 <BEV>
A:Cross-references: EMBL:AL133421
A:Experimental source: cultivar Columbia; BAC clone F13G24
C:Genetics:
A:Map position: 5
A:Introns: 53/3; 66/1; 127/2; 177/1; 256/1; 319/2; 361/2; 394/3
A:Note: F13G24.30

Query Match
Best Local Similarity 14.6%; Score 416; DB 2; Length 521;
Matches 154; Conservative 68; Mismatches 184; Indels 122; Gaps 24;

OY 75 LGSPLKLTARGLSPAYLRFGCTKDTFLRDPKKESTFEERSYOSOVNODICKYSGIRP 134
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 55 LTRPLLTAKIKAFKPLRIRIGSLQDPQVIVDGNLKT-----PCR----- 94

OY 135 DVEEKLRLMPYODOLLREHYOKFRNS---TYSRSV-----DVLITFRANGSLDLIF 186
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 95 -----PFQKM-----NSGLFGFSKGLMKRMDELNSFLTATGAVVTF 132

OY 187 GLNALRTADLQ-----WSSNAOLLIDYCSKSGYNI-SWELGNPNPFLKADIFIN 238
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 133 GLNALGRHKLRGKANGAMNDHINTODFLNLYTSKGVIDSWFENLSC--SGVGASYS 190

OY 239 GSQLEDYIOLHKLKSTFKNAKLYGPDVGOP-----RRTKAKMLKSLKAGEVIDSV 293
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 191 AELYGDDLVLKDVINK-VYKNSMLHPLIYARFGFEQOQWYKLEI---SGPSVVDV 246

OY 294 TMHHYULNGRT--ATREDELNPVLDLFISSVQVF-----QVESSTRPGKKVVLGETSSA 347
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 247 THHIIYNGSGNDPALVKKIMDPG---YLSOVSKTRDVNQTIOEHGPMASPVWGSGGA 302

OY 348 YGGGAPLLSDPTFAAGFEMLDKGLSARMGIEVYVROVFGAGVNHLYDE--NFRPLDPYML 406
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 303 YNCGRHHVSDPTFIDSFYIDLQGLMSARHNKVVICROTLVG--GYGLEKKTFFPNPDYS 361

OY 407 SLLEFKLVGTVLMASVQSGRRKLRLVYLICTNDNPRYKESDGLTVYAINLHNTVYL-- 464
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 362 ALLMHLRMGKGLAVQDGRP--QLRYAHNSK-----GRACVTLILLINLSQSDFTYS 413

OY 465 -----RLPYPS---NKQVDKYLRL---LGPNG--LLSKSVOL 495
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 414 VSNGINVNLAEGRKKSLIDTLKRPFSWIGSKASDGYLNRREYHLTPENGVLRSKTMVL 473

OY 496 NGLTLKAVDDOTLPLMEKPLRP--GSSIGLPASYSFVIRNAKVAAC 542
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 474 NGAS.KPRTATGDIPLSL-EPVLRSVNSPLNVLPLSMSTFIYLPNDASAC 520

```

```

RESULT 3
T01953
hypothetical protein T2L5.6 - Arabidopsis thaliana
C:Species: Arabidopsis thaliana (mouse-ear cross)
C:Date: 26-Feb-1999 #sequence_revision 26-Feb-1999 #text_change 21-Jan-2000
C:Accession: T01953
R:Geisel, C.; Smith, A.; Le, T.
submitted to the EMBL Data Library, October 1998
A:Description: The sequence of A. thaliana T2L5.
A:Reference number: 214470
A:Accession: T01953
A:Status: translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-190 <GEI>
A:Cross-references: EMBL:AF096371; NID:g3695386; PID:g3695392
A:Experimental source: cultivar Columbia
C:Genetics:
A:Map position: 4
A:Introns: 36/2; 69/3
A:Note: T2L5.6
C:Superfamily: Arabidopsis thaliana hypothetical protein T2L5.6

Query Match
Best Local Similarity 6.0%; Score 169.5; DB 2; Length 190;
Matches 54; Conservative 34; Mismatches 57; Indels 49; Gaps 9;

OY 382 ROYFPGAGVNHVD--ENPDLPDPYMLSLFKLVGTVKVLMAVQSGRRKRLRYLHCTNT 440
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 12 ROSLIG-GNGLNTNTFPNPDPYSALIMROLGKRALFTTSGTK--KINSYTHCA-- 66

OY 441 DNPYKESDGLTVYAINLHNV-----TKYLRPYPSNKOVDKYLRLPL 483
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 67 ---RQSG-KG-ITVLMMLDNTTVYAKVELNNSFLRHTKMK-----SYKRASSQLFG-- 115

OY 484 GPRGGL-----SKVOLNGLTLKAVDDOTLPLMEKPLRPGSSGLPAPS 528
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 116 GPMGVIOREHYLTKAGNMLHSOTMLNGLNGLVNSGDLPLPIPIHINSTPIITAPYS 175

OY 529 YSFFVIRNAKVAAC 542
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 176 YFVHMRNVVPRAC 189

RESULT 4
F64383
hypothetical protein M10670 - Methanococcus jannaschii
C:Species: Methanococcus jannaschii
C:Date: 13-Sep-1996 #sequence_revision 13-Sep-1996 #text_change 21-Jul-2000
C:Accession: F64383
R:Bull, C.J.; White, O.; Olsen, G.J.; Zhou, L.; Fleischmann, R.D.; Sutton, G.G.;
Retch, C.I.; Overbeek, R.; Kirkness, E.F.; Weinstock, K.G.; Merrick, J.M.; Glo
rson, J.D.; Sadow, P.W.; Hanna, M.C.; Cotton, M.D.; Roberts, K.M.; Hurst, M.A.
Science 273, 1058-1073, 1996
A:Authors: Kaine, B.P.; Borodovsky, M.; Klenk, H.P.; Fraser, C.M.; Smith, H.O.; V
A:Title: Complete genome sequence of the methanogenic archaeon, Methanococcus jar
A:Reference number: A64300; MUID:96337999; PMID:8688087
A:Accession: F64383
A:Status: preliminary; nucleic acid sequence not shown; translation not shown
A:Molecule type: DNA
A:Residues: 1-356 <BU>
A:Cross-references: GB:U67514; GB:L77117; NID:g2826304; PIDN:AAB98664.1; PID:g155
C:Genetics:
A:Map position: REV596956-595886
A:Start codon: GTG

Query Match
Best Local Similarity 4.0%; Score 112.5; DB 2; Length 356;
Matches 85; Conservative 48; Mismatches 143; Indels 125; Gaps 18;

OY 126 ICKY-----GSTPPVEEKLRLMPYODOLLREHYOKKFKKSTYSRSSVD----- 171
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

```

Db 14 JAKYKINNGKEDIKERLIKE-----LKEEHVETEDGTTLKADEEEMHSKV 66
 Oy 172 -----VLTFFANCGLDIFPLMLRTADLOMSSNQLLDVCSGYNISNELGEP 226
 Db 67 GALKELAIYKFAKPS-----KITDL-----SNPR-VLDLCSGYNIAIALHYNK 109
 Oy 227 NS-----FL-----KKADIFINGSGEDYIOAHKLKRSTF 258
 Db 110 NAEIDMVEICEVLEFLTLPLPYKEHEITDKVREYFLN--KIGIEF-----KSDY 159
 Oy 259 KNAKLYGPDVGQPRRKTAAMKLSFLKAGEVIDSVTMHHYLYNGRTAF--REDFLNPVYL 316
 Db 160 DNIMLY---VGDARKEIISKDKY-----NVFHDARSPRKDPITYLTYDFL----- 202
 Oy 317 DIFISSVOKVFOVESTPRPKKVMLGESSAYGGAPLLSTFAAGFPMLDKLGISAMG 376
 Db 203 -----KEIKRMEDN--GVLI-----SYSSAIPFRSALVDCGFIYSEKESGRRKG 246
 Oy 377 IEVVMROVFFCAGNVHLVDENFD-----PLPDVWLSLFLKKLVTGVLMASVOGSKRR 429
 Db 247 ITLAVKPNFPRKPRINEYDERVIALSVALPYPDETSLTKDKITIEDREERREKLKEKLI 306
 Oy 430 KLRVYLHCTNTDNPRYKEGDLTYLA--INLHNVTKYLRLPY 468
 Db 307 KIGYVLSKTKOJKKGNIPPEILKIOKEDLNSSEIITKMMRLKF 347

RESULT 5

112094
 beta-fructofuranosidase (EC 3.2.1.26) - fava bean
 C:Species: *Vicia faba* (fava bean)
 C:Date: 16-Jul-1999 #sequence_revision 16-Jul-1999 #text_change 21-Jul-2000
 C:Accession: T12094
 R:Webster, H.; Borisjuk, L.; Helm, U.; Buchner, P.; Wobus, U.
 A:Title: Seed coat-associated invertases of Fava bean control both unloading and storage
 A:Reference number: Z17416; MUID:96093423; PMID:855137
 A:Accession: T12094
 A:Status: preliminary; translated from GB/EMBL/DBJ
 A:Molecule type: mRNA
 A:Residues: 1-575 <WEB>
 A:Cross-references: EMBL:Z35162; NID:9861154; PIDN:CAA84526.1; PID:9861155
 A:Experimental source: cv. Fribo, seed coat
 C:Genetics:
 A:Gene: CWI1N1
 C:Superfamily: beta-fructofuranosidase
 C:Keywords: cell wall; glycoprotein; glycosidase; hydrolase

Query Match 3.9%; Score 111.5; DB 2; Length 575;

Best Local Similarity 21.4%; Pred. No. 2.5; Matches 72; Conservative 48; Mismatches 107; Indels 109; Gaps 19;

Oy 46 QEPHLVLS-----PSFLSVTIDANLATDPRFLILGSPKRLTLARGLS-----P 89
 Db 228 KHPHSARRTGMMECPDPRVYSLGKNGLD--LSMMGMNNKHYLKNLSDLTTRYEYITG 285
 Oy 90 AYLR-----FGGKTDF-----LIFPKKSTFEENSYW---QSOVNO 124
 Db 286 TYLQMODKVIIPDKTSEDDMGRLRYDGNFYASKSFDPJK---NRIITGMANESDKE 341
 Oy 125 DICKG-----SIPPDV-----EERLREMPYOEOLLR-----EHYOKKFNSTYSRSV 170
 Db 342 DDVKKMGAGIOAIPRTVYLDSSRRQLR--QMPVEELNRLKRGQOVENKKNLKKGGT----L 396
 Oy 171 DVLYTFANCGLDIFGLNALRLTADLOWNSSNAQLLDYCSSKGYNISWELGNEPNSFL 230
 Db 397 EVKGITASQADVAVTFSSSLDKAEAPDPNMEAE--DLCAQKSGKVRGVG--PGLL 451
 Oy 221 KKADIFINGSGEDYIOL-----HKLL-----RKSTFKNAKLYGP-----DV 268
 Db 452 TLA-----SKRLEEYTSVFFRVKANKHAIIMCSDAKSSLSLRELKYPSPAGFVNDL 505
 Oy 269 GQPRRKTAAMKLSFLKAGEVIDSVTMHHYLYNGRT 304

Db 506 GNNKKLSRLS-----IDHSVSEFCVGGKT 531

RESULT 6

110666
 hypothetical protein F6E21.40 - *Arabidopsis thaliana*
 C:Species: *Arabidopsis thaliana* (mouse-ear cress)
 C:Date: 16-Jul-1999 #sequence_revision 16-Jul-1999 #text_change 16-Feb-2001
 C:Accession: T10666
 R:Bevan, M.; Lennard, N.; Quail, M.; Harris, B.; Rajandream, M.A.; Barrell, B.G.;
 submitted to the Protein Sequence Database, June 1999
 A:Reference number: Z16533
 A:Accession: T10666
 A:Molecule type: DNA
 A:Residues: 1-670 <BEV>
 A:Cross-references: EMBL:AL049914; GSPDB:GN00062; ATSP:F6E21.40
 A:Experimental source: cultivar Columbia; BAC clone F6E21
 C:Genetics:
 A:Gene: ATSP:F6E21.40
 A:Map position: 4
 A:Insertions: 47/3; 87/1; 123/3; 203/3; 230/2; 255/3; 284/3; 305/1; 335/3; 347/3; 370.
 C:Superfamily: Schizosaccharomyces pombe negative regulator of mitosis skbl

Query Match 3.9%; Score 111; DB 2; Length 670;

Best Local Similarity 22.4%; Pred. No. 3.4; Matches 123; Conservative 77; Mismatches 194; Indels 156; Gaps 33;

Oy 51 LVSPFLSVTIDANLATDPRFLILGSPKRLTLARGLSPAY--LRFGGTKTDFLIFPK- 107
 Db 47 LVDPYSRSLVEGN--GVDTOVLPGGSDLY-----LSPSQMSSHYVGKISSMIDLOSE 99
 Oy 108 -----KESTFEERSYQOVNODICKYGSIPPDVEEKRLREMPYOEOLLRREHYOKKFK 161
 Db 100 EVLMDSETTLKOEIATVATHLSLMCE-----PD-----LTPRHYLAGCL 139
 Oy 162 NSTYSRSV---DVLV-----TFANCS--GIDLIFGLNALRTADLOWNSSNQLD 207
 Db 140 RVSCRSSEFISDEFTLKYITFNQALTFGSSLPCLNVTSAKLMLRPLV---SEGDGM 196
 Oy 208 LDYCSSKGYNISWELGN-----EPNSFLKKA-DIFIN-----GSOLGEDYIOLHKL 253
 Db 197 DD--TSEGLNSWELMNSFRLCEHDSKLSVALDYLSLTPSETSLGRMGES--VRAATLS 253
 Oy 254 RKSTFKNAKLYGPVGP--RRKTAAMKLSFL--KAGEVIDSVTMHHYLYNGRTATREDF 310
 Db 254 TDAFLTNAR-----GYPCLSKRHOKLTFAGFDHAAQVYIGKRVHNLQKPLDSSSECTE 307
 Oy 311 LNPVDLIFISSVOKVFOVESTPRPKKVMLGESSAYGGAPLLSDFFAAGFPMMDKLG 370
 Db 308 KNP--LRITLDYVAVLFOKMESLSEOEKTELIGYRDFLOAPLOPLMDNLEAQTITFE--- 362
 Oy 371 LSAHMGIEVVMROVFFCAGNVHLVDENFDPLPDVWLSLFLKKLVTGVLM----- 420
 Db 363 ---RDSVKYIYQ---RAVEKALVDR---VPDEKASL-----TYLVAVVVGAGRGPLY 406
 Oy 421 -ASVQSKR--RKLRYVLHCTNTDNPRYKEGDLTYLAINLHNVTK-----YLRPLPY 468
 Db 407 RASLOAAEEDTRKLRKY---AVERNPN-----AAVTLLNLVKMEGMEDEVVTIISCDM 455
 Oy 469 PFNS--QOVDEYLLRPFGHGLSKSVQLNGLTLLKNVDDOTRPLM---EKPLRGGSSLG 523
 Db 456 RFMAAPRADILVELLSGFS-----DNEISPECLDGAQVFLAP--DGIS 498
 Oy 524 LPAFSYFFV 533
 Db 499 IPS-SYTSFI 507

RESULT 7

S32961
 hypothetical protein YBR259W - yeast (*Saccharomyces cerevisiae*)
 N:Alternate names: hypothetical protein YBR1727

C.Species: Saccharomyces cerevisiae
 C.Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 19-Apr-2002
 C.Accession: S32961; S46140
 R.Dolignon, F.; Bileau, N.; Crouzet, M.; Aigle, M.
 Yeast 9, 189-199, 1993
 A.Title: The complete sequence of a 19,482 bp segment located on the right arm of chromo
 A.Reference number: S29348; MUID:93220397; PMID:8465606
 A.Accession: S32961
 A.Status: translation not shown
 A.Molecule type: DNA
 A.Residues: 1-688 <DOI>
 A.Cross-references: EMBL:X70529; NID:q1907246; PIDN:CA449923.1; PID:9296558
 R.Aigle, M.; Bacle, M.C.; Barthe, C.; Bileau, N.; Crouzet, M.; Dolignon, F.
 submitted to the Protein Sequence Database, August 1994
 A.Reference number: S45940
 A.Accession: S46140
 A.Molecule type: DNA
 A.Residues: 1-688 <AIG>
 A.Cross-references: EMBL:Z36128; NID:q536684; PIDN:CA485222.1; PID:9536685; MIPS:YBR259W
 C.Genetics:
 A.Cross-references: SGD:S0000463
 A.Map position: 2R
 C.Superfamily: Saccharomyces cerevisiae hypothetical protein YBR259w

Query Match 3.9%; Score 111; DB 2; Length 688;
 Best Local Similarity 22.5%; Pred. No. 3.5;
 Matches 67; Conservative 45; Mismatches 94; Indels 92; Gaps 16;

OY 126 ICKYSIPPDVEKRLERPEYOEOLLRHYOKKRNSTYSSS-----VDVLYT 175
 DB 164 MAEYSGLMDSDKKRQLOLMTEFRMKLKECLVKEFNFDLOKSDPLKELIIPWEKIYV 223
 OY 176 FANCSLDLIFGLNALRLTADLQNNSSN-----AQLLDL-----YCSSKGY----- 216
 DB 224 -ANC-IDAFTGEQYRIGACELIMTSKMLVFSSISSAVLRLLDLMNMSAFRYPGEALY 280
 OY 217 -----NISWELGNEPNSFLKA---DIF--INGSLG--EDVYQLHLKLR----- 255
 DB 281 QDFAHRLSLKMDSNKVESLIRALLFNDMFYFNKEQYDTRKDGIFLLRLKRNKEHIN 340
 OY 256 -----STPKRK--AKLYGPDVGPGRKRTAKMLKSLFAGGEV-----IDSV 293
 DB 341 DVKDRHIOYIKYLSQFKNMNSTLMTSSKTDRKSHNPPSILDDGNKTMGHVSPIDE- 399
 OY 294 TWHNYLLN-----RTATREDFLNPDVLDIFISSVOKFQVVESTR---PGKK 338
 DB 400 -YSHFIDNEPLMRDKVYPRKIYTNQOTPTPDASAIIDS--HKIYALISLRVLYPEKR 454

RESULT 8
 T49648
 hypothetical protein B8B20.20 [imported] - Neurospora crassa
 C.Species: Neurospora crassa
 C.Date: 02-Jun-2000 #sequence_revision 02-Jun-2000 #text_change 02-Jun-2000
 C.Accession: T49648
 R.Schulte, U.; Aign, V.; Hoheisel, J.; Brandt, P.; Partmann, B.; Holland, R.; Nyakatura,
 submitted to the Protein Sequence Database, May 2000
 A.Reference number: Z25022
 A.Accession: T49648
 A.Status: preliminary
 A.Molecule type: DNA
 A.Residues: 1-2298 <SCH>
 A.Cross-references: EMBL:ALJ55933; GSPDB:GN00116; NCSP:B8B20.20
 A.Experimental source: BAC clone B8B20; strain OR74A
 C.Genetics:
 A:Gene: NCSP:B8B20.20
 A:Map position: 6
 A:Introns: 426/3

Query Match 3.9%; Score 111; DB 2; Length 2298;
 Best Local Similarity 19.3%; Pred. No. 22;
 Matches 114; Conservative 79; Mismatches 190; Indels 208; Gaps 28;

OY 78 PKLRFLARGLSPA-----YLRFGTKYDFLIDPDKKESTFEERSYOSOV-NODIC 127
 DB 1447 PRVLDIERLRTISNMHKEACLINIRAMNOLARLVNCGSAPFPRTIRNNVNFQILD 1506
 OY 128 KYGSIPDVEEKL-----LEMPYOEOLLRHYOKKRNSTYSSSVDVLYTPAN 178
 DB 1507 QYMSAESDLEQDFRALSAMNMSIDAANREELITKN-----KATADLIHTSAR 1555
 OY 179 CSGDLIFGLNAL-----LRTADLQ-----NNSNAOLLDDCSSKGYNI 218
 DB 1556 AS-LDVLAQAKTLEAITYTLANTLOAKMCTTLHFGSPGDFGLNVAL-----DTHAHL 1609
 OY 219 SN-ELGNEPNSFLKADIFINGSLGEDIYQLHLKLRSTFNNAKLYGPDVGPARRKTA 277
 DB 1610 GWIFTSSEEOYSNNESSADIDPROLEDAILLQEKLTKEFFWMA-----RELLAL 1659
 OY 278 MLKSFLKAGGEYID-SYVHHNYLLGRRTATREDFLNPDVLDIFISSVOKFQVVESTRPG 336
 DB 1660 PLKAITTEGKQEQVACTEKTVTYLAAKLAAR-----FIO--ERVTVLPYPOPG 1706
 OY 337 K-----KWLGETSSAYGGAPLLSDTFAG-----FMWLDK 368
 DB 1707 KYGLFPPDKPKNMSGPERKRL-----PLFIATLVKNKVPDFKDIETMILSNWOS 1755
 OY 369 LGLSAR-MGIEVYMRQVFFGAGNYHL--VDENFDLPDYWLSL-LFKKLYG--TRVL--- 419
 DB 1756 IKKPRFLGYETYLEAVLQORCLPFLAEDVDSAGWTPDYNIHLDFSRALHYMRKALRG 1815
 OY 420 -----MASVOGSK-----RRKLRYLHCTNDPRKESGLTLYALNLHVTVYL 464
 DB 1816 ATPPAGVYTSASVSTAGSSAOSIROREFSH----- 1847
 OY 465 RLPPFPSSKQVDRKYLLRPLG-----PHGLSKSVOLNGLTKMVD-- 504
 DB 1848 TLQLAMTNIKKDLFLRLALADPRASSTEEHROVMAFTHGJLS-LIASHGIVYVDSF 1906
 OY 505 -----DQTLPLMEKPLRPG-----SSLGPAFSYSP-FVIRAKVA 540
 DB 1907 FLTPSDSYSPLODQPLHTAGIMAYGVRLSEKDVPAASQLFWYLRNNPKVA 1957

RESULT 9
 E91031
 probable outer membrane protein Ecs3221 [imported] - Escherichia coli (strain O15
 C.Species: Escherichia coli
 C.Date: 18-Jul-2001 #sequence_revision 18-Jul-2001 #text_change 18-Jul-2001
 C.Accession: E91031
 R.Hayashi, T.; Makino, K.; Ohnishi, M.; Kurokawa, K.; Ishii, K.; Yokoyama, K.; He
 gasawara, N.; Yasunaga, T.; Kuhara, S.; Shibata, T.; Hattori, M.; Shinagawa, H.
 DNA Res. 8, 11-22, 2001
 A.Title: Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 a
 A.Reference number: A99629; MUID:21156231; PMID:11258796
 A.Accession: E91031
 A.Status: preliminary
 A.Molecule type: DNA
 A.Residues: 1-879 <HAY>
 A.Cross-references: GB:BA000007; PIDN:BA836644.1; PID:913362691; GSPDB:GN00154
 A.Experimental source: strain O157:H7, substrain R1MD 0509952
 C.Genetics:
 A:Gene: Ecs3221

Query Match 3.9%; Score 109.5; DB 2; Length 879;
 Best Local Similarity 20.1%; Pred. No. 6.7;
 Matches 130; Conservative 68; Mismatches 208; Indels 241; Gaps 33;

OY 52 VSPFLSTTIANLATORRFLILGSPRLKRLAAGLSPAYLRFSGTDTDLFPPPKKEST 111
 DB 20 MSGSYVNAWAEENIQFOSRFLKGDTRKI-DLKRSSGCVPEP--RYNLQVOLNKPPLT 76
 OY 112 FEERSYMOGVNODICKGSIIPDVEEKL-----RLMPYOEOLLRHYOKKFKNS 163
 DB 77 EYDIYVWASENDSKTYACLTPELVAFQGLKEDVAKNLQNIHNGKCLAKPOLE----- 130

OY 164 TYSSRSVDLYTFANCGLDIFGL--NALLRTADLQNMSSN-----AQLLDYC----- 211
 DB 131 -----GIDIK--ADLSGSALVLSLPQAVLEYTDLINMDPRSMWDGICSLINDYSTAOT 182
 OY 212 -----SSKGYNI--SWEL--GNEPNSFL--KKADIFINGSO----- 241
 DB 183 RHEENGDDSEISGNGFYGVNLGAMRLRADQDTYLSKSNDDVDVINDDOTOKNMWESR 242
 OY 242 -----LGEDYIOLHKLKSTF-----KKAALYGPV 268
 DB 243 YYAMRALPSLAKLGLGDDY-----LNSDIFDGFNVGGSISTDDOMLPPULRGYAPDI 296
 OY 269 GPRRRKTAKMLKSLKAGGEVY-----DSVTMHHYLLNGRATREDFLN 312
 DB 297 SGVAHTTAKVYSOL-----GRVYEVQVAPGPRRIODLDGDSV-----SGLTIHIFIEON 346
 OY 313 PDVLDIFISSYOKVFOVESTRPCK--KVMV-----GETS----- 345
 DB 347 GOVOEYDINTASMP-----LTPGQVRYKLMKGRPOEMGHVEGFGSGEASMGIANGM 402
 OY 346 SAYGGAPLLSD-----TFPA-----GFMMLDKL-----GLSAR 374
 DB 403 SLYGGA---LADENYOSALGVRDLVYGAFAFDITSHRFLDKETAYGKSGSLDGNFR 459
 OY 375 MGI-----EVMAROVFGAGNYHLVDENFDPLPDYWLSQLFKLYGT---KVLMAVQGS 426
 DB 460 LSYKDFPELNSRYTFAG---YRSEENFMYSEY--LQASDEMYRTGNDKEMTYATYNO 515
 OY 427 KRRRLRYLHCTNTDNPRYKEDLTLVAT---NLHNVTK----- 462
 DB 516 NFRDQGVSVLYNRYTHRTYWDREOTNYVMMLSHYFNGLSIRMSISMGRYREYDNOADK 575
 OY 463 ---YLRLPYFSPKQVYDKYLRLPHGLSKSVQVLNGLTAKVDDOT 507
 DB 576 GYVLSLMPMGDOSTISY---NGMYGSGSDSOVG--YFSRVDDAT 616

RESULT 10

S74760

hypothetical protein slr1617 - *Synechocystis* sp. (strain PCC 6803)C:Species: *Synechocystis* sp.

A:Variety: PCC 6803

C:Date: 25-Apr-1997 #sequence_revision 25-Apr-1997 #text_change 08-Oct-1999

C:Accession: S74760

R:Keneko, T.; Sato, S.; Kotani, H.; Tanaka, A.; Asamizu, E.; Nakamura, Y.; Miyajima, N.;

O, K.; Okumura, S.; Shimpo, S.; Takeuchi, C.; Wada, T.; Watanabe, A.; Yamada, M.; Yasuda

DNA Res. 3, 109-136, 1996

A:Title: Sequence analysis of the genome of the unicellular cyanobacterium *Synechocystis*

S.

A:Reference number: S74322; MUID:97061201; PMID:8905231

A:Accession: S74760

A:Status: preliminary

A:Molecule type: DNA

A:Residues: 1-411 <KAN>

A:Cross-references: EMBL:D090901; GB:AB001339; NID:g1651897; PIDN:BAA16911.1; PID:0101764

A:Note: the nucleotide sequence was submitted to the EMBL Data Library, June 1996

Query Match

3.8%; Score 108.5; DB 2: Length 411;

Best Local Similarity 21.4%; Pred. No. 2.5;

Matches 66; Conservative 55; Mismatches 94; Indels 93; Gaps 17;

OY 159 KFKNSTYSSVDLYTFANCGLDIF--GLNALLRTADLQNMSSNAOL----- 206
 DB 151 EFRLLISPTREOIDI--FAGSTKLDLASEENIDICIVHLANRVYTSNVMKQTLTMLRN 207
 OY 207 LLDYSSKSG---YNIWEL-----GNEPNSFLK-----ADIFINGSOIGE 244
 DB 208 VIDVCLADIDPLIYSSMEIYSGVAGTTHADESTPALPRGPYGETKYLAEILI----- 260
 OY 245 DYIQLHKLKSTFKNALYGPVQOPRRKTKAKMLKSLKAGGEYIDSVTYMHHYLLNGRFT 304
 DB 261 DHCRTRLCAILRRSPVYGSMDKP-----KTFNFKKASOQOKIVT--HHYING-- 311

OY 305 ATREDFLNPDV-----LDIFISSYOKVFOVESTRPCKVWLGESTSSAYGCGAPLLSDTFA 360
 DB 312 -----NPKDLHLHIDDLISSIVATL-----KSNFIGNLMI-----GGOSSSTLK 351
 OY 361 AGFMWLDKLGISA-----RMGIEVVMROVFGAGNYHLVDENFDPLPDYWLSQLFKLYG 415
 DB 352 IAEIMREDELSSSSMIQIQEVNTEVASIAMNYGRAN--HYLD-----MEPVIFFE--QG 400
 OY 416 TKVLMASV 423
 DB 401 LKSLHLOI 408

RESULT 11

DB87541

beta-xyloridase [imported] - *Caulobacter crescentus*C:Species: *Caulobacter crescentus*

C:Date: 20-Apr-2001 #sequence_revision 20-Apr-2001 #text_change 20-Apr-2001

C:Accession: DB87541

R:Nierman, W.C.; Feldblyum, T.V.; Paulsen, I.T.; Nelson, K.E.; Eisen, J.; Heidelberg

B.; Laub, M.T.; Deboy, R.T.; Dodson, R.J.; Durkin, A.S.; Gwin, M.L.; Haft, D.H.;

n, J.; Ermolaeva, M.; White, O.; Salzberg, S.L.; Shapiro, L.; Venter, J.C.; Fraser

Proc. Natl. Acad. Sci. U.S.A. 98, 4136-4141, 2001

A:Title: Complete Genome Sequence of *Caulobacter crescentus*.

A:Reference number: A87249; MUID:21173698; PMID:11259647

A:Accession: DB87541

A:Status: preliminary

A:Molecule type: DNA

A:Residues: 1-500 <STO>

A:Cross-references: GB:AE005673; NID:g13423886; PIDN:AAK24328.1; GSPDB:GN00148

A:Gene: CC2357

Query Match 3.8%; Score 107.5; DB 2: Length 500;
 Best Local Similarity 25.7%; Pred. No. 4;
 Matches 56; Conservative 35; Mismatches 80; Indels 47; Gaps 15;

OY 165 YSRSSVDLYTFANCGLDIFGLN--ALLRTAD--LOW--NSSNAOL-----LLD-- 209
 DB 81 YDMKIIDLYDALAKGIRKPIELGFTPEAMKTSQDTTFYKMGNTSHRKLGPWRLLDAF 140
 OY 210 -YCSSKGYNI-----SW--ELGNEPN--SFLKKADIFINGSOIGEDYIOLHKLKSTPKN 260
 DB 141 VHLHARVGEVETRVFPEVWNEPRLDGFWEKAD-----QAAYFELYDV---TARA 188
 OY 261 AKLYGPD--VGOPRRKTKAKMLKSLP---KAGCEVIDSVTYMHHYLLNG---RTATREDPL 311
 DB 189 IKAIDPSLRVGGPARAGAWPEFLAHYKKSASAVDFYTHYGVGDFLDEKGVQDTRL 248
 OY 312 NPDVLDIFISSYOKVFOVE--STRPGKKVMLGESTSSAY 348
 DB 249 SPS-DAVVGDRVRREOIEASAPFGLPLYPTEWSTSY 285

RESULT 12

F85875

probable fimbrial usher Z3600 [imported] - *Escherichia coli* (strain O157:H7, subsp.C:Species: *Escherichia coli*

C:Date: 16-Feb-2001 #sequence_revision 16-Feb-2001 #text_change 14-Sep-2001

C:Accession: F85875

R:Perna, N.T.; Plunkett III, G.; Burland, V.; Mau, B.; Glasner, J.D.; Rose, D.J.;

Miller, L.; Grobeck, E.J.; Davis, N.W.; Lim, A.; Diallante, E.; Potamoudis, K.; Apr

Nature 409, 529-533, 2001

A:Title: Genome sequence of enterohemorrhagic *Escherichia coli* O157:H7.

A:Reference number: A85480; MUID:21074935; PMID:11206551

A:Accession: F85875

A:Status: preliminary

A:Molecule type: DNA

A:Residues: 1-879 <STO>

A:Cross-references: GB:AE005174; NID:g12516702; PIDN:AGS7446.1; GSPDB:GN00145; UK

A:Experimental source: strain O157:H7, substrain EDL933

A:Gene: Z3600

A:Gene: ADF1; SPDB:SPBC405.01
A:Map position: 2
C:Superfamily: Saccharomyces cerevisiae ADE5 multifunctional protein; phosphoribosylamid
C:Keywords: cyclo-ligase; purine nucleotide biosynthesis
F:5-425/Domain: phosphoribosylamine-glycine ligase homology <PGL>
F:439-767/Domain: phosphoribosylformylglycinamide cyclo-ligase homology <PFCL>

Query March 3.7%; Score 104.5; DB 1; Length 788;

Best Local Similarity 27.7%; Pred. No. 13; Mismatches 114; Indels 33; Gaps 11;

Matches 70; Conservative 36; Mismatches 114; Indels 33; Gaps 11;

OY 297 HYLNGRTATRE--DPLNPDV-LDIFISSVQKVFQVEST-RPGKRWLGETSSAY---- 348

DB 424 HNALNPKRKTREILLEYSGSVSDNGNEFYQIKDLVSTRPADADIGCGGIFDLKQ 483

OY 349 -GGAPLL-SDTFAAGFMKDLGASAR--MGIEVVMROVFFGAGNYHLVDENFPPL--P 402

DB 484 AGMNDPLVSAITDGVSGSKLLIALSLNKHDTVGIDLVAMNV-----NDLVVQGAEPFLIFL 537

OY 403 DYMLSLRLKLVGTAVLMAVSGSKRRKLRVYLHCTNTDNPRYKEGDLTLVAJNLHNVTK 462

DB 538 DIFATGSLDLKAVSTFVEGVAGCKQACGALVGETSEMPGLYHDGHIYDANGTSVGAISR 597

OY 463 YLRLPYPSNKOVDKYLRLPLGPHGLSKSVQNLGLTL--KMYD----DQTLPLMEKPL 516

DB 598 DDILPKPESFSKGDILL-----GLASDGVHNGSVSLVRKIVEYSDLEYTSVCPMDKNV 650

OY 517 RPPSSGLPASFY 529

DB 651 RLGDSLILPTRIY 663

RESULT 15

F70411

adenylosuccinate synthetase - Aquifex aeolicus

C:Species: Aquifex aeolicus

C:Date: 08-May-1998 #sequence_revision 08-May-1998 #text_change 16-Jul-1999

C:Accession: F70411

R:Decker, G.; Warren, P.V.; Gaasterland, T.; Young, W.G.; Lennox, A.L.; Graham, D.E.; O'V.

Nature 392, 353-358, 1998

A:Title: The complete genome of the hyperthermophilic bacterium Aquifex aeolicus.

A:Reference number: A70300; MUID:98196666; PMID:9537320

A:Accession: F70411

A:Status: preliminary; nucleic acid sequence not shown; translation not shown

A:Molecule type: DNA

A:Residues: 1-432 <AOE>

A:Cross-references: GB:AE000733; NID:g2983720; PIDN:AAC07286.1; PID:g2983724; GB:AE00065

A:Experimental source: strain VF5

C:Genetics:

A:Gene: pura

C:Superfamily: adenylosuccinate synthase

Query Match 3.7%; Score 104; DB 2; Length 432;

Best Local Similarity 23.9%; Pred. No. 5.8;

Matches 96; Conservative 39; Mismatches 128; Indels 138; Gaps 22;

OY 15 LLLGLPLGFLSPGALPPRPAQADVDLD-----FFTQEPHLVSPS 55

DB 51 ILHLPLFTGILHEHVKGIVIAQGM-VVDLEVLHKEVKNLEEKGIYVKERLFTSDRAHLVMPY 109

OY 56 PLSTVITDALNADPRFLILGSPK--LRTLARGLSPAYL-RFGCTDPLIFDPKKESTF 112

DB 110 H-----KLLDSLFEKKKIGITTLKIGIPAYMEKYG--RKGIKISDLKDEKRF 154

OY 113 EERSYVQSQVNDICKYKGIIPDVEK-----LRLEMPYQEQLLRHHYOKKFNSTY 165

DB 155 ----YTLLEDNLDIVK-----NICEKVFCEKFDLDINOIYERQL---RYPEEFKENV- 199

OY 166 SNSSVDVLYTFANCSGLDLIFGLNALLRTADL---QMNSSNAQLLDYCSSKGYNISWE 221

DB 200 ----VDLIRFFNTQKGSVLFEGAGTLLDVMGTYPYVTSNASAL-----GLSNG 246

OY 222 LGNEPNSFLKKADIFING-----SOL-GBDYIOLHKLKSTFKNAKLYG 265

DB 247 TGMPPKRYF---SDAPFLGVAKAYTTRVCEGPFTELKGECEKELREL-----GGEYG 295

OY 266 PDVGPRR---KTAKMLKSLKAGEVIDSVTHHHIYILNGRTATREDFLNP----- 313

DB 296 STTGRPRRCGLDLVALKYAAQVNG-----LDGFVYTKLDVLDLTFDEVKCVVA 343

OY 314 ----DVLIDIFISSVQKVFQV--VESTPRGKRWLGETSSA 347

DB 344 YELDGEVIDYPPASTSELIRKVPYKTKLG---WKKSTKGA 381

Search completed: November 20, 2002, 11:38:11
Job time : 25 secs

GenCore version 5.1.3
Copyright (c) 1993 - 2002 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 20, 2002, 11:34:27 : Search time 14 Seconds

(without alignments)
1608.689 Million cell updates/sec

Title: US-09-759-207-2

Sequence: 1 MLRSKPLPPLPPLLLGLP.....LPNFSYFVIRNAKVACI 543

Scoring table: BLOSUM62

Gapop 10.0, Gapext 0.5

Searched: 112892 seqs, 41476328 residues

Total number of hits satisfying chosen parameters: 112892

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database: SwissProt_40:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	112.5	4.0	356	Y670_METUA	Q50804 methanococ
2	111	3.9	688	YB9F_YEAST	P38338 saccharomyc
3	105.5	3.7	1031	TEPT_EUPAE	O00939 epiflores ae
4	104.5	3.7	788	PUR2_SCHPO	P20722 s bifuncio
5	104	3.7	432	PUR2_KOUAE	O67321 aquifex ae
6	104	3.7	716	RRP2_IATK1	O91742 influenza a
7	103	3.6	796	PKK_CLOAB	O97363 clostridium
8	100.5	3.5	805	GYRB_CHLPM	Q94873 chlamydia p
9	99.5	3.5	837	XYNZ_CLOTM	P10478 clostridium
10	99	3.5	897	DYHC_HUMAN	Q14204 homo sapien
11	99	3.5	4644	DYHC_RAT	P38650 ratius nov
12	98.5	3.5	629	T3MH_HAELN	P71366 haemophilus
13	98.5	3.5	654	N05M_RHIST	P50367 rhizobium st
14	98.5	3.5	746	RHTA_RHIME	O94395 rhizobium m
15	98	3.4	716	RRP2_IATV1	P31343 influenza a
16	97.5	3.4	454	YUAE_CAEFL	P52715 caenorhabdi
17	97.5	3.4	804	GYRB_CHLTR	O84193 chlamydia t
18	97.5	3.4	1314	SS22_YEAST	P25390 saccharomyc
19	96.5	3.4	595	TH1C_BACHD	O94874 bacillus ha
20	96	3.4	327	XYNA_ASPAC	O95859 aspergillus
21	96	3.4	557	COX1_NEUCR	P03945 neurospora
22	96	3.4	716	RRP2_IATZ1	P31175 influenza a
23	96	3.4	1044	ITAV_MOUSE	P44406 mus musculu
24	95.5	3.4	358	VAL1_BCTV	P14991 beet curly
25	95.5	3.4	620	HEMA_MEASY	P28081 measles vir
26	95.5	3.4	5255	BACA_BACLI	O68006 b bacillaci
27	95	3.3	716	RRP2_IAKOR	P13170 influenza a
28	95	3.3	772	LP1G_DROME	P11997 drosophila
29	95	3.3	2214	SORL_HUMAN	O92673 h sortilin
30	95	3.3	4644	DYHC_MOUSE	O91674 mus musculu
31	94.5	3.3	437	INV2_DAUCA	Q36192 daucus caro
32	94	3.3	437	ERF1_XENLA	P35615 xenopus lae
33	94	3.3	804	GYRB_CHLMU	O94873 chlamydia m

34	93.5	3.3	657	GRAD_TREPA	O83062 treponema p
35	93.5	3.3	766	GAP1_SCHPO	P33277 schizosacch
36	93.5	3.3	1787	UVRA_CHLMU	O94660 chlamydia m
37	93	3.3	449	AAM1_MOUSE	O94660 mus musculu
38	93	3.3	726	CATA_ECOLI	P13029 escherichia
39	93	3.3	2733	RRPB_CVMA5	P16342 murine coro
40	92.5	3.3	455	MURF_BUCAL	P57315 buchiera ap
41	92.5	3.3	738	YAS9_SCHPO	O10145 schizosacch
42	92.5	3.3	828	YVPA_YEAST	P43585 saccharomyc
43	92	3.2	485	YAB4_HAELN	P71367 haemophilus
44	92	3.2	716	RRP2_IAMN	P21427 influenza a
45	92	3.2	1536	GLSF_ANTSP	O06434 antithamio

ALIGNMENTS

RESULT 1	Y670_METUA	STANDARD:	PRT:	356 AA.
AC	O50804			
DT	01-NOV-1997 (Rel. 35, Created)			
DT	01-NOV-1997 (Rel. 35, Last sequence update)			
DT	16-OCT-2001 (Rel. 40, Last annotation update)			
DE	Hypothetical protein M0670.			
CN	M0670.			
OS	Methanococcus jannaschii.			
OC	Archaea: Euryarchaeota: Methanococci: Methanococcales:			
OC	Methanocaldococcaceae: Methanocaldococcus.			
OX	NCBI_TaxID=2190;			
RN	[1]			
RC	SEQUENCE FROM N.A.			
RC	STRAIN-JAL-1 / DSM 2661 / ATCC 43067;			
RX	MEDLINE=96337999; PubMed=6888087;			
RA	Bult C.J., White O., Olsen G.-J., Zhou L., Fleischmann R.D.,			
RA	Sutton G.G., Blake J.A., Fitzgerald L.M., Clayton R.A., Gocayne J.D.,			
RA	Kerlavage A.R., Dougherty B.A., Tomb J.F., Adams M.D., Reich C.I.,			
RA	Overbeek R., Kirkness E.F., Weinstock K.G., Merrick J.M., Glodek A.,			
RA	Scott J.L., Geoghagen N.S.M., Weidman J.F., Fuhrmann J.L., Nguyen D.,			
RA	Uutterback F.R., Kelley J.M., Peterson J.D., Sadow P.W., Hanna M.C.,			
RA	Cotton M.D., Roberts K.M., Hurst M.A., Kalne B.P., Borodovsky M.,			
RA	Klenk H.-P., Fraser C.M., Smith H.O., Weese C.R., Venter J.C.;			
RT	"Complete genome sequence of the methanogenic archaeon, Methanococcus jannaschii".			
RL	Science 273:1058-1073(1996).			
CC	-----			
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration			
CC	between the Swiss Institute of Bioinformatics and the EMBL outstation -			
CC	the European Bioinformatics Institute. There are no restrictions on its			
CC	use by non-profit institutions as long as its content is in no way			
CC	modified and this statement is not removed. Usage by and for commercial			
CC	entities requires a license agreement (See http://www.isb-sib.ch/announce/			
CC	or send an email to license@isb-sib.ch).			
CC	-----			
DR	EMBL: U67514; AAB98664.1; -			
DR	TIGR: M0670;			
DR	InterPro: IPR000051; SAM_bind.			
KW	Hypothetical protein; Complete proteome.			
SO	SEQUENCE 356 AA; 41683 MW; D/BB8BA2E16A92E11 CRC64;			
Query Match	4.0%: Score 112.5; DB 1; Length 356;			
Best Local Similarity	21.2%: Pred. No. 0.38;			
Matches	85; Conservative 48; Mismatches 143; Indels 125; Gaps 18;			
OY	126 ICKY-----GSPDVEKRLRLMPYQDOLLREHYOKKFNSTYSRSSVD-----171			
DB	14 IRKWKIKYGNKDKIKRLIKE-----LKEEVLVETEDGYTTLKAEDEEMHNSKV 66			
OY	172 -----VLTFFANGSGDLIFGLNALRLTRADLOMNSNMQLLDYCSSGYNINSMELGEP 226			
DB	67 GALKKATYKFKPS-----KITDL-----SNPR-VLDLCSSGYNIAALAHYNK 109			
OY	227 NS-----FL-----KKADIFINGSQLCEDYIQLHLKLRKSTF 258			


```

Db 110 NAEDIVEICEEVLFLFLFDIPYKEHEITKDKVREYFLN--KIGLEY-----KSDY 159
Oy 259 KNAKLYPDYGOQPRKRTAKMLKSLKAGGEYIDSVTHHHYLLNGRTAT--REDFLNDVL 316
Db 160 DNINLY---VGDAKKFKTIKSDKKY-----NVVHDAFSPKRDPTLYTDFL----- 202
Oy 317 DIFISSVQKVOVESTRPCKKVMWLGTSSTAYGGCAGLLSDTFAAGFMWLDKGLSARMG 376
Db 203 -----KEIYKRMEDN--GVLI-----SYSAIPFRSALVDCGCVISEKESVGKRG 246
Oy 377 IEVVMROVFFGAGNYVHLVDENFD-----PLDPYMLSLFKLVGTRKVLMAVSGSKRR 429
Db 247 ITLAYKKPNFKPNRINIEVDREVALSVIALPYRDETLSLKDKITIEDREPREKMLKELI 306
Oy 430 KLRVYLHCTNTDNPRIYEGSLLYA--INLHNTKYLRLPY 468
Db 307 KICKYLTSTQIKKGNIPETILKIQEKEDLNSSEIHKMKLKF 347

```

RESULT 2

```

YB9F_YEAST
ID YB9F_YEAST STANDARD: PRT: 688 AA.
AC P38338;
DT 01-OCT-1994 (Rel. 30, Created)
DT 01-OCT-1994 (Rel. 30, Last sequence update)
DT 15-JUL-1998 (Rel. 36, Last annotation update)
DE Hypothetical 80.4 kDa protein in POP4-SH1L intergenic region.
GN YBR259W OR YBR1727.
OS Saccharomyces cerevisiae (Baker's yeast).
OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
OC Saccharomycetales; Saccharomycetaceae; Saccharomycetes.
OX NCBI_TaxID=4932;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=5288C;
RX MEDLINE=93220397; PubMed=8465606;
RA Doignon F., Bileau N., Crouzet M., Aigle M.;
RT "The complete sequence of a 19,482 bp segment located on the right
RT arm of chromosome II from Saccharomyces cerevisiae."
RL Yeast 9:189-199(1993).
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC EMBL: X70529; CAA49923.1; -
CC DR EMBL: Z36128; CAA85222.1; -
CC DR PIR: S12961; S32961.
CC DR SCD: S0000463; YBR259W.
CC KW Hypothetical protein.
CC SEQUENCE 688 AA: 80426 MW: 0BA84837BD7AAB30 CRC64;

```

Query Match

Best Local Similarity 3.9%; Score 111; DB 1; Length 688;
Matches 67; Conservative 45; Mismatches 94; Indels 92; Gaps 16;

```

Oy 126 ICAYGSIIPDVEEKLRLLEMPYQEOQLREHYOKKFNKSTYSRSS-----VVLVT 175
Db 164 MAEYSSMKHSDSKROQOFYEFPMKLECLVAFYENFDLOKSSDPLKELIIPWEKIVYV 223
Oy 176 FANCSGLDIFGLMALRLTADLOMNSN-----AQLLD-----YSSKCY----- 216
Db 224 -ANC--IDAFTEGOVRLDGLMELTWSKNLVFSSISSAVLRLNDLOMNFSAFPRYGEALY 280
Oy 217 -----NISELGNENPSFLKKA--DIF--INGSOIG--EDYIOLHKLRLK----- 255
Db 281 QDFAHRSRLKWDNSNDKVESLIRALLINDMFPYFNKEQVDTKADGIFFLRLRNFKHEHN 340

```

```

Oy 256 -----STFKN--AKLYGPDYGOQPRKRTAKMLKSLKAGGEY-----IDSV 293
Db 341 DVKDFHIQVLYKYLNSQFKNNYSTLMTSSKTQDRKSKNNMPSSTLDDGONKIGHAVPTDE- 399
Oy 294 TWHHYLLNG-----RTATREDFLNDVLDFISSVQKVOVESTR--PGK 338
Db 400 -YSHFIDNDEPLMRDQVYPRKTYTNEQTPPDASAIFDS--HKIYAIISLRYLPEKR 454

```

RESULT 3

```

TEPT_EUPAE
ID TEPT_EUPAE STANDARD: PRT: 1031 AA.
AC 000939;
DT 30-MAY-2000 (Rel. 39, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DT 30-MAY-2000 (Rel. 39, Last annotation update)
DE telomerase reverse transcriptase (EC 2.7.7.-) (telomerase catalytic
DE subunit) (telomerase subunit p123).
OS Euplotis aediculatus.
OC Eukaryota; Alveolata; Ciliophora; Spirotrichea; Hypotrichia;
OC Euplotida; Euplotidae; Euplotes.
OX NCBI_TaxID=5940;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=97274210; PubMed=9110970;
RA Lingner J., Hughes T.R., Shevchenko A., Mann M., Lundblad V.,
RA Cech T.R.;
RT "Reverse transcriptase motifs in the catalytic subunit of
RT telomerase."
RL Science 276:561-567(1997).
CC -!- FUNCTION: TELOMERASE IS A RIBONUCLEOPROTEIN ENZYME ESSENTIAL FOR
CC THE REPLICATION OF CHROMOSOME TERMINI IN MOST EUKARYOTES. IT
CC ELONGATES TELOMERES. IT IS A REVERSE TRANSCRIPTASE THAT ADDS
CC SIMPLE SEQUENCE REPEATS TO CHROMOSOME ENDS BY COPYING A TEMPLATE
CC SEQUENCE WITHIN THE RNA COMPONENT OF THE ENZYME.
CC -!- SUBCELLULAR LOCATION: Nuclear.
CC -!- SIMILARITY: BELONGS TO THE REVERSE TRANSCRIPTASE FAMILY.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC EMBL: U95964; AAC47515.1; -
CC DR InterPro: IPR000477; RYISe.
CC DR InterPro: IPR003545; Telomerase_RT.
CC DR Pfam: PF00078; rty1.
CC DR PRINTS: PR01365; TELOMERASERT.
CC KW Transferase; RNA-directed DNA polymerase; Telomere; Nuclear protein;
CC DNA-binding.
CC SEQUENCE 1031 AA: 122562 MW: 57B87A63AIPED60F CRC64;

```

Query Match

Best Local Similarity 3.7%; Score 105.5; DB 1; Length 1031;
Matches 81; Conservative 56; Mismatches 133; Indels 117; Gaps 17;

```

Oy 102 LIFDPKKESTFEERSYQSOVNODICKYGSIPDVEEKLRLLEMPYQEOQLREHYOKKFK 161
Db 694 LIVEAKQNRVYFKKNDLQGVIN--ICQYNYI-----NNGKRY 729
Oy 162 NST-----YSSSDVLYTFPANCGLDIF-----GLNALRTAD-----LOVN 200
Db 730 KQTKGIPQGLCVSSILSSFYATLESSSLGFLRDESMNPENNVNLMRLTDYLLITQ 789
Oy 201 SSNAOLLDYSSKGINISMEIGNE-----PNSFLKKADIFINISOLEGYI 247
Db 790 ENNAVLFIF-----KLINVSRENGKFKPMKKLDTSPPLSPSKAKGMSVEQDNIVQDYC 845
Oy 248 QL-----HKLRLKSTFKNAKLYG-----PDVGQPRKRTA-----KMLKSLKAGGEYIDSV 293

```

```

DB      846 DWIGISIDMKTLALMPNINILIEGLICTLNLNMQTKASMMWLKLLKSLP-----MNNI 899
OY      294 TNNHHYLNCRATREDFLNPDVLDIFISSVQVFOVESTROCKKVVLCGETSSAICGGAP 353
DB      900 T--HYF--RKTTTDEDFANKTLNKLFLISGVYKMOCAKCYKHDFKNLMSMIDLEVSK 955
OY      354 LTSDFFAAGFMWLDKLGISARMCIEVVMQVFFGAGNLYLVDENDPLDYLSLL----- 409
DB      956 ILYSTRAFFKYL-----VCNLTDTTFGEERH-----PDFLSTLTKHFI 994
OY      410 ----FKLVGTVLVNASVQGSRRKRLR 432
DB      995 EIFSTKKYIFNRVCM--ILKAKEAKLK 1019

RESULT 4
PURA_SCHPO STANDARD: PRT: 788 AA.
AC P20772: 09UUM5:
DT 01-FEB-1991 (Rel. 17, Last sequence update)
DT 01-FEB-1991 (Rel. 17, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Bifunctional purine biosynthetic protein Ade1 [includes:
DE Phosphoribosylamine--glycine ligase (EC 6.3.4.13) (GARS) (Glycinamide
DE ribonucleotide synthetase) (Phosphoribosylglycinamide synthetase);
DE Phosphoribosylformylglycinamide cyclase (EC 6.3.3.1) (AIRS)
DE (Phosphoribosyl-aminolimidazole synthetase) (AIR synthase)].
GN ADE1 OR SPBC4Q3.02C OR SPBC405.01.
OS Schizosaccharomyces pombe (Fission yeast).
OC Eukaryota: Fungi: Ascomycota: Schizosaccharomycetes:
OC Schizosaccharomycetales: Schizosaccharomycetaceae:
OC Schizosaccharomyces.
OX NCBI_TaxID=4896;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=972:
RX MEDLINE=89003164: PubMed=3502942;
RT McKenzle R., Schuchert P., Kibbey B.:
RT "Sequence of the bifunctional ade1 gene in the purine biosynthetic
RT pathway of the fission yeast Schizosaccharomyces pombe."
RL Curr. Genet. 12:591-597(1987).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=972:
RX MEDLINE=21848401: PubMed=11859360;
RA Wood V., Gwilliam R., Rajandream M.A., Lyne M., Lyne R., Stewart A.,
RA Sgouros J., Peat N., Hayles J., Baker S., Basham D., Bowman S.,
RA Brooks K., Brown D., Brown S., Chillingworth T., Churcher C.M.,
RA Collins M., Connor R., Cronin A., Davis P., Fellwell T., Fraser A.,
RA Gentles S., Goble A., Hamlin N., Harris D., Hidalgo J., Hodgson G.,
RA Holtroyd S., Hornsby T., Howarth S., Huckle E.J., Hunt S., Jagels K.,
RA James K., Jones L., Jones M., Leather S., McDonald S., McLean J.,
RA Mooney P., Moule S., Mungall K., Murphy L., Mablet D., Odell C.,
RA Oliver K., O'Neill S., Pearson D., Quail M.A., Rabinowitsch E.,
RA Rutherford K., Rutter S., Saunders D., Seeger K., Sharp S.,
RA Skelton J., Stimmings M., Squares R., Squares S., Stevens K.,
RA Taylor K., Taylor R.G., Tivey A., Walsh S.V., Warren T., Whitehead S.,
RA Woodward J., Volckaert G., Aert R., Robben J., Gymnopoulos B.,
RA Wellens J., Vanstreels E., Rieger M., Schaefer M., Mueller Auer S.,
RA Gabel C., Fuchs M., Fritzc C., Holzer E., Moestl D., Hilbert H.,
RA Borzym K., Langer I., Beck A., Lehrach H., Reinhardt R., Pohl T.M.,
RA Eger P., Zimmermann W., Medler H., Wambutt R., Purnelle B.,
RA Goffeau A., Cadieu E., Dreano S., Gloux S., Lelaue V., Mottier S.,
RA Galibert F., Aves S.J., Xiang Z., Hunt C., Moore K., Hurst S.M.,
RA Lucas M., Rochet M., Galliard C., Tallada V.A., Garcon A., Rhode G.,
RA Daga R.R., Cruzado L., Jimenez J., Sanchez M., del Rey F., Benito J.,
RA Dominguez A., Revuelta J.L., Moreno S., Armstrong J., Forsburg S.L.,
RA Cerrutti L., Lowe T., McCombie W.R., Paulsen I., Potashkin J.,
RA Shpakovski G.V., Ussery D., Barrell B.G., Nurse P.:
RA "The genome sequence of Schizosaccharomyces pombe."
RL Nature 415:871-880(2002).
CC -i- CATALYTIC ACTIVITY: ATP + 5-phospho-D-ribosylamine + glycine = ADP

```

```

CC      + phosphate + N(1)-(5)-phospho-D-ribosylglycinamide.
CC      -i- CATALYTIC ACTIVITY: ATP + 2-(formamido)-N(1)-(5)-phospho-D-
CC      ribosyl)acetamide = ADP + phosphate + 5-amino-1-(5)-phospho-D-
CC      ribosyl)imidazole.
CC      -i- PATHWAY: De novo purine biosynthesis: second step.
CC      -i- PATHWAY: De novo purine biosynthesis: fifth step.
CC      -i- SIMILARITY: IN THE N-TERMINAL SECTION; BELONGS TO THE GARS FAMILY.
CC      -i- SIMILARITY: IN THE C-TERMINAL SECTION; BELONGS TO THE AIRS FAMILY.
CC      -----
CC      This SWISS-PROT entry is copyright. It is produced through a collaboration
CC      between the Swiss Institute of Bioinformatics and the EMBL Outstation -
CC      the European Bioinformatics Institute. There are no restrictions on its
CC      use by non-profit institutions as long as its content is in no way
CC      modified and this statement is not removed. Usage by and for commercial
CC      entities requires a license agreement (see http://www.isb-sib.ch/announce/
CC      or send an email to license@isb-sib.ch).
CC      -----
DR      EMBL: X06601: CAA29820.1: -
DR      EMBL: AL021730: CAA16823.1: -
DR      EMBL: AL035655: CAB38600.1: -
DR      PIR: S00652; S00652.
DR      HSSP: P08178; ICL1.
DR      InterPro: IPR000728; AIRS-related.
DR      InterPro: IPR000115; Gars.
DR      InterPro: IPR004733; PurM_c1igase.
DR      Pfam: PF00586; AIRS; 1.
DR      Pfam: PF01071; GARS; 1.
DR      Pfam: PF02769; AIRS_C; 1.
DR      Pfam: PF02842; GARS_B; 1.
DR      Pfam: PF02843; GARS_C; 1.
DR      Pfam: PF02844; GARS_N; 1.
DR      TIGRfams: TIGR00877; purD; 1.
DR      TIGRfams: TIGR00878; purM; 1.
DR      PROSITE: PS00184; GARS; 1.
DR      Multifunctional enzyme: Purine biosynthesis; ligase.
FT      DOMAIN 1 430
FT      DOMAIN 2 440 750
FT      DOMAIN 3 750 750
FT      DOMAIN 4 750 750
SO      SEQUENCE 788 AA; 85231 MM; 0PDE64EA5F9095D CXC64;

Query Match 3.7%; Score 104.5; DB 1; Length 788;
Best Local Similarity 27.7%; Pred. No. 4.8;
Matches 70; Conservative 36; Mismatches 114; Indels 33; Gaps 11;

OY      297 HYLYNGRATRE--DELMPDV-LDIFISSVQVFOVEST--PPGKKVWLGETSSAY----- 348
DB      424 HHALPKRRTRREILTYEYSGVSDVNGNEFVRKIDLVSTRPPGADADIGGFGGIFDLKO 483
OY      349 -GGCAPLL-SDFFAAGFMWLDKLGISAR--MGIEVVMQVFFGAGNLYLVDENDPL--P 402
DB      484 AGWNPPLVYASNDVGSKLLALSLNKHDTVGIDLVANV-----NDLVYGGAEPLIFL 537
OY      403 DYWLSLFRKVLGTVLVNASVQGSRRKRLRYVLCCTNTDNPYKGGDLTLVAIINLHNYTK 462
DB      538 DVFAGSIDLKAKSTSEFVGVAVKCKQACALVCGETSEMPGLYHGDYDANCTSGAVSR 597
OY      463 YRLPYPSNKOVDYVLLRPLGPHGLSKSVQNLGTL--KWDV-----DQTLPLMLKPL 516
DB      538 DDILKPPSPFSKGDILL-----GLASDGVHNSGYSLVRKIVESYDLEIYTSVCPWMDNV 650
OY      517 RFGSSILGPARSY 529
DB      651 RIGDSLILPTRYI 663

RESULT 5
PURA_AOUAE STANDARD: PRT: 432 AA.
AC 067321:
DT 15-DEC-1998 (Rel. 37, Last sequence update)
DT 15-DEC-1998 (Rel. 37, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Adenylosuccinate synthetase (EC 6.3.4.4) (IMP--aspartate ligase)
DE (AASS) (AMPase).

```

[illegible]

```

Oy 393 LVDENPDLPOYWLSLKRLKLVGTAKVLASVQSGSKRRKRLVLTCTNDPNPKYKEDDLTL 452
Db 527 LTPDLLE--PHKWEKYCVLEI--GDMILRSAGIOMSRPMLVVRNGTSKIKMKMGEMR 582
Oy 453 YAI--NLINHWRYLRPLPFPFSKNQVDKYLR-----PLG--PHG-----LLS 490
Db 583 RCLDSLOQIESMIAEBSVSKEDMTKEFFENKSEAMPFGESPKEVGEISGKVCRTLLA 642
Oy 491 KSV-----OLNGLTLKMYDDQTLPLPMKPLRPGS 520
Db 643 KSVFNSLYASPOLGEGFSAESRKLTLVQALRDNLPGT 680

```

RESULT 7

```

PHK_CLOAB STANDARD: PRT: 796 AA.
ID PHK_CLOAB
AC 097JEB3:
DT 15-JUN-2002 (Rel. 41, Created)
DT 15-JUN-2002 (Rel. 41, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Probable phosphoketolase (EC 4.1.2.*).
GN CAC1343.
OS Clostridium acetobutylicum.
OC Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;
OC Clostridium.
OX NCBI_Taxid=1489;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-ATCC 824 / DSM 792 / VKM B-1787;
RC MEDLINE=21359325; PubMed=11466286;
RA Noelling J., Breton G., Omelchenko M.V., Makarova K.S., Zeng O.,
RA Glison R., Lee H.M., Dubois J., Oiu D., Hilti Y.I.,
RA Tatusov R.L., Sabathe F., Doucette-Stamm L., Soucaille P., Daly M.J.,
RA Bennett G.N., Koonin E.V., Smith D.R.;
RT "Genome sequence and comparative analysis of the solvent-producing
RT bacterium Clostridium acetobutylicum."
RL J. Bacteriol. 183:4823-4838(2001).
CC -1- COFACTOR: Thiamine pyrophosphate (Potential).
CC -1- SIMILARITY: BELONGS TO THE XFP FAMILY.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC
CC EMBL: AE007645; AAK79311.1;
DR PROSITE: PS60002; PHOSPHOKETOLASE_1; 1.
DR PROSITE: PS60003; PHOSPHOKETOLASE_2; 1.
DR PROSITE: PS00187; PEP_ENZYMES; FALSE_NEG.
KW Lyase; Flavoprotein; Thiamine pyrophosphate; Complete proteome.
SQ SEQUENCE 796 AA; 90640 MW; 488219DC9778FAEF CRC64;

```

Query Match

Best Local Similarity 3.6%; Score 103; DB 1; Length 796;
Matches 77; Conservative 51; Mismatches 114; Indels 114; Gaps 18;

```

Oy 27 GALPPAQAQDVDDPFOEPRLHVSPEFLSVTIDA--NLATDPRL-LILGSPKLT 82
Db 238 CMKPFVEGDEPETHMKLMAETLDIVTEILMIQNAKARNNDSCSRKPMIYLRTPK--- 294
Oy 83 LARGLSPAYLRFPGTGTDFLFPDKKESTFEERSYQSGVNDICKYGSIPDVEKLT 142
Db 295 -----GWTGPRFV-----DGVNPGSFRAGQVPLAVDRYHTENDQLE--- 332
Oy 143 EM--PYEQQLREHYQ--KKFKNSTYSRSSVDVLYTFRANGGLDITGLNALLTADQ 198
Db 333 EMLKSYKDEELFEDENYRLIPELEELTPKGNKRMANLIAN--GGL-----LARELTPDR 386
Oy 199 WNSNAQLLLDYCSSKSGYNIWELGNPNRSLKKADIFNGSOLGEDDYIQLHKLLR---- 254

```

```

Db 387 -----DYA-----VDPFPGSTVQDMIELKYYKDYVK 415
Oy 255 -KSTFRNAKLYPD-----VGOPRRKTAAKMK---SFLKAGEVIDSVTWH-- 297
Db 416 LMEDFRNFRIFPGPDEFMSNRMLVAVEGTRKQMLSEIKEPNDFLSNDRIVDSMLSEHL 475
Oy 298 -----YYLNGRTATREDPLNDVLDIFISSQKQFOYVES--TRGKVMGLGFS 345
Db 476 EGMLEGYLLTGRHG-----FFASYEARLIVDSMTIOHGK--WLKVT 516

```

RESULT 8

```

GYRB_CHLPN STANDARD: PRT: 805 AA.
ID GYRB_CHLPN
AC 092BR3: Q9J044;
DT 30-MAY-2000 (Rel. 39, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE DNA gyrase subunit B (EC 5.99.1.3).
GN GYRB OR CP04275 OR CP0484.
OS Chlamydia pneumoniae (Chlamydia pneumoniae).
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.
OX NCBI_Taxid=83558;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-CWL029;
RC MEDLINE=99206606; PubMed=10192388;
RA Kaiman S., Mitchell W., Marathe R., Lammie C., Fan J., Hyman R.W.,
RA Olinger L., Grimwood J., Davis R.W., Stephens R.S.;
RT "Comparative genomes of Chlamydia pneumoniae and C. trachomatis."
RL Nat. Genet. 21:385-389(1999).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN-AR39;
RC MEDLINE=20150255; PubMed=10684935;
RA Read T.D., Brunham R.C., Shen C., Gill S.R., Heidelberg J.F.,
RA White O., Hickey E.K., Peterson J., Utterback T., Berry S.,
RA Linher K., Weidman J., Khouri H., Craven B., Bowman C., Dodson R.,
RA Gwin M., Nelson W., Deboy R., Kolonay J., McClarty G., Salzberg S.L.,
RA Eisen J., Fraser C.M.;
RT "Genome sequences of Chlamydia trachomatis MoPn and Chlamydia
RT pneumoniae AR39."
RL Nucleic Acids Res. 28:1397-1406(2000).
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN-J138;
RC MEDLINE=20330349; PubMed=10871362;
RA Shirai M., Hirakawa H., Kimoto M., Tabuchi M., Kishi F., Ouchi K.,
RA Shiba T., Ishii K., Hattori M., Kuhara S., Nakazawa T.;
RT "Comparison of whole genome sequences of Chlamydia pneumoniae J138
RT from Japan and CWL029 from USA."
RL Nucleic Acids Res. 28:2311-2314(2000).
CC -1- FUNCTION: DNA GYRASE NEGATIVELY SUPERCOILS CLOSED CIRCULAR DOUBLE-
CC STRANDED DNA IN AN ATP-DEPENDENT MANNER AND ALSO CATALYZES THE
CC INTERCONVERSION OF OTHER TOPOLOGICAL ISOMERS OF DOUBLE-STRANDED
CC DNA RINGS, INCLUDING CATENANES AND KNOTTED RINGS.
CC -1- CATALYTIC ACTIVITY: ATP-dependent breakage, passage and rejoining
CC of double-stranded DNA.
CC -1- SUBUNIT: MADE UP OF TWO CHAINS. THE A CHAIN IS RESPONSIBLE FOR DNA
CC BREAKAGE AND REJOINING; THE B CHAIN CATALYZES ATP HYDROLYSIS. THE
CC ENZYME FORMS AN A2B2 TETRAMER.
CC -1- SIMILARITY: BELONGS TO THE TYPE II TOPOISOMERASE FAMILY.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC
CC EMBL: AE001612; AAD18424.1;

```

DR EMBL: AE002210; AAF38314.1; -
 DR EMBL: AP002546; BAA98485.1; -
 DR HSSP: P06982; JA6.
 DR PHCI-2DPAGE: 0928R3; -
 DR TIGR: CP0484; -
 DR InterPro: IPR003594; ATPbind_ATPase.
 DR InterPro: IPR002288; DNA_gyraseB_C.
 DR InterPro: IPR001241; DNA_topoisomII.
 DR InterPro: IPR002936; DNAPrim_toprim.
 DR Pfam: PF00204; DNA_gyraseB_1.
 DR Pfam: PF00986; DNA_gyraseB_C_1.
 DR Pfam: PF01751; toprim_1.
 DR Pfam: PF02518; HATPase_C_1.
 DR PRINTS: PR00418; TP12FAMILY.
 DR ProDom: PD00616; DNA_topoisomII_1.
 DR ProDom: PD14633; DNA_gyraseB_C_1.
 DR SMART: SM00387; HATPase_C_1.
 DR SMART: SM00433; TOP2c_1.
 DR TIGRFAMs: TIGR01059; gyrb_1.
 DR PROSITE: PS00177; TOPOISOMERASE_II; 1.
 KM Topoisomerase: Isomerase: ATP-binding: Complete proteome.
 SO SEQUENCE 805 AA; 90571 MW; C082DF4CC6C71ECC CRC64;

Query Match 3.5%; Score 100.5; DB 1; Length 805;
 Best Local Similarity 20.4%; Pred. No. 9.9;
 Matches 121; Conservative 71; Mismatches 169; Indels 231; Gaps 32;

OY 48 PLHLVSPS-----FLSVTDANLATPPRLILGSKLRTLARGLSPAVL 92
 DB 161 PLQVYSDRQCTEIVYPPDKIFSTCTD-----KSLMKRLLELFLNMGIT----- 209
 OY 93 REGGTWTDLPIDPKKESTFEERSYMQOVNODICKYGSIPDPVEEKLRLNMPYEQALL 152
 DB 210 -----IYEDDDRDVDFDKVTTFYE-----GGIQSVS----- 236
 OY 153 REHYOKKFNSTYSRSSVDVLTFFANGSGLDLFLGALLLRADLOMNSSNQLLDYCS 212
 DB 237 ---YLONKRESLFS---EPYICGTGVGDD---GEIEFALLOMNSGYSLVSYAN 284
 OY 213 SKGCVNI-SMELONERNPSFLKADIFINGSOLEDYIOLKRLKSTFKKAK--LYGPDVG 269
 DB 285 ---NLPTRGGGTHLTGFSTALTRVIN-----TYIKAHNLA-----KNNKLTALTGEDI- 328
 OY 270 OPRRKAKMLKSLFKAGCEVDSVTWHYLYNGRTATREDPLNDV-----LDI 318
 DB 329 -----REGLTAIVTSVKYPNPQFEGQ--TKOKLNSDYSSAAQOVYGEALTI 372
 OY 319 FISS-----VQKVF-----QVESTP-PCK-----K 338
 DB 373 FFEENPOIARMIVDKVFVAQAAREAAKKARELTLRKALDSARLPCKLIDCLEKEPEKE 432
 OY 339 VMIGETSSAYGCGA-----PLSDTFAGFMULDKGLSARNGIEVMQVVF 386
 DB 433 MYIVEEDSA-GGSAKOGRRRPOALPIGKILINVEKARLOKIFQOETGIIIALGCGI 491
 OY 387 GAGNYHLYVENFDPLPDYMLSLFKLVGCTKYL--ASYOGSKRRLRY--YLHCTN-- 439
 DB 492 GADNFFL-----SKLRVRI-----IIMTDADVDSGHIRLLLTFFYRHMTALI 535
 OY 440 -----TNPRYKSGDLTLVAINLHNVTLYRLPYFESNKOVDKYLRLPGPH--GLLS 490
 DB 536 ENECVYIAOPPLYK-----VSKKKDFRYITLSEKEMDSYLLM-LGNTNSSLIF 581
 OY 491 KSV--QLNGLTLK-----NVDQOTLPLMEKPLRPGS-----SLGIPAF 527
 DB 582 KSTERELGAELESPFINVLIDVESFINLLEKKAIPSEPLEMYKEGIGPLY 633

RESULT 9
 XYNZ_CLOCIN
 ID XYNZ_CLOCIN STANDARD: PRT: 837 AA.
 AC P10478;
 DT 01-JUL-1989 (rel. 11, Created)

DT 01-NOV-1991 (rel. 20, Last sequence update)
 DT 15-JUL-1999 (rel. 38, Last annotation update)
 DE Endo-1,4-beta-xylanase Z precursor (EC 3.2.1.8) (Xylanase Z)
 DE (1,4-beta-D-xylan xylohydrolase Z).
 GN XYNZ.
 OS Clostridium thermocellum.
 OC Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;
 OC Clostridium.
 OX NCBI_TaxID=1515;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=NCIB 10682;
 RX MEDLINE=89008072; PubMed=3139632;
 RA Grepinet O., Cheprou M.-C., Beguin P.;
 RT "Nucleotide sequence and deletion analysis of the xylanase gene
 (xynZ) of Clostridium thermocellum.";
 RL J. Bacteriol. 170:4582-4588(1988).
 RN [2]
 RP X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 515-837.
 RC STRAIN=NCIB 10682;
 RX MEDLINE=95393242; PubMed=7664125;
 RA Dominguez R., Soucchon H., Spinelii S., Dauter Z., Wilson K.S.,
 RA Chauvaux S., Beguin P., Alzart P.M.;
 RT "A common protein fold and similar active site in two distinct
 RT families of beta-glycanases.";
 RL Nat. Struct. Biol. 2:569-576(1995).
 CC -I- CATALYTIC ACTIVITY: Endohydrolysis of 1,4-beta-D-xylosidic
 CC linkages in xylans.
 CC -I- DOMAIN: A 24 RESIDUES DOMAIN IS REPEATED TWICE IN THIS ENZYME AS
 CC WELL AS IN OTHER C.THERMOCELLUM CELLULOSE ENZYMES. THIS DOMAIN
 CC MAY FUNCTION AS THE BINDING LIGAND FOR THE SL COMPONENT.
 CC -I- SIMILARITY: BELONGS TO CELLULOSE FAMILY F (FAMILY 10 OF GLYCOSYL
 CC HYDROLASES).
 CC -I- SIMILARITY: CONTAINS 1 XYNZ-TYPE CELLULOSE-BINDING DOMAIN (CBD).
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (see <http://www.isb.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC EMBL: M22624; AAA23286.1; -
 CC PIR: A31842; A31842.
 DR PDB: 1XYZ; 29-JAN-96.
 DR InterPro: IPR005084; CBM_6.
 DR InterPro: IPR002105; Dockerin_1.
 DR InterPro: IPR002048; EF-hand.
 DR InterPro: IPR001000; Glyco_hydro_10.
 DR InterPro: IPR000379; Ser_estra_site.
 DR Pfam: PF00331; Glyco_hydro_10; 1.
 DR Pfam: PF00404; Dockerin_1; 2.
 DR Pfam: PF03422; CBM_6; 1.
 DR PRINTS: PR00134; GLHYDRLASE10.
 DR PROSITE: PS00018; EF_HAND; UNKNOWN_2.
 DR PROSITE: PS00448; CLOS_CELLULOSOME_RPT; 2.
 DR PROSITE: PS00591; GLYCOSYL_HYDROL_F10; 1.
 KM xylan degradation; Hydrolyase; Glycosidase; Repeat; Signal;
 KW 3D-structure.
 FT SIGNAL 1 28
 FT CHAIN 29 837
 FT ACT_SITE 645 645
 FT ACT_SITE 754 754
 FT DOMAIN 328 416
 FT DOMAIN 430 487
 FT REPEAT 430 453
 FT REPEAT 464 487
 FT DISULFID 783 789
 SO SEQUENCE 837 AA; 92262 MW; DD4C29F04D1B6CD CRC64;
 Query Match 3.5%; Score 99.5; DB 1; Length 837;
 Best Local Similarity 19.3%; Pred. No. 12;

Matches: 63; Conservative 48; Mismatches 107; Indels 109; Gaps 16;

```

OY 145 PYOEOLLE-----HYOKF-----KNSTYSSSVLYTYFANCGLDIFGLNALIR 193
DB 543 PTYSIILOREFSMVVCENEMKFDALOPRONVDFSKGDLAFARNQO-----MK 594
OY 194 TADLOWNSSNOLLID-----YCSKGYNISMEIGNE-----PNSF 229
DB 595 GHTLWMHONPSWLTNGNMNRDLSLAVKMNHTTWTYHKGIKIVEDVANGMDSGKGL 654
OY 230 LKKADIFNGSOLGEDIYQLHKLKRSFKNAKLYCP-----DYCGOPRKR7AK 277
DB 655 --RSSIMRN--VIGODYIDY-----AFRYAREADPPALLFYNDYNIEDLGPKSNAYFN 703
OY 278 MLKSPFLKAGGEYDSVTNHHIYLNKRTATREDPLMPDV-----LDIFISSVOKVQVYES 332
DB 704 MKS--MKRGVPIDCVGCFCHEFNGMSPEYLASIDONIKRYAEIVISFTEIDIRIPOS 762
OY 333 TRPG-----KKVWLGERTSAVGGGAPLSDTFAGFMW--LDKLGLSARMG1 377
DB 763 ENPATAFOVOANNKELMKICLANPN-----CNTFV--MMGFTDKY----- 801
OY 378 EYVMROVFFGAGNYHLVDENEDPLDPY 404
DB 802 -TWIPGTFPGYGNPLIYDSNVNPKPAY 827

RESULT 10
DYHC_HUMAN
ID DYHC_HUMAN STANDARD: PRT: 897 AA.
AC 014204: 092814:
DT 01-NOV-1997 (Rel. 35, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Dynein heavy chain, cytosolic (DYHC) (Cytoplasmic dynein heavy chain
DE 1) (DHC1) (Fragment).
GN DNCH1 OR DNECL.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=96234671; PubMed=8666668;
RA Vaisberg E.A., Grissom P.M., McIntosh J.R.;
RT "Mammalian cells express three distinct dynein heavy chains that are
RT localized to different cytoplasmic organelles."
RL J. Cell Biol. 133:831-842(1996).
RN [2]
RP SEQUENCE OF 755-895 FROM N.A.
RX MEDLINE=94043467; PubMed=8227145;
RA Vaisberg E.A., Koone M.P., McIntosh J.R.;
RT "Cytoplasmic dynein plays a role in mammalian mitotic spindle
RT formation."
RL J. Cell Biol. 123:849-858(1993).
CC - FUNCTION: DYNEIN HAS ATPASE ACTIVITY. CYTOPLASMIC DYNEIN ACTS AS A
CC MOTOR FOR THE INTRACELLULAR RETROGRADE MOTILITY OF VESICLES AND
CC ORGANELLES ALONG MICROTUBULES.
CC - SUBUNIT: CONSISTS OF AT LEAST TWO HEAVY CHAINS AND A NUMBER OF
CC INTERMEDIATE AND LIGHT CHAINS.
CC - SUBCELLULAR LOCATION: Cytoplasmic.
CC - SIMILARITY: BELONGS TO THE DYNEIN HEAVY CHAIN FAMILY.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
DR EMBL: U53530: AAB09727.1: -
DR EMBL: L23958: AAI16065.1: -

```

```

DR GeneW: HGNC:2961; DNCH1.
DR MW: 600112:
KW Motor protein; Microtubules; Dynein; ATP-binding; Coiled coil.
FT DOMAIN 1 42 74 COILED COIL (POTENTIAL).
FT DOMAIN 102 123 COILED COIL (POTENTIAL).
FT DOMAIN 228 244 COILED COIL (POTENTIAL).
FT NP_BIND 777 784 ATP (POTENTIAL).
FT CONFLICT 812 812 R -> M (IN REF. 2).
FT NON_TER 897 897
SQ SEQUENCE 897 AA; 103012 MW; 7A95514D06CA7D42 CRC64:

Query Match 3.5%; Score 99; DB 1; Length 897;
Best Local Similarity 19.9%; Pred. No. 15;
Matches 114; Conservative 81; Mismatches 174; Indels 204; Gaps 27;

OY 41 LDFPTQEPHLVSPSFLSTIDANLATPDRFLILGSPKLTPLAGLSPAYLRFGCTKT 100
DB 214 IDOMKEQWVSVQPRKLRQNDLALLNQLSF-----PARLRQYASVEFVORLLKGYMKIN 268
OY 101 FLIFDPKKESTFEERSTYQSOVNO-----DICKYGSIPPDV----- 136
DB 269 MLVIELKSEA-LKDR-HWKOLMKRLHVMVWVSELTGQIMVDLOKNEAIYKVDVLLVAG 326
OY 137 -----EKLEWPYOEOLLRREHYOKKFNSTYSSSVYLYTFANCGLDIFGLN 189
DB 327 EMALKEFLKQIREVNTYELDLV--NYONKCR-----LIRGWD 362
OY 190 ALLRTADLOWNSSNOLLIDYCSSKGYNI-----SMELGNEPNSFLKKADIPTN----- 238
DB 363 DLFNKVKELINSVSAMKLSPY-----YKVFEDALSWE--DKLNRIMALFDWIDVORRW 415
OY 239 -----GS-----QLCEDYIQLHLKRSKTFKNAKLYGPVYGOPRKT 275
DB 416 VYLEGIFYGSADIKILLPVEQRFOSISTEFALMKKSKSPVMDVNIQOVOSLERI. 475
OY 276 AKMLKSPFKAGGEV1--DSVTMHNYLYNCRTRATREDPLNPDLDI-----ISSVQVFO 328
DB 476 ADLLCKIOKALGEYLERESSFPRTFVG-----DEDLLEITGSKNVAKLOKHIF- 525
OY 329 VESTRPGKKYWLGETSSAYGGGAPLSDTFAGFMWLDKLGLSARMG1EYVMROVFFGA 388
DB 526 -----KKMFAGVSSI-----ILNEDNSV-----VGLISSEGEVEWFKTP----- 560
OY 369 GNYHLVDENFPLPPTWYLSLFLKLVGKTVLMASVQSKRRKRLRYLHCTNTDNRYEG 448
DB 561 -----VSITEHPKIMELTLVEREM--RYTLAKLLAESVTEVEIFGATSIDPNTY--- 609
OY 449 DLTLYAINLHNTKYRLRPYFSNKQVDKY-----LRLPLPHG-- 487
DB 610 -----IT-----WIDRYQAOVLVLSNOJAMSENVETALSSMGGGDA 646
OY 488 LLSKSVOLN-GTLTKMVDQTL--PMLKEPL 516
DB 647 APSDSVLNVSEYTLNVLADSVLMGPPRLRRRL 679

RESULT 11
DYHC_RAT
ID DYHC_RAT STANDARD: PRT: 4644 AA.
AC P38650: 063178:
DT 01-FEB-1995 (Rel. 31, Created)
DT 01-FEB-1995 (Rel. 31, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Dynein heavy chain, cytosolic (DYHC) (Cytoplasmic dynein heavy chain)
DE (MAP 1C).
GN DNCH1 OR DNCH1 OR DNECI OR MAP1C.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP SEQUENCE FROM N.A.

```

```

0y      41 LDFFTOEPHLVSPFSLSVTIDANLATDPRFLILIGSPKLRPLARGLSPAYLRFEGCTKD 1000
      :: :: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

```

CC A HOMOTETRAMER (BY SIMILARITY).

	RESULT 13
NU5M_RH1ST	
ID	NU5M_RH1ST
AC	P50367;
DT	01-OCT-1996 (Rel. 34, Created)
DT	01-OCT-1996 (Rel. 34, Last sequence update)
DT	15-DEC-1998 (Rel. 37, Last annotation update)
DE	NAD5-ubiquinone oxidoreductase chain 5 (EC 1.6.5.3).
GN	NAD5 OR NAD5.
OS	Rhizopus stolonifer (Rhizopus nigricans).
OG	Mitochondrion.
OC	Eukaryota; Fungi; Zygomycota; Zygomycetes; Mucorales; Mucoraceae;
OC	Rhizopus.
OX	NCBI_TaxID=4846;
RN	[1]
RP	SEQUENCE FROM N.A.
RC	STRAIN=DAOM 148428;
RA	Paquin B., Roewer I., Wang Z., Lang B.F.;
RT	"A robust fungal phylogeny using the mitochondrially encoded nad5

[illegible]

	RESULT	14
RHTA_RHIME		
ID	RHTA_RHIME	STANDARD:
AC	G92305:	PRT; 746 AA.
DT	30-MAY-2000 (Rel. 39, Created)	
DT	30-MAY-2000 (Rel. 39, Last sequence update)	
DT	15-JUN-2002 (Rel. 41, Last annotation update)	
DE	Rhizobactin receptor precursor (TonB-dependent siderophore recep	
DE	rhta).	
GN	RHTA OR RA1265 OR SMA2414.	
OS	Rhizobium meliloti (Sinorhizobium meliloti).	
OG	Plasmid pSYMA (megaplasmid 1).	
OC	Bacteria; Proteobacteria; alpha subdivision; Rhizobiaceae group;	
OC	Rhizobiaceae; Sinorhizobium.	
OX	NCBI_TaxID=382;	
RN	(1)	
CC	SEQUENCE FROM N.A.	
CP	STRAIN-RCR2011 / S047;	


```

RX MEDLINE-21172875; PubMed-11274118;
RA Lynch D., O'Brien J., Welch T., Clarke P., Cuiv P.O., Croa J.H.,
RA O'Connell M.;
RT "Genetic organization of the region encoding regulation, biosynthesis,
RT and transport of rhizobactin 1021, a siderophore produced by
RT Sinorhizobium meliloti."
RN J. Bacteriol. 183:2576-2585(2001).
RP
RC
RD
RE
RF
RG
RH
RI
RJ
RK
RL
RM
RN
RO
RP
RS
RT
RV
RW
RX
RY
RZ
SA
SB
SC
SD
SE
SF
SG
SH
SI
SJ
SK
SL
SM
SN
SO
SQ
ST
SU
SV
SW
SX
SY
SZ
TA
TB
TC
TD
TE
TF
TG
TH
TI
TJ
TK
TL
TM
TN
TO
TP
TQ
TR
TS
TT
TV
TW
TX
TY
TZ
UA
UB
UC
UD
UE
UF
UG
UH
UI
UJ
UK
UL
UM
UN
UO
UP
UQ
UR
US
UT
UU
UV
UW
UX
UY
UZ
VA
VB
VC
VD
VE
VF
VG
VH
VI
VJ
VK
VL
VM
VN
VO
VP
VQ
VR
VS
VT
VV
VW
VX
VY
VZ
WA
WB
WC
WD
WE
WF
WG
WH
WI
WJ
WK
WL
WM
WN
WO
WP
WQ
WR
WS
WT
WW
WX
WY
WZ
XA
XB
XC
XD
XE
XF
XG
XH
XI
XJ
XK
XL
XM
XN
XO
XP
XQ
XR
XS
XT
XU
XV
XW
XX
XY
XZ
YA
YB
YC
YD
YE
YF
YG
YH
YI
YJ
YK
YL
YM
YN
YO
YP
YQ
YR
YS
YT
YU
YV
YW
YX
YY
YZ
ZA
ZB
ZC
ZD
ZE
ZF
ZG
ZH
ZI
ZJ
ZK
ZL
ZM
ZN
ZO
ZP
ZQ
ZR
ZS
ZT
ZU
ZV
ZW
ZX
ZY
ZZ

```

Best local similarity 3.5%; Score 98.5; DB 1; Length 746;
Matches 105; Conservative 55; Mismatches 159; Indels 163; Gaps 25;

```

OY 385 PEGAGNYHLVDENFDPLDPYWLSTLFKLVGTRKVLMAVSGSKRRRLRVYLCTNTDMPR 444
DB 519 YXGIGNVSFGS-----GHYTLVNSV----- 538
OY 445 YKEGDLTYAILNHLNVTYKRLPLPPSKQVNDKYLRLPGPLLSKSVQLN--GLTLKM 502
DB 539 -NWGDSALEAIVKTNSEFGEYRILDGTFNLETAAY-----YSLSDRSINLRSSIAVEI 590
OY 503 VD 504
DB 591 ID 592
RESULT 15
RRP2_IHAV17 STANDARD: PRT: 716 AA.
AC P31343;
DT 01-JUL-1993 (rel. 26, Created)
DR 01-JUL-1993 (rel. 26, Last sequence update)
DT 15-JUN-2002 (rel. 41, Last annotation update)
DE RNA-directed RNA polymerase subunit P2 (EC 2.7.7.48) (polymerase
DE acidic protein) (PA).
OS Influenza A virus (strain A/Victoria/3/75).
OC Viruses; ssRNA negative-strand viruses; Orthomyxoviridae;
OC Influenza A viruses; Influenzavirus A.
OX NCBI_TaxID=11483;
RN [1]
RP
RS
RT
RV
RW
RX
RY
RZ
SA
SB
SC
SD
SE
SF
SG
SH
SI
SJ
SK
SL
SM
SN
SO
SQ
ST
SU
SV
SW
SX
SY
SZ
TA
TB
TC
TD
TE
TF
TG
TH
TI
TJ
TK
TL
TM
TN
TO
TP
TQ
TR
TS
TT
TV
TW
TX
TY
TZ
UA
UB
UC
UD
UE
UF
UG
UH
UI
UJ
UK
UL
UM
UN
UO
UP
UQ
UR
US
UT
UU
UV
UW
UX
UY
UZ
VA
VB
VC
VD
VE
VF
VG
VH
VI
VJ
VK
VL
VM
VN
VO
VP
VQ
VR
VS
VT
VV
VW
VX
VY
VZ
WA
WB
WC
WD
WE
WF
WG
WH
WI
WJ
WK
WL
WM
WN
WO
WP
WQ
WR
WS
WT
WW
WX
WY
WZ
XA
XB
XC
XD
XE
XF
XG
XH
XI
XJ
XK
XL
XM
XN
XO
XP
XQ
XR
XS
XT
XU
XV
XW
XX
XY
XZ
YA
YB
YC
YD
YE
YF
YG
YH
YI
YJ
YK
YL
YM
YN
YO
YP
YQ
YR
YS
YT
YU
YV
YW
YX
YY
YZ
ZA
ZB
ZC
ZD
ZE
ZF
ZG
ZH
ZI
ZJ
ZK
ZL
ZM
ZN
ZO
ZP
ZQ
ZR
ZS
ZT
ZU
ZV
ZW
ZX
ZY
ZZ

```

Best local similarity 3.4%; Score 98; DB 1; Length 716;
Matches 100; Conservative 80; Mismatches 194; Indels 144; Gaps 25;

```

0y 393 LVENFDPLPYMLSLFKKLVGKCYALMASVQSKRRKLLVYLHCTTNDPRKKEGDTL 452
Db 527 LTRDPRLE--PIKWKERYCVLEI--GDMLLRSALIGMSRPMVLVFTNGTSKIKKKWGMEMR 582
0y 453 YAI--NLHNVVKYRLPYPSNKQVDKYYLLR-----PLG--PHG-----LLS 490
Db 583 RCLQSLQLOIESMI EAESSVKEKDMTK EFPENKSETWPIESPKGYEEGSIGKVCRTLLA 642
0y 491 KSV-----QLNGLLTKWVDQDTLPPLMEKPLRPS 520
Db 643 KSVFNSLYASFOEGFSAESKSKLLLVQALRDNLEPQT 680

```

Search completed: November 20, 2002, 11:36:35
Job time : 19 secs

GenCore version 5.1.3
Copyright (c) 1993 - 2002 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: November 20, 2002, 11:34:52 ; Search time 39 Seconds
(without alignments)
2868.810 Million cell updates/sec

Title: US-09-759-207-2

Perfect score: 2842
Sequence: 1 MLRSKPALPPMLLLGP.....LPASFSFVIRNAKVAACI 543

Scoring table: BIOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 671580 seqs, 206047115 residues

Total number of hits satisfying chosen parameters: 671580

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database :

SPTREMBL_21: *
1: sp_archaea: *
2: sp_bacteria: *
3: sp_fungi: *
4: sp_human: *
5: sp_invertebrate: *
6: sp_mammal: *
7: sp_mhc: *
8: sp_organelle: *
9: sp_phage: *
10: sp_plant: *
11: sp_rodent: *
12: sp_virus: *
13: sp_vertebrate: *
14: sp_unclassified: *
15: sp_virus: *
16: sp_bacteriophage: *
17: sp_archaeal: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2838	99.9	543	4	O9Y251
2	2817	99.1	543	4	O9UL39
3	2282	80.3	545	6	O9MY10
4	2123	74.7	536	11	O9QZFE
5	1645.5	57.9	523	13	O9OYK5
6	1154.5	40.6	592	4	O9HB37
7	1146.5	40.3	592	4	O8WMQ2
8	1015.5	35.7	548	4	O8WMQ1
9	936.5	33.0	534	4	O9HB38
10	897.5	31.6	480	4	O9HB39
11	696	24.5	515	5	O8T108
12	416	14.6	521	10	O9SDA1
13	416	14.6	543	10	O9PFI0
14	381	13.4	527	10	O9LRC8
15	363	12.8	536	10	O9FZP1
16	352.5	12.4	516	10	O9FLK8

17	169.5	6.0	190	10	O82604	082604 arabidopsis
18	160	5.6	935	5	O9VE79	O9VE79 drosophila
19	130.5	4.6	493	17	O9HK01	O9HK01 thermoplasma
20	122.5	4.3	408	3	O9HEZ2	O9HEZ2 phanerochaete
21	122.5	4.3	408	3	O9HEZ1	O9HEZ1 phanerochaete
22	116.5	4.1	617	12	O40996	O40996 measties vir
23	113.5	4.0	617	12	O83295	O83295 measties vir
24	113.5	4.0	1829	2	O9KH44	O9KH44 pantoea agg
25	113	4.0	390	17	O8TP47	O8TP47 methanosarc
26	112.5	4.0	617	12	O83647	O83647 measties vir
27	111.5	3.9	493	17	O97980	O97980 thermoplasma
28	111.5	3.9	575	10	O43855	O43855 vicia faba
29	111.5	3.9	617	12	O40991	O40991 measties vir
30	111.5	3.9	617	12	O98V15	O98V15 measties vir
31	111	3.9	670	10	O9M090	O9M090 arabidopsis
32	111	3.9	2319	3	O96U00	O96U00 neurospora
33	110.5	3.9	475	5	O8SU17	O8SU17 encephalito
34	109.5	3.9	617	12	O911F6	O911F6 measties vir
35	109.5	3.9	617	12	O910N9	O910N9 measties vir
36	109.5	3.9	879	16	O8XCP4	O8XCP4 escherichia
37	109	3.8	617	12	O98V76	O98V76 measties vir
38	108.5	3.8	411	16	P72895	P72895 synechocyst
39	108.5	3.8	617	12	O11381	O11381 measties vir
40	107.5	3.8	500	16	O9A5U0	O9A5U0 caulobacter
41	107.5	3.8	617	12	O89631	O89631 measties vir
42	107.5	3.8	617	12	O89764	O89764 measties vir
43	107.5	3.8	617	12	O40990	O40990 measties vir
44	107.5	3.8	617	12	O83633	O83633 measties vir
45	107.5	3.8	617	12	O83645	O83645 measties vir

ALIGNMENTS

RESULT 1
O9Y251 PRELIMINARY: PRT: 543 AA.
AC O9Y251;
DT 01-NOV-1999 (TREMBL) 12, Created)
DT 01-NOV-1999 (TREMBL) 12, Last sequence update)
DT 01-JUN-2002 (TREMBL) 21, Last annotation update)
DE HEPARANASE.
GN HPA.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE-PLACENTA;
RX MEDLINE=99321249; PubMed=10395326;
RA Hulst M.D., Freeman C., Hamdorf B.J., Baker R.T., Harris M.J.,
RA Parish C.R.;
RT "Cloning of mammalian heparanase, an important enzyme in tumor
RT invasion and metastasis."
RT Nat. Med. 5:803-809(1999).
RN [2]
RP SEQUENCE FROM N.A.
RA Vlodavsky I., Friedman Y., Elkin M., Aingorn H., Atzmon R.,
RA Ishai-Michaeli R., Bitan M., Pappo O., Peretz T., Michael I.,
RA Spector L., Pecker I.;
RT "Mammalian heparanase: a novel gene involved in tumor progression and
RT metastasis."
RT Submitted (Apr-1999) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RX MEDLINE=9937052; PubMed=10446189;
RA Toyoshima M., Nakajima M.;
RT "Human heparanase: Purification, characterization, cloning, and
RT expression."
RL J. Biol. Chem. 274:24153-24160(1999).
RN [4]
RP SEQUENCE FROM N.A.

RC TISSUE=PLACENTA; PubMed=10405343;
 RA MEDLINE=99335379; Huijmes J.D., Ludwig D., Patel S., Navarro E.C.,
 RA Kusie P.H., Huijmes J.D., Ludwig D., Patel S., Navarro E.C.,
 RA Seddon A.P., Giorgio N.A., Bohlen P.,
 RT "Cloning and Functional Expression of a Human Heparanase Gene";
 RL Biochem Biophys. Res. Commun. 261:183-187(1999).
 DR EMBL: AF165154; AAD4539.1;
 DR EMBL: AF144325; AAD41342.1;
 DR EMBL: AF155510; AAD54941.1;
 DR EMBL: AF152376; AAD54669.1;
 DR InterPro: IPR005199; Glyco_hydro_79n.
 DR Pfam: PF03662; Glyco_hydro_79n; 1.
 SO SEQUENCE 543 AA; 61176 MW; AD262EC267334AB2 CRC64;

Query Match 99.9%; Score 2838; DB 4; Length 543;
 Best Local Similarity 99.8%; Pred. No. 7.8e-214;
 Matches 542; Conservative 1; Mismatches 0; Indels 0; Caps 0;

OY 1 MLRSKRALPPMLLLGLPLSPGALPPRAQADVDLDFTOEPHLVSPFLSVT 60
 DB 1 MLRSKRALPPMLLLGLPLSPGALPPRAQADVDLDFTOEPHLVSPFLSVT 60
 OY 61 IDANLATDPPRFLILGSPKLTARGLSPAYLRFSGTKTDFLIDPKKESTFEERSYWS 120
 DB 61 IDANLATDPPRFLILGSPKLTARGLSPAYLRFSGTKTDFLIDPKKESTFEERSYWS 120
 OY 121 QVNODICKYGSIPDVEEKLRLMPYOEQLLREHYOKKFNSTYSRSSVDVLYTFANCS 180
 DB 121 QVNODICKYGSIPDVEEKLRLMPYOEQLLREHYOKKFNSTYSRSSVDVLYTFANCS 180
 OY 121 QVNODICKYGSIPDVEEKLRLMPYOEQLLREHYOKKFNSTYSRSSVDVLYTFANCS 180
 DB 121 QVNODICKYGSIPDVEEKLRLMPYOEQLLREHYOKKFNSTYSRSSVDVLYTFANCS 180
 OY 181 GLDLIFGLNALLRTADLQWSSNAQLLDYCSSKGYNISWELGNEPNSFLKKADIFING 240
 DB 181 GLDLIFGLNALLRTADLQWSSNAQLLDYCSSKGYNISWELGNEPNSFLKKADIFING 240
 OY 241 QLGEDYIOLHLKLRKSTFKNAKLGPVVGOPRRRTAKMLKSLFAGGEVIDSVTHNYL 300
 DB 241 QLGEDYIOLHLKLRKSTFKNAKLGPVVGOPRRRTAKMLKSLFAGGEVIDSVTHNYL 300
 OY 301 NGRTATREDPLNPVDLIFISSVQKVFQVESTPRGKVMLGESSAAGCAPLLSDTFA 360
 DB 301 NGRTATREDPLNPVDLIFISSVQKVFQVESTPRGKVMLGESSAAGCAPLLSDTFA 360
 OY 361 AGFMWLDLGLSARMGIEVVMKQVFFGAGNHLVDENPDLPDWSLFLFKKLVGTAVL 420
 DB 361 AGFMWLDLGLSARMGIEVVMKQVFFGAGNHLVDENPDLPDWSLFLFKKLVGTAVL 420
 OY 421 ASVGSRRRLRVYLHCNTNDNPRYKESDGLTYA1NLNHYKYLRLPYPSNKOVDXYL 480
 DB 421 ASVGSRRRLRVYLHCNTNDNPRYKESDGLTYA1NLNHYKYLRLPYPSNKOVDXYL 480
 OY 481 RPLGPHGLSKSVQNLGLTLKMDVDTLPPLMEKPLRPGSSGLPAFSYFFVIIRNAKVA 540
 DB 481 RPLGPHGLSKSVQNLGLTLKMDVDTLPPLMEKPLRPGSSGLPAFSYFFVIIRNAKVA 540
 OY 541 ACI 543
 DB 541 ACI 543

RESULT 2
 O9UL39 PRELIMINARY; PRT; 545 AA.

AC 09UL39; 01-OCT-2000 (Tremblrel. 13, Created)
 DT 01-MAY-2000 (Tremblrel. 13, Last sequence update)
 DT 01-JUN-2002 (Tremblrel. 21, Last annotation update)
 DE Heparanase.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
 OX NCBI_TaxID=9606;
 RN 11
 RP SEQUENCE FROM N.A.

RC TISSUE=PLACENTA; PubMed=10764835;
 RA MEDLINE=20229546; Dempsey L.A., Plummer T.B., Coombs S.L., Platt J.L.,
 RA "Heparanase expression in invasive trophoblasts and acute vascular
 RT damage";
 RL Glycobiology 10:467-475(2000).
 DR EMBL: AF084467; AAD5416.1;
 DR InterPro: IPR005199; Glyco_hydro_79n.
 DR Pfam: PF03662; Glyco_hydro_79n; 1.
 SO SEQUENCE 545 AA; 61418 MW; 67B80ACD73C5A9A1 CRC64;

Query Match 99.1%; Score 2817; DB 4; Length 545;
 Best Local Similarity 99.4%; Pred. No. 3.5e-212;
 Matches 542; Conservative 1; Mismatches 0; Indels 2; Caps 2;

OY 1 MLRSKRALPPMLLLGLPLSPGALPPRAQADVDLDFTOEPHLVSPFLSVT 58
 DB 1 MLRSKRALPPMLLLGLPLSPGALPPRAQADVDLDFTOEPHLVSPFLSVT 58
 OY 59 VTIDANLATDPPRFLILGSPKLTARGLSPAYLRFSGTKTDFLIDPKKESTFEERSYWS 118
 DB 59 VTIDANLATDPPRFLILGSPKLTARGLSPAYLRFSGTKTDFLIDPKKESTFEERSYWS 118
 OY 119 QSVNODICKYGSIPDVEEKLRLMPYOEQLLREHYOKKFNSTYSRSSVDVLYTFAN 178
 DB 119 QSVNODICKYGSIPDVEEKLRLMPYOEQLLREHYOKKFNSTYSRSSVDVLYTFAN 178
 OY 121 QSVNODICKYGSIPDVEEKLRLMPYOEQLLREHYOKKFNSTYSRSSVDVLYTFAN 180
 DB 121 QSVNODICKYGSIPDVEEKLRLMPYOEQLLREHYOKKFNSTYSRSSVDVLYTFAN 180
 OY 179 CSGDLIFGLNALLRTADLQWSSNAQLLDYCSSKGYNISWELGNEPNSFLKKADIFIN 238
 DB 181 CSGDLIFGLNALLRTADLQWSSNAQLLDYCSSKGYNISWELGNEPNSFLKKADIFIN 240
 OY 239 GSGEDYIOLHLKLRKSTFKNAKLGPVVGOPRRRTAKMLKSLFAGGEVIDSVTHNYL 298
 DB 241 GSGEDYIOLHLKLRKSTFKNAKLGPVVGOPRRRTAKMLKSLFAGGEVIDSVTHNYL 300
 OY 299 YLNGRTATREDPLNPVDLIFISSVQKVFQVESTPRGKVMLGESSAAGCAPLLSDT 358
 DB 301 YLNGRTATREDPLNPVDLIFISSVQKVFQVESTPRGKVMLGESSAAGCAPLLSDT 360
 OY 359 FAAGFMWLDLGLSARMGIEVVMKQVFFGAGNHLVDENPDLPDWSLFLFKKLVGTAV 418
 DB 361 FAAGFMWLDLGLSARMGIEVVMKQVFFGAGNHLVDENPDLPDWSLFLFKKLVGTAV 420
 OY 419 LMASVGSRRRLRVYLHCNTNDNPRYKESDGLTYA1NLNHYKYLRLPYPSNKOVDXY 478
 DB 421 LMASVGSRRRLRVYLHCNTNDNPRYKESDGLTYA1NLNHYKYLRLPYPSNKOVDXY 480
 OY 479 LMRPLGPHGLSKSVQNLGLTLKMDVDTLPPLMEKPLRPGSSGLPAFSYFFVIIRNAK 538
 DB 481 LMRPLGPHGLSKSVQNLGLTLKMDVDTLPPLMEKPLRPGSSGLPAFSYFFVIIRNAK 540
 OY 539 VAACT 543
 DB 541 VAACT 545

RESULT 3
 O9MY40 PRELIMINARY; PRT; 545 AA.

AC 09MY40; 01-OCT-2000 (Tremblrel. 15, Created)
 DT 01-JUN-2001 (Tremblrel. 17, Last sequence update)
 DT 01-JUN-2002 (Tremblrel. 21, Last annotation update)
 DE Heparanase.
 OS Bos taurus (Bovine).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidea;
 OX NCBI_TaxID=9913;
 RN 11
 RP SEQUENCE FROM N.A.
 RC TISSUE=PLACENTA;
 RA Kizaki K., Nakano H., Takahashi T., Imai K., Hashizume K.;

RT "Expression of Heparanase mRNA in Bovine Placenta During Gestation."
 DR Submitted (APR-2001) to the EMBL/GenBank/DBJ databases.
 RL EMBL: AF281160; AF87301.2; -.
 DR InterPro: IPR005199; Glyco_hydro_79n.
 DR Pfam: PF03662; Glyco_hydro_79n; 1.
 SO SEQUENCE 545 AA: 61076 MW; FACC4BDFED855B933 CRC64;

Query Match	80.3%	Score 2282;	DB 6;	Length 545;
Best Local Similarity	79.8%;	Pred. NO. 2.9e-170;		
Matches 435; Conservative	35;	Mismatches 73;	Indels 2;	Gaps 1.

Oy		1	MILSKRPRLPMLL--LLGPRGLSPRALPPRAQNOVDVDFDFOERLYHVSFSLT	58
Dd		1	MLACRKEQLRRPLLLRLPLGRPGSCRGPAARAADDAELEFFTERLHLIVSAFLS	60
Oy		59	VTIDANLATDRPLLIGSGPMRTLAGSLSPALRFEGSTKDELFDPRKKESTFEERSYW	118
Dd		61	FTIDANLATDRPFPTFGSSKLRTLAGSLAPARYLFCGNKGDFELFPKKKEPAFEERSYW	120
Oy		119	OSQYNODICKGSIIPROVEEKLRYEMRYOEDLLREIYOJKFKFNSTYSRSXSVULTPPAN	178
Dd		121	LSQSNODICKSGSIPSDEEEKLRLEMPFOEDVULLREYOJOKKFNTNSTYSRSXYDLTYTFAS	180
Oy		179	CSGIDLIFGLNALLRTADLOMNSNAOLLDDYCCKSYNIISWELEGNEPNSEFLKKADIFIN	238
Dd		181	CSGIANLIFGVALLRTTDIMNDSSNAOLLDDYCCKSKYNIISWELEGNEPNSEFORAKAGIFIN	240
Oy		239	GSQLGEDYIOHLKLLRKSTFRMAKLYGPDPGCPRRKTAKMLKSFLNAGEEVIDSVMYNY	298
Dd		241	GROLGEDPIEFRRKLLGKSASFNAKLYGRDIGOPRRNTRYKMLKSFLNAGEEVIDSMYNNY	300
Oy		299	YLNRGTATREDFLMRDVLDLFISSVOKVPOVESTIRGGKVVYLGESSAYOGGARPLYSDT	358
Dd		301	YVNRIATRKEDFLMRDILLDFIISVQOTLRIVERTRPKLYMWLEGESSAFAGGAPELSMT	360
Oy		359	FAAGFMMLDKTGLSARNGIEVYMWOFVFAGANGHYLVENEDPRDYLSLFFEKLVGYV	418
Dd		361	FAAGFMMLDKTGLSARNGIEVYMWOLVFGANGHYLVGENEPRLPDYLSLFFEKLVGNKY	420
Oy		419	LMAVSQSKRRRLRVLYLHCTNTONPRKYEGSDLTYALNLHNVTYRLRLPYRFSNKOVDX	478
Dd		421	LMAVSQSGDRSKRFVYLYHCTNTKHPRYKECDLTLYALNLHNVTYRLRLPHLNFKNQOVDX	480
Oy		479	LLRPLGPHGLSKSVOLNGCLTKMKVDOOTLPRLMEKRLRGSSSLGARFYSEFVLIRNKK	538
Dd		481	LKPSGDGCLSKSVOLNGOLLKMWDEOTLPALTEKRLHGSSSLGMFRSFYGFVIRNKK	540
Oy		539	VAACI 543	
Dd		541	VAACI 545	
<hr/>				
RESULT 4				
	O90Zf8			
ID	O90Zf8	PRELIMINARY:	PRT:	536 AA.
AC	O90Zf8:			
DT	01-MAY-2000 (TREMBLrel_13, Created)			
DT	01-MAY-2000 (TREMBLrel_13, Last sequence update)			
DT	01-JUN-2002 (TREMBLrel_21, last annotation update)			
DE	Heparanase.			
GN	HBP.			
OS	Rattus norvegicus (Rat).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
CC	Mammalia; Eubethia; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.			
NCBI	NCBI_TaxID=10116;			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RA	Podyma K.A., Yokote H., Sakaguchi K., Ikuta M., Yanagishita M.;			
RT	"Heparanase from parathyroid cell line.";			
RL	Submitted (SEP-1999) to the EMBL/GenBank/DDBJ databases.			
DR	EMBL: AF184967; AAF04563.1; -			
DR	InterPro: IPR005199; Glyco_hydro_79n.			
DR	Pfam: PF03662; Glyco_hydro_79n; 1.			

SO	SEQUENCE	536	AA:	60569	MM:	6208B1FFD5EE28421	CNC64:
	Query Match		74.7%;	Score 2123;	DB 11;	Length 536;	
	Best Local Similarity		75.7%;	Pred. No. 8e-158;			
	Matches 405;	Conservative	51;	Mismatches	79;	Indels	0;
						Gaps	0;

OY	9	LPRPLMLLLCPLCPPLSGALPPRAQOQDVYDJDFFQOEPLHLVSPFSLSTTDIANTLATO	68
Db	2	LRLPLLLMLMGRALTAITOGTPAGTAPPKQDVYDLEFYTKRLFOVSYPFSLSTTIDASLATO	61
OY	69	PRFLILGSPKRLTLRANGLSPAYLRFSGTKTDFLIPDKKSESTPEERSVQOSQYONDICK	128
Db	62	PRFLTFEGSPRLRALANGLSPAYLRFSGTKTDFLIPDKNEPTPEERSVQOSQYONDICG	121
OY	129	YGSIPPDVEEKLRLDEMPYQEODLRLREHYOKKFKNSTYSRSSVDVLYTFANCGLDILFGL	188
Db	122	SEVSADVLKRLQHEMPFOEILLRLREJOYREHFNKSTYSRSSVDVLYTFANCGRIDLIFGL	181
OY	189	NALLRTADLQWNNSSNAQULLDDYCSGSKGYINSMELGNPNPSFLKKAODIFINGSOULGEYIQ	248
Db	182	NALLRTPDLRNSSNAQULLLNYCSSKGYINSMELGNPNPSFWKKAQIISDGLDGEDFVE	241
OY	249	LHLKLRKSTFENAKLYGDDVQOPRRKTAKMKSPFLKAGGEYIDSVTHNHYLYNGRTPRE	308
Db	242	LHLKLLQSAFONALYGDIGOPRPGKYVKLLRSLFKAGGEYIDSLVTHNHYLYNGRVAATKE	301
OY	309	DFLNPDVLDLFTISSVQVWFQVVESTTRGCKKMYLGETSSAYGCGAPLLSDTFFAAGFMWLDK	368
Db	302	DFLSSVDVLDFTLISVQKILAKYTKEMTPGCKKMYLGETSSAYGCGAPLLSNTPFAAGFMWLDK	361
OY	369	LGLSARMGIEVVMQVQVFFGAGCNHLVDENFDLPDYWLSSLFKKLYGTVKYLMAVSQSKR	428
Db	362	LGLSAQJGIEVVMQVQVFFGAGCNHLVDENFEPLPDYWLSSLFKKLYGTVKYLMAVSQSKR	421
OY	429	RKLRYVLIHCTMDNPRKKEGDLTYALINLHNVTYLLRLPFPISKQYODKTLRLRPLGHGL	488
Db	422	SKLRVYLIHCTNVYHPRRYREGDLTYVLNLHNVTYHLRLPRMFSRPADKTLRLRPFSGDL	481
OY	489	LKSKVQJNGLGLKKWVDQOTPLMEKKPLRQSSIGLPAFVSFPFVINNAVNACT	543
Db	482	LKSKVQJNGLGLKKWVDQOTPLALTEKPLRQSSLSVAFSTGCFVINNAKIAACT	536

Query Match	57.9%	Score 1645.5	DB 13	Length 523
Best Local Similarity	60.2%	Pred. No. 2e-120		
Matches 320; Conservative	87	Mismatches 114	Indels 11	Gaps 3

[illegible]

Query Match	40.68;	Score 1154.5;	DB 4;	Length 592;
Best Local Similarity	44.28;	Pred. No. 7.1e-82;		
Matches 251;	Conservative 81;	Mismatches 199;	Indels 37;	Gaps 8;

0y 10 pEPLMLLLGLGGLSPALPR-----AQQDVVDLDFQEPGLHLYSPFSLSVTI 61
Db 24 PGLYLLALLHLSSQAGDRRLPVDRAAGLAKETLLILDVSTKPNVKNFNEFSLQL 83
62 DANLATDPRFLLLGSPKRLTLARGLSPAYLRFQGTDTDLF---DPKKESTFEERSY 117
84 DPTSIHO-GMIDPFSKRLVTLARGLSPAFLRFQGTDTDFQFONLNNPKSKGPGPDV 142

Oy	118	MOSOVNODI-----	CHXGSTRPDXEKLRLBMPQOVL-LREHYOKKFFKNST	166
Db	143	YUKNTEDDI VNSDYALDKOKCKQIAQ-	HPDYMBLELOREKAOMH.VLLEKEDOFNMYSNLI	201
Oy	165	YSRSDVLDLYPFANCGLDILJFGINALRTADLOMNSSNAOLLDLDYSSKRYNJSWEJGN	224	
Db	202	LTARSLDKDLYNFADCSQHLHJFALNALRFRNPNMSSNSALSLLKYSASKKYNI SWEJGN	265	
Oy	225	EPNSTLKKADYFJNGSOLGEDYIOLHKILKR-SIFKNAKLYGPVGOBPRKTKAMLSFL	287	
Db	262	EPNNTFTMHGRAVNGSQOLQKYIOLKSLDOPIRIYSRASLYGPIGRKKVVALDLGFM	322	
Oy	284	KAGCEVIDSYMHNYLYLKGATREDPFLNPVLIYFISYOKVOUYESTRPKKVMJGE	345	
Db	322	KVAGSTVDAYVMOICNIDGRKVVKMYDLKTYLLDLOLSOIKRJKKVNTITPRGKKIMJEG	387	
Oy	344	TSSAYGCGAPLLSDTPFAAGFMYMDIKGLSLASRIGIEVUMROYFGAGNYHVDENFDRPD	403	
Db	382	VUTTSAGCTNNLSISYAAAGFLMYLTMLCANOGIDVUYI RHSEFDHGNYNHLVDONFNPLR	444	
Oy	404	YMLSLLEFKILVSTSVULMAASVQSGSKRR-----	455	
Db	442	YMLSLTLKRLGPRVULVHVAIGLOKRRPGRVJBDKLTLYANCSNHNHNHNHNKVSITLFI	501	
Oy	455	INLHNVTKYULRPYFNSKQOYDKLRLPYLPGHGLSSVOLONGLTLKMYVDOTDPTLMEK	514	
Db	502	INLHRSRKKIKLAGTLDKDYLVNOHLLROYGEGELSKSVQDONGORLVAMVDGCTLPRLKPR	565	
Oy	515	PLRPGSSILGURPAFSYFFVIRNAKVAAC	542	
Db	562	PLRAGRTLVLRPYTMGFVYKKNVALAC	589	

```

RESULT 7
08WM02
ID 08WM02 PRELIMINARY: PRF: 592 AA.
AC 08WM02:
DT 01-MAR-2002 (TReMBLrel, 20, Created)
DT 01-MAR-2002 (TReMBLrel, 20, last sequence update)
DT 01-JUN-2002 (TReMBLrel, 21, last annotation update)
DE Heparanase 2
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=PROSTATE;
RA Pessegue Salontas B.J.O.P.S.;
RL Submitted (SEP-2000) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=PROSTATE;
RA Legoux P., Legoux R., O'Brien D., Salome M.;
RL Submitted (JAN-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL: AJ299719; CAC82491.1;
DR InterPro: IPR005199; Glyco_hydro_79n.
DR Pfam: PF03662; Glyco_hydro_79n; 1.
SO Sequence 592 AA; 66520 MW; 947884JFACDS58B CRC64;

Query Match 40.3% Score 1146.5; DB 4; Length 592;
Best Local Similarity 44.0% Pred. No. 3e-81;
Matches 250; Conservative 81; Mismatches 200; Indels 37; Gaps 8;

```

0y 62 DANLADPRFLILGSKLTTLARGSPAYLRFGCKTDFLF---DPKKESTFEERY 117
 84 DPSTLMD-GULDFSSNRLLTLAGSPAPLRFGCGRTPTFLQNLNPAKSSGCGPQY 142
 Db 24 PGALYALLLHLHSSQAGDRPRLPDVDRAGLKEKTLILLDVSTKNIVRVNENFSLQL 83
 0y 10 PPLMLLLPLGLSGALPRP-----AAQDVVDLFTFOEIRLVSSFSV71 61
 0y 10 PPLMLLLPLGLSGALPRP-----AAQDVVDLFTFOEIRLVSSFSV71 61


```

Db 194 ---SNTYS-----NLIL-----202
Oy 219 SMLGNENPFLKADIFINGSQLEDYIOLHLLRK-STFKNAKLYGPDVGOPRRKTAK 277
Db 203 -----TEPNNTYRTMHGRAVNGSOLGKXDYIOLKSLDPIRISRSALYGPNIGRKKNVIA 257
Oy 278 MLKSFLLAGGEVIDSVTHMHYLLNGRTATREDPLNPVDLFISSVOKVEOVESTRPGK 337
Db 258 LLDFPMYVAGSTVDAYVMOHCYIDGRVKKVMDPLKTRLLDPLSDQIRKIOGVNVTYTPGK 317
Oy 338 KVMLEGTSSAAGCAPLLSOTFAAGFMMLKLGISARNGIEVVMKOVFFGAGNHLVDEN 397
Db 318 KIMLEGVATTSAGGTNNLSDSYAGFLMLNTLGMLANOGIDVYIRHSFFDHGNHLVDON 377
Oy 398 FDPPLPDYVLSLFFKKLVGTYKLYMASVQSKRR-----KLRYVLIHCTNTDPRYKEG 448
Db 378 FNPPLPDYVLSLKYKRLIGPKLVAVVAGLOKPRPGVYIRKLLIYAHCTNNHNNHNVYRG 437
Oy 449 DLTLYAINLHNVTYKRLPYPPFSNKOVKYLLRPLGPHGLSKSVQNLGLTKLVNDOTL 508
Db 438 SITLFIINLHRSRKKIKIAGTLRDKLVHGYLLDPYGOEGLKSKSVQNLGQPLVVDGDTL 497
Oy 509 PRLMEKPLRPGSSLGAPAFSFFVIRAKVAAAC 542
Db 498 PELKPRPLRAGRTLVIIPVTMGFFVYKNNVALAC 531

```

```

RESULT 10
Oy 09HB39 PRELIMINARY: PRT: 480 AA.
AC 09HB39;
DT 01-MAR-2001 (TREMBLrel. 16, Created)
DT 01-MAR-2001 (TREMBLrel. 16, last sequence update)
DT 01-JUN-2002 (TREMBLrel. 21, last annotation update)
DE Heparanase-like protein HP2a.
OS Homo sapiens (human).
OC Eukaryota; Metazoa; Chordata; Cranialata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_TaxID=9606;
RN 11)
RP SEQUENCE FROM N.A.
RX MEDLINE=20483645; Pubmed=11027606;
RA McKenzie E., Tyson K., Stamps A., Smith P., Turner P., Barry R.,
RA Hircock M., Patel S., Barry E., Stubberfield C., Terrett J., Page M.;
RT "Cloning and Expression Profiling of Hpa2, a Novel Mammalian
RT Heparanase Family Member.";
RL Biochem. Biophys. Res. Commun. 276:1170-1177(2000).
DR EMBL: AF282885; AAG23421.1;
DR InterPro: IPR005199; Glyco_hydro_79n.
DR Pfam: PF03662; Glyco_hydro_79n.1;
SQ SEQUENCE 480 AA: 53900 MW: F75F89F67AC1FFB3 CRC64:

```

Query Match 31.6%; Score 897.5; DB 4; Length 480;
 Best Local Similarity 36.0%; Pred. No. 7e-62;
 Matches 202; Conservative 74; Mismatches 146; Indels 139; Gaps 9;

```

Oy 20 PLGLSPGAL-----PRPA-----QAQDVYDLDFPOEPLHLVSPS 55
Db 18 PPAALGALYALLLHLSSSQAGRRPLPVRAAGLKEKTLILLVSTKNRYTYNEN 77
Oy 56 FLVSTIDANLATDPRILLGSPKRLTLARGLSPAYLRFSGTKTDPLIF---DPKKEST 111
Db 78 FLISQDLPSTIHD-GMLDFLSSKRLVTLARCLSPAFLPFGKRTDFOQLRNPAPKSR- 135
Oy 112 FEESYNOSONODICVYGSIPRVEEKLRLKLEMPYQOLLREHYOKKFKNSYTSRSVD 171
Db 136 -----GGGPRP-----YLLKNYE-----148
Oy 172 VLYTFANCGLDLIFGLNALRLTADLOMNSNOLLDDYSSKGYNISWEIGNEPNSFLK 231
Db 149 -----DEPNRYT 156
Oy 232 KADIFINGSQLEDYIOLHLLRK-STFKNAKLYGPDVGOPRRKTAKMLKSLKAGEVIT 290

```

```

Db 157 MHGRAVNGSOLGKXDYIOLKSLDPIRISRSALYGPNIGRKKNVIALLDGFMKXAGSTV 216
Oy 291 DSVTHMHYLLNGRTATREDPLNPVDLFISSVOKVQVVESTRPGKKNVYLGESSAYGC 350
Db 217 DAVTMOHCYIDGRVKKVMDPLKTRLLDPLSDQIRKIOGVNVTYTPGKIMLEGVVTSAG 276
Oy 351 GAPLLSDTFAAGFMMLKLGISARNGIEVVMKOVFFGAGNHLVDENFDPLPYVLSLIF 410
Db 277 GTNNLSDSYAGFLMLNTLGMLANOGIDVYIRHSFFDHGNHLVDONFNLPTWLSLTY 336
Oy 411 KLVGTVLMASVQSKRR-----KLRYVLIHCTNTDPRYKEGDTLTYAINLHNVT 461
Db 337 KRLIGPKLVAVVAGLOKPRPGVYIRKLLIYAHCTNNHNNHNVYRGSTLFIINLHRSR 396
Oy 462 KYLRPLPYPPFSNKOVKYLLRPLGPHGLSKSVQNLGLTKLVNDOTLPRLMKPLRPGSS 521
Db 397 KIKLAGTLRDKLVHGYLLDPYGOEGLKSKSVQNLGQPLVVDGDTLPELKPRLRAGRT 456
Oy 522 LGAPAFSFFVIRAKVAAAC 542
Db 457 LVIPVTMGFFVYKNNVALAC 477

```

```

RESULT 11
Oy 08T108 PRELIMINARY: PRT: 515 AA.
AC 08T108;
DT 01-JUN-2002 (TREMBLrel. 21, Created)
DT 01-JUN-2002 (TREMBLrel. 21, last sequence update)
DT 01-JUN-2002 (TREMBLrel. 21, last annotation update)
DE Heparanase-like protein.
CN BHMPPA.
OS Bombyx mori (Silk moth).
OC Eukaryota; Metazoa; Arthropoda; Tracheata; Hexapoda; Insecta;
OC Pterygota; Neoptera; Endopterygota; Lepidoptera; Glossata; Ditrysia;
OC Bombycoidea; Bombycidae; Bombyx.
OX NCBI_TaxID=7091;
RN 11)
RP SEQUENCE FROM N.A.
RC STRAIN=P50; TISSUE=POSTERIOR SILK GLAND;
RA Koike Y., Simada T., Suzuki M.G., Mita K., Abe H., Maeda S.,
RA Oseogawa K., DeJong P.J.;
RT "Genomic sequence of 320kb containing a kettin orthologue on the Z
RT chromosome in Bombyx mori.";
RL Submitted (FEB-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL: AB079660; BAB85191.1;
SQ SEQUENCE 515 AA: 59769 MW: FB8100ABE6EDDADB CRC64:

```

Query Match 24.5%; Score 696; DB 5; Length 515;
 Best Local Similarity 35.1%; Pred. No. 4.8e-46;
 Matches 183; Conservative 83; Mismatches 182; Indels 74; Gaps 18;

```

Oy 46 QEPPLHLVSPSLSVTIDANLATDPRILLGSPKRLTLARGLSPAYLRFSGTKTDPLIFD 105
Db 42 QEDIKLISEDFLFGID-TIEIENVYRINSOTRLRELAALSPARLRIGTMSERLIF- 99
Oy 106 PKKESTFEESYNOSONODICVYGSIPRVEEKLRLKLEMPYQOLLREHYOKKFKNSY 165
Db 100 -SKENI-----PLSCNCSYKSYPSKSLQ-LIEKPC-----KKHAKFLPFFIM 140
Oy 166 SRSSVDLYTFANCGLDLIFGLNALRLTADLOMNSNOLLDDYSSKGYNISWEIGNE 225
Db 141 TGNEMNDINDFCKKTNLKLFLSLMAMLRD-NHGMNKNMRELIEFSKIKHOYAIOWDOLGNE 199
Oy 226 PNSFLKKADIFINGSQLEDYIOLHLLRKSTFKNAKLYGPDVGOP---RRKTAKMLKSF 282
Db 200 PMSFOHVFNEYSYPOILADFEKLRKLNNHNGYRHSLIYGVQDTPRQPHREPECLKYMIEF 259
Oy 283 LKAGEVIDSVTHMHYLLNGRTATREDPLNPVDLFISSVOKVQVVESTRPGKKNV-W 340
Db 260 LGNGSHYINVRSHOYLLNSKTAKLEDPMNPEFDLL---RDOIETMOMOTKKYKNYKPM 316

```



```

OY - 341 LGETSSAGCGGAPLLSDTFFAAGFMVLDKGLSARMKLEVMROVFPGACNTHLVDENDP 400
      |||||::|||||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db   317 LSEFSSSYGGCAGPGASNTAYTACSPMLIDKLGLSAKRNISIVINOSPLIG-GYTSVDENLKP 375

OY 401 LPDYWLSLFLFKLYCTVKVLMAVSOGSKRRKLRYVLHCTNTDNPRIKE--GDLTLYAIN-- 456
      ||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db   376 LPDMWJSLVYLKKLVGNKVLL--OVQNCNSCFORLTIHCTR---KYTNDSAVTLGVNL 430

OY 457 -----LNH-----VTIKYLRLPFPFSKQYDKYLLRPLGRHGLSKSVOLNGTL 500
      |::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db   431 MAKARFPLNGTALHDDDLIHXYI-ISAAPSNNRK-----SKTILANGMPL 474

RESULT 12
09SDA1 PRELIMINARY: PRT: 521 AA.

AC 09SDA1:
DT 01-MAY-2000 (TREMBLrel_13, Created)
DT 01-MAY-2000 (TREMBLrel_13, Last sequence update)
DT 01-JUN-2002 (TREMBLrel_21, Last annotation update)
DE Hypothetical 57.8 kDa protein.
CN F13G24.30.
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophytes; Magnoliophyta; eudicotyledons; core eudicots; Rosidae;
OC eurosids II; Brassicales; Brassicaceae; Arabidopsids.
CX NCBI_TaxId=3702;
RN [1]
RP SEQUENCE FROM N.A.
RA Bevan M., Van Der Schueren J., Chuang Y.J., Voet M., Robben J.,
RA Volckaert G., Bancroft I., Meyers H.W., Lemcke K., Mayer R.F.X.;
RL Submitted (DEC-1999) to the EMBL/Genbank/DBJ databases.
RP [2]
RP SEQUENCE FROM N.A.
RA EU Arabidopsis sequencing project;
RA Submitted (DEC-1999) to the EMBL/Genbank/DBJ databases.
RL EMBL: AL133421; CAB62595.1; -.
DR InterPro: IPR005199; Glyco_hydro_79n.
DR InterPro: IPR001254; Ser_protasee_Try.
DR Pfam: PF03662; Glyco_hydro_79n.1.
DR PROSITE: PS00135; TRYPSIN_SER; UNKNOMN_1.
KM Hypothetical protein.
SQ SEQUENCE 521 AA; 57831 MW; 07D8664AAB305CC2 CRC64;

Query Match 14.6%; Score 416; DB 10; Length 521;
Best Local Similarity 29.2%; Pred. No. 4.2e-24;
Matches 154; Conservative 68; Mismatches 184; Indels 122; Gaps 24

OY 75 LGSPKLFRLARLSFAVIRFGTGRTDFLFDPKKKESTFEERSYMQSQVNODICKYGSIFP 134
      |::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db   55 LTRPLLTAIAIKFKRLAIRIGSIDOVYIDVGNLKT-----PCR----- 94

OY 135 DVEEKLRLPEMYOEOLLREHYKKFKFN--TYSRSSV----DYLTTFANCSGIDLIF 186
      |::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db   95 -----PROKM-----NSGLRGFSKGLCHMKRMDELNSFLATGAVTF 132

OY 187 GLNALLRPAADLO-----WNSSNAQLDIDYSSKGYNI-SNELGNEPMSFLKADIPIIN 238
      |||||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db   133 CINALRGHNRHKLGKAMGAMGMDHIINODFLNTYVSGYVDSIEFGNELSC--SGVASVS 190

OY 239 GSQAGEDYIOLIKLKRSFTKNAKIYGPPVGP-----RRTKAKMKSLFKKAGEVIDSY 293
      |::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db   191 AELYGKDILVLRKDVINK-VYKNSMLHKPLVAPEGGEYEDQMRTKLEI---SGPSVADV 246

OY 294 TWHNYLYNGRT--ATREFDLNPDYLDIFISSYQKYF---QVESTRPCKKYWLGETSSA 347
      |::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db   247 THNIYNLCGNDPALVKKIMDP-----YLSQYSKTFKXDNVNOITDHGCPMASPVGSGGA 302

OY 348 YGGCAPLLSDTFFAAGFMVLDKGLSARMKLEVMMROVFPGACNTHLVDE-NFDPLPDYWL 406

```

```

Db      303  YNSGGRHVSDFPIIDSFVWLDDOLGMSARINFTKVCYQOTIYVG--GFGIQLLEKGFVYNNPDYIS 361
OY      407  SLEFKKLVKTVKLMSVOCSSRRKLRYVLIHCITNTDNPYKREGDULVAILNLHWTKYI-- 464
Db      362  ALLMRLMKGKGVLAQVOTGPP--OLRVYAHCSK-----GRAGVTLTLILNLSNOSDPTVS 413
OY      465  -----RLPYPS--NKQVDXYLLRP--LGHG--LLLSKSQOL 495
Db      414  VSNGINVVLNMSERKKSLDPLTKRPFSWIGSKASDGLNLEEHYHLIPENCVLRSKTMVL 473
OY      456  NGLTLTKMYDDQDTPLPIMEKPLRP--GSSGLPLAFYSFVFINNAKVAAC 542
Db      474  NKSLSKLPATGDIPLSL--EPVLRSVNSPLNLVPLMSISFIVLNPDSASAC 520

RESULT 13
O9FF10  O9FF10  PRELIMINARY:  PRT:  543 AA.
AC  O9FF10:
DT  01-MAR-2001 (TREMBLrel, 16, Created)
DT  01-MAR-2001 (TREMBLrel, 16, Last sequence update)
DT  01-JUN-2002 (TREMBLrel, 21, Last annotation update)
DE  Similarity to heparanase.
OS  Arabidopsis thaliana (mouse-ear cress).
OC  Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC  Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae;
OC  eucosids 11; Brassicales; Brassicaceae; Arabidopsis.
OX  NCBI_TaxID=3702;
RN  [1]
RP  SEQUENCE FROM N.A.
RC  STRAIN=COLUMBIA;
RX  MEDLINE=97471969; PubMed=9330910;
RX  Sato S., Kotani H., Nakamura Y., Kaneko T., Asamizu E., Fukami M.,
RA  Miyajima N., Tabata S.;
RT  "Structural analysis of Arabidopsis thaliana chromosome 5. I. Sequence
RT  features of the 1.6 Mb regions covered by twenty physically assigned
RT  pl clones."
RL  DNA Res. 4:215-230(1997).
DR  EMBL; AB005249; BAB0947.1;
DR  InterPro: IPR005199; Glyco_hydro_79n.
DR  InterPro: IPR001254; Ser_protease_Try.
DR  Pfam; PF03662; Glyco_hydro_79n; 1.
DR  PROSITE; PS00135; TRYPSIN_SER; UNKNOWN.1.
SO  SEQUENCE 543 AA; 60250 MW; 0FA2248948282PF6 CRC64;

Query Match 14.6%; Score 416; DB 10; Length 543;
Best Local Similarity 29.2%; Pred. No. 4.5e-24;
Matches 154; Conservative 68; Mismatches 184; Indels 122; Gaps 24;

OY 75 LGSPLRLTLARCLSPAYLRFGCTKTDPLIPDKKSEPFERSYMOSONVDICRYGSIIP 134
Db 77 LTRPLTLTAIKAFKRLRLIRIGSSLDQYIYDGNLKT-----PCR----- 116
OY 135 DVEEKLRLMEPYOEOLLREHYOKFKKS---TISRSSV-----DLYTFPANCGLDLIF 186
Db 117 -----PFQKM-----NSGLFGEFSKGLIMKRWDELNSFPLTAGAVVTF 154
OY 187 GLNALLTRADQ-----WSSNMQLLDYCSSKGYNI--SMELGNEPNSFLKADIFIN 238
Db 135 GINALRLGRHKLRKMGACGAMDIITNODPLNTVTSKGYVIDMEGENSELGG--SGVGASVS 212
OY 239 GSGLEDGYTOLIKLILKRSCTFKNAKLYGPDVCP-----RRRTAAMLSFLKAGEVIDSV 293
Db 213 AELYKDKLIYLVKDVINK--VYKNSMLHKRLILVAAPGFYEQQVYTKLEI---SGRVSVDV 268
OY 294 TWHIHYLNGRT--ATREDFLNPDVLDIFTSSQYVF---OVESTRPCKVVLGETSSA 347
Db 269 THHITINLGSQNDPALYVKIIMDPS-----YLSQVSKTFKDVNOTIEHGFMASPMWGESGA 324
OY 348 YGGGAPLILSDYFPAAGFMALDKLIGLSARMCIEVYWRQVFPFAGCNYHLVDE--NFDLPLPYWL 406
Db 325 YNSGGRHVSDFPIIDSFVWLDDOLGMSARINFTKVCYQOTIYVG--GFGIQLLEKGFVYNNPDYIS 383

```


DB 500 DLPPIEPHINSTEPTITAPYSIVFVHMNRNVVPAC 535

Search completed: November 20, 2002, 11:37:17
Job time : 40 secs

GenCore version 5.1.3
Copyright (c) 1993 - 2002 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 20, 2002, 11:31:59 : Search time 39 Seconds

(without alignments)
1855.259 Million cell updates/sec

Title: US-09-759-207-2

Perfect score: 2842
Sequence: 1 MLRSKPPALPPLMLLLGP.....LPAPSYFFVIRAKVAACT 543

Scoring table:

BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A_Geneseq_101002.*
1: /SID52/gcgdata/geneseq/geneseq-emb1/AA1980.DAT.*
2: /SID52/gcgdata/geneseq/geneseq-emb1/AA1981.DAT.*
3: /SID52/gcgdata/geneseq/geneseq-emb1/AA1982.DAT.*
4: /SID52/gcgdata/geneseq/geneseq-emb1/AA1983.DAT.*
5: /SID52/gcgdata/geneseq/geneseq-emb1/AA1984.DAT.*
6: /SID52/gcgdata/geneseq/geneseq-emb1/AA1985.DAT.*
7: /SID52/gcgdata/geneseq/geneseq-emb1/AA1986.DAT.*
8: /SID52/gcgdata/geneseq/geneseq-emb1/AA1987.DAT.*
9: /SID52/gcgdata/geneseq/geneseq-emb1/AA1988.DAT.*
10: /SID52/gcgdata/geneseq/geneseq-emb1/AA1989.DAT.*
11: /SID52/gcgdata/geneseq/geneseq-emb1/AA1990.DAT.*
12: /SID52/gcgdata/geneseq/geneseq-emb1/AA1991.DAT.*
13: /SID52/gcgdata/geneseq/geneseq-emb1/AA1992.DAT.*
14: /SID52/gcgdata/geneseq/geneseq-emb1/AA1993.DAT.*
15: /SID52/gcgdata/geneseq/geneseq-emb1/AA1994.DAT.*
16: /SID52/gcgdata/geneseq/geneseq-emb1/AA1995.DAT.*
17: /SID52/gcgdata/geneseq/geneseq-emb1/AA1996.DAT.*
18: /SID52/gcgdata/geneseq/geneseq-emb1/AA1997.DAT.*
19: /SID52/gcgdata/geneseq/geneseq-emb1/AA1998.DAT.*
20: /SID52/gcgdata/geneseq/geneseq-emb1/AA1999.DAT.*
21: /SID52/gcgdata/geneseq/geneseq-emb1/AA2000.DAT.*
22: /SID52/gcgdata/geneseq/geneseq-emb1/AA2001.DAT.*
23: /SID52/gcgdata/geneseq/geneseq-emb1/AA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2842	100.0	543	20	AAV02345
2	2842	100.0	543	21	AAAB0849
3	2842	100.0	543	21	AAV57590
4	2842	100.0	543	21	AAV52990
5	2842	100.0	543	22	AAV97635
6	2842	100.0	543	23	AB07813
7	2842	100.0	592	20	AAV02346
8	2842	100.0	592	21	AAAB0850
9	2838	99.9	543	20	AAV17082
10	2838	99.9	543	22	AAAB6206

11	2838	99.9	588	20	AAV30124	A human protein w/
12	2826	99.4	543	22	AAAB8361	Human membrane or
13	2764	97.3	530	20	AAV34173	Human pre-prohepar
14	2737	96.3	532	20	AAV17083	Seq ID No: 15 of W
15	2673.5	94.1	527	23	AB07815	Chicken signal pep
16	2146	75.5	535	21	AAAB08851	A murine heparanas
17	2146	75.5	535	23	AB07811	Mouse heparanas s
18	2123	74.7	536	23	AB07812	Rat heparanas seq
19	1645.5	57.9	523	23	AB07814	Chicken heparanas
20	1614	56.8	380	20	AAV17085	Rat heparanas enz
21	1602	56.4	380	20	AAV17084	Mouse heparanas e
22	1154.5	40.6	592	22	AAV07424	Human heparanas-1
23	1154.5	40.6	592	22	AAV7632	Human heparanas-2
24	1148.5	40.4	592	22	AAAB1052	Human heparanas-2
25	1147.5	40.4	592	22	AAAB5215	Heparanas-1 like pr
26	1142.5	40.2	582	23	AAE18336	Human heparanas-2
27	1112.5	39.1	538	22	AAV97633	Human heparanas-
28	1106.5	38.9	528	23	AAE18337	Human heparanas-
29	936.5	33.0	534	22	AAAB5216	Heparanas-1 like pr
30	936.5	33.0	534	22	AAAB5037	Human prepro-hepar
31	927.5	32.6	492	22	AAAB4664	Amino acid sequenc
32	897.5	31.6	480	22	AAU07418	Novel human extrac
33	897.5	31.6	480	22	AAAB5217	Heparanas-1 like pr
34	897.5	31.6	480	22	AAV97634	Human heparanas-
35	892.5	31.4	470	23	AAE18338	Human heparanas-2
36	891.5	31.4	439	22	AAU07423	Human heparanas-1
37	788	27.7	331	23	AAAB50383	Human heparanas-1
38	663	23.3	488	22	AAAB1469	Amino acid sequenc
39	645	22.7	488	22	AAAB1470	Amino acid sequenc
40	642	22.6	488	22	AAAB1472	Amino acid sequenc
41	622	21.9	488	22	AAAB1471	Amino acid sequenc
42	528.5	18.6	214	22	AAAB9905	Human excretory re
43	528.5	18.6	214	22	AAAB3704	Human bladder anti
44	338.5	11.9	156	22	AAAG5963	Human heparanas-1
45	277.5	9.8	256	21	AAAG3479	Arabidopsis thalia

ALIGNMENTS

RESULT 1
AAV02345
ID AAV02345 standard; Protein: 543 AA.
AC AAV02345:
XX
XX 09-JUL-1999 (first entry)
DT
XX
XX A human heparanas protein.
DE
XX
XX Heparanas: hp; modulator; heparin-binding growth factor;
KW cellular response; cytokine; cell interaction; plasma lipoprotein;
KW cellular susceptibility; infection; disintegration;
KW neurodegenerative plaque; wound healing; angiogenesis; restenosis;
KW atherosclerosis; inflammation; neurodegenerative disease; neutralise;
KW plasma heparin; micrometastasis; autoimmune lesion; renal failure.
XX
XX Homo sapiens.
XX
XX WO9911798-A1.
XX
XX PD 11-MAR-1999.
XX
XX PF 31-AUG-1998; 98WO-US17954.
XX
XX PR 02-JUL-1998; 98US-0109386.
XX
XX PR 02-SEP-1997; 97US-0922170.
XX
XX (FRIE//) FRIEDMAN M M.
XX (HADA-) HADASIT MEDICAL RES SERVICES & DEV.
XX (INST-) INSICHT STRATEGY & MARKETING LTD.
XX
XX Feinstein E, Pecker I, Vlodavsky I;

Dh 181 GLDLFGILNALLRTADLQNMSSNAQLLDLYCSSKGYINISWELGNEPNSFLKKADIFINGG 240
Oy 241 QLGEDVYQLHKLKSTFKNAKLYGPVQOPRRKTAMKLSFLKAGEVIDSVTHHYYL 300
Dh 241 QLGEDVYQLHKLKSTFKNAKLYGPVQOPRRKTAMKLSFLKAGEVIDSVTHHYYL 300
Oy 301 NGRATREDFLNPVDLFISSVOKVQVVESTPRGKWLGETSSAYGGAPLLSDTFA 360
Dh 301 NGRATREDFLNPVDLFISSVOKVQVVESTPRGKWLGETSSAYGGAPLLSDTFA 360
Oy 361 AGFWMLDKLGISARMGIEVVMROVFGAGNHLVDENFDPLPDYWLSLFKKLVGTAVLM 420
Dh 361 AGFWMLDKLGISARMGIEVVMROVFGAGNHLVDENFDPLPDYWLSLFKKLVGTAVLM 420
Oy 421 ASVQSKRRKRLRVYLHCTNTDNPVKKEGDLTLVAIINLHNVTKYLRPLPYPSNKOVDYLL 480
Dh 421 ASVQSKRRKRLRVYLHCTNTDNPVKKEGDLTLVAIINLHNVTKYLRPLPYPSNKOVDYLL 480
Oy 481 RPLGPHGLSKSVOLNGLTLKMYDDOTLPLMEKPLRPGSSLGIPAFYSFFVIRNAKVA 540
Dh 481 RPLGPHGLSKSVOLNGLTLKMYDDOTLPLMEKPLRPGSSLGIPAFYSFFVIRNAKVA 540
Oy 541 ACI 543
Dh 541 ACI 543
RESULT 3
AAV52990
ID AAV52990 standard; Protein: 543 AA.
XX
AC AAV52990:
XX
DT 02-MAR-2000 (first entry)
XX
DE Human heparanase.
XX
KW Human: heparanase; hpa; genetic modification; expression; anticancer;
KW angiogenesis; anti-angiogenic; antiproliferative; antiviral; antitumor;
KW anti-atherosclerotic; anti-inflammatory; antineurodegeneration;
KW heparan sulphate; heparin-binding growth factor; tumour angiogenesis;
KW metastasis; wound healing; restenosis; atherosclerosis; inflammation;
KW neurodegeneration; viral infection; cystic fibrosis; cancer; diagnosis;
KW micrometastasis; autoimmune lesion; kidney failure.
XX
OS Homo sapiens.
XX
PN W09957244-A1.
XX
PD 11-NOV-1999.
XX
PE 29-APR-1999: 99WO-US09256.
XX
PR 01-MAY-1998: 98US-0071618.
XX
PR 02-MAR-1999: 99US-0260038.
XX
PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
XX
PI Ben-Artzi H, Ayal-Herskovitz M, Yacoby-Zeevi O, Pecker I, Feleg Y;
PI Shlom Y;
XX
DR WPI: 2000-062144/05.
XX
DR N-PSDB: AA239195.
XX
PT Engineered cells that express recombinant heparanase, useful
PT therapeutically, e.g. for treating angiogenesis and to screen for
PT specific inhibitors, potential anticancer agents
XX
PS Claim 3: Page 107-109; 118pp; English.
XX
CC The present invention describes genetically modified cells (A) containing
CC a polynucleotide (I) that encodes a polypeptide with heparanase activity.

CC and express recombinant heparanase (II). Heparanase cleaves heparan
CC sulphate (HS) at specific intrachain sites, resulting in release of
CC heparin-binding growth factors, enzymes and proteins that are sequestered
CC by HS in basement membranes, extracellular matrix or cell surfaces. It
CC may also be implicated in tumour angiogenesis and metastases. (II) is
CC potentially useful in wound healing and for treating angiogenesis,
CC restenosis, atherosclerosis, inflammation, neurodegeneration, viral
CC infection and cystic fibrosis. It can also be used to neutralise heparin
CC (an alternative to protamine) and to screen for specific inhibitors
CC (potentially useful for treating cancer and metastases). Antibodies
CC raised against (II) are used for immunodetection and diagnosis of
CC micrometastases, autoimmune lesions and kidney failure. (A) provide (II)
CC in large quantities, in a form that is homogeneously processed and
CC activated/neutralised by a dedicated protease. The present sequence
CC represents human heparanase.
XX
SO Sequence 543 AA:
Query Match 100.0%; Score 2842; DB 21; Length 543;
Best Local Similarity 100.0%; Pred. No. 1,3e-273;
Matches 543; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1 MLRSKRALPPRLMLLLGLPLGRLSPGALPPPAQADVVDLDFPTQPLHLVSPSLVT 60
Dh 1 MLRSKRALPPRLMLLLGLPLGRLSPGALPPPAQADVVDLDFPTQPLHLVSPSLVT 60
Oy 61 IDANLATDPREFLLGSPKLTTLARGLSPAYLRFSGTKTDFLFDPKKESTFEERSYWG 120
Dh 61 IDANLATDPREFLLGSPKLTTLARGLSPAYLRFSGTKTDFLFDPKKESTFEERSYWG 120
Oy 121 QVNODICKYGSIPDVEEKRLLEMPYOEOLLRHYOKKKNSTYSRSSVDLYTFANCS 180
Dh 121 QVNODICKYGSIPDVEEKRLLEMPYOEOLLRHYOKKKNSTYSRSSVDLYTFANCS 180
Oy 181 GLDLFGILNALLRTADLQNMSSNAQLLDLYCSSKGYINISWELGNEPNSFLKKADIFINGG 240
Dh 181 GLDLFGILNALLRTADLQNMSSNAQLLDLYCSSKGYINISWELGNEPNSFLKKADIFINGG 240
Oy 241 QLGEDVYQLHKLKSTFKNAKLYGPVQOPRRKTAMKLSFLKAGEVIDSVTHHYYL 300
Dh 241 QLGEDVYQLHKLKSTFKNAKLYGPVQOPRRKTAMKLSFLKAGEVIDSVTHHYYL 300
Oy 301 NGRATREDFLNPVDLFISSVOKVQVVESTPRGKWLGETSSAYGGAPLLSDTFA 360
Dh 301 NGRATREDFLNPVDLFISSVOKVQVVESTPRGKWLGETSSAYGGAPLLSDTFA 360
Oy 361 AGFWMLDKLGISARMGIEVVMROVFGAGNHLVDENFDPLPDYWLSLFKKLVGTAVLM 420
Dh 361 AGFWMLDKLGISARMGIEVVMROVFGAGNHLVDENFDPLPDYWLSLFKKLVGTAVLM 420
Oy 421 ASVQSKRRKRLRVYLHCTNTDNPVKKEGDLTLVAIINLHNVTKYLRPLPYPSNKOVDYLL 480
Dh 421 ASVQSKRRKRLRVYLHCTNTDNPVKKEGDLTLVAIINLHNVTKYLRPLPYPSNKOVDYLL 480
Oy 481 RPLGPHGLSKSVOLNGLTLKMYDDOTLPLMEKPLRPGSSLGIPAFYSFFVIRNAKVA 540
Dh 481 RPLGPHGLSKSVOLNGLTLKMYDDOTLPLMEKPLRPGSSLGIPAFYSFFVIRNAKVA 540
Oy 541 ACI 543
Dh 541 ACI 543
RESULT 4
AAV52990
ID AAV52990 standard; Protein: 543 AA.
XX
AC AAV52990:
XX
DT 21-FEB-2000 (first entry)
XX
DE Human heparanase protein sequence.

KW Human; heparanase; hpa; diagnosis; therapy; tumour; cytostatic;
KW antidiabetic; immunomodulatory; anti-inflammatory; nephrotropic;
KW metastasis; adenocarcinoma; squamous cell carcinoma; teratocarcinoma;
KW mesothelioma; melanoma; lymphoma; leukemia; cancer; sepsis; diabetes;
KW inflammation; haemorrhagic nephritis; nephrotic syndrome;
KW autoimmune disease; anticancer; kidney disease.
OS Homo sapiens.
XX
XX MO957153-A1.
XX
XX 11-NOV-1999.
XX
XX 29-APR-1999; 99WO-US09255.
XX
XX 01-MAY-1998; 98US-0071739.
XX
XX (INSI-) INSIGHT STRATEGY & MARKETING LTD.
XX (HADA-) HADASIT MEDICAL RES SERVICES & DEV.
XX (FRIE/) FRIEDMAN M M.
XX
XX Pecker I, Vlodavsky I, Friedman Y, Perets T;
XX
XX WPI: 2000-052944/04.
XX
XX N-PSDB: AA233290.
XX
XX
XX Heparanase-specific molecular probes useful for diagnosis and
XX treatment, e.g. of tumors, and for targeted drug delivery -
XX
XX Example: Page 81-82; 90pp: English.
XX
XX The present invention describes heparanase-specific molecular probes,
XX useful for methods of detecting heparanase in situ. The probes and
XX anti-heparanase antibodies are used to detect or quantify the expression
XX of heparanase, for diagnosis and monitoring of diseases (especially
XX metastasis), for treatment of heparanase-associated diseases (e.g.
XX tumors, (adeno)carcinoma, squamous cell carcinoma, teratocarcinoma,
XX mesothelioma, melanoma, lymphoma or leukemia, a solid cancer (or its
XX metastases) derived from liver, prostate, bladder, breast, ovary
XX cervix, colon, skin, intestine, stomach, uterus and pancreas, kidney
XX disease, diabetes and inflammation, haemorrhagic nephritis, nephrotic
XX syndrome, sepsis and inflammatory or autoimmune disease), for targeted
XX drug delivery (e.g. of anticancer agents) and as research reagents.
XX The present sequence represents human heparanase, which is used in the
XX exemplification of the present invention.
XX
XX Sequence 543 AA:
SQ
Query Match 100.0%; Score 2842; DB 21; Length 543;
Best Local Similarity 100.0%; Pred. No. 1.3e-273;
Matches 543; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 301 NGRTATREDFLNDPVDLIDIFISSVQKVFQVESTRPCKKWMJGFTSSAYGGAPLSDTPA 360
OY 361 AGFMWLDKLGSLSRMGI EYVMRQVFFGAGNYHLVDENFDPLPYWLSLFFKLVGTRKVM 420
DB 361 AGFMWLDKLGSLSRMGI EYVMRQVFFGAGNYHLVDENFDPLPYWLSLFFKLVGTRKVM 420
OY 421 ASVQSKRRRLRYVLYHCTMTDNPRYKEGDTLTAI NLUHNTKYLRLPYPSNKOVDKYL 480
DB 421 ASVQSKRRRLRYVLYHCTMTDNPRYKEGDTLTAI NLUHNTKYLRLPYPSNKOVDKYL 480
OY 481 RPLGPHGLSKSVQVNLGLTKWVDOTLPLMEKPLRPSSSLGLPAFSYSPFYIRAKVA 540
DB 481 RPLGPHGLSKSVQVNLGLTKWVDOTLPLMEKPLRPSSSLGLPAFSYSPFYIRAKVA 540
OY 541 ACT 543
DB 541 ACT 543
RESULT 5
ID AAY97635 standard; Protein: 543 AA.
XX AAY97635;
XX
XX 20-APR-2001 (first entry)
XX
XX Human heparanase protein sequence.
XX
XX DE Heparanase; hnp1; wound healing; angiogenesis; restenosis; Scurvy;
XX KW atherosclerosis; inflammation; pulmonary disease; Alzheimer's disease;
XX KW neurodegenerative disease; Creutzfeldt-Jakob disease; viral infection;
XX KW gene therapy; human.
XX
XX OS Homo sapiens.
XX
XX PN WO200100643-A2.
XX
XX PD 04-JAN-2001.
XX
XX PF 19-JUN-2000; 2000WO-IL00358.
XX
XX PR 25-JUN-1999; 99US-0140801.
XX
XX (INSI-) INSIGHT STRATEGY & MARKETING LTD.
XX
XX PI Pecker I, Michael I, Itzhaki H;
XX
XX DR WPI: 2001-137930/14.
XX
XX PT New polynucleotides and polypeptides that are distantly homologous to
XX heparanase, useful in wound healing, as well as in gene therapy
XX PT protocols for angiogenesis, restenosis, atherosclerosis, or
XX PT inflammation -
XX
XX PS Disclosure: Page 64-65; 67pp: English.
XX
XX CC This sequence represents a heparanase of the invention.
XX CC The heparanase DNA and protein sequences are useful in wound healing,
XX CC angiogenesis, restenosis, atherosclerosis, inflammation, pulmonary
XX CC diseases, neurodegenerative diseases (such as Scurvy, Alzheimer's
XX CC disease, and Creutzfeldt-Jakob disease) or viral infections. The
XX CC heparanase coding sequence is particularly useful in gene therapy.
XX
XX SQ Sequence 543 AA:
Query Match 100.0%; Score 2842; DB 22; Length 543;
Best Local Similarity 100.0%; Pred. No. 1.3e-273;
Matches 543; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 MLRSKPALPPMLLLGPGLSGALPRPAQADVDLDFTFQEPHLVSPSFLSVT 60
|||||

```
Db 1 MLRSKRALPPPLMLLLGLPLGSLPGALPPRAQADVDLDFFTOEPLHLVSPSFLSVT 60
Oy 1 DANLATDPRLILLGSPKRLTLARGLSPAYLRFSGTKTDFLIPDKKESTFEERSYWS 120
Db 61 IDANLATDPRLILLGSPKRLTLARGLSPAYLRFSGTKTDFLIPDKKESTFEERSYWS 120
Oy 121 QVNODICKYGSIPRVEEKLRLKSTFKNAKLYGPDVGOPRRKTAAMKLSFLKAGCEVIDSVTHNYLL 180
Db 121 QVNODICKYGSIPRVEEKLRLKSTFKNAKLYGPDVGOPRRKTAAMKLSFLKAGCEVIDSVTHNYLL 180
Oy 181 GLDLIFGLNALRLTADLQMNSSNAQLLDYCSSKGYNISWELGNEPNSFLKKAADIFINGS 240
Db 181 GLDLIFGLNALRLTADLQMNSSNAQLLDYCSSKGYNISWELGNEPNSFLKKAADIFINGS 240
Oy 241 QLGEDYIOLHLKLRKSTFKNAKLYGPDVGOPRRKTAAMKLSFLKAGCEVIDSVTHNYLL 300
Db 241 QLGEDYIOLHLKLRKSTFKNAKLYGPDVGOPRRKTAAMKLSFLKAGCEVIDSVTHNYLL 300
Oy 301 NGRTATREDPLNPVDLDFISSVOKVFOVESTRPCKKVMGLGETSSAYGGAPLLSDTFA 360
Db 301 NGRTATREDPLNPVDLDFISSVOKVFOVESTRPCKKVMGLGETSSAYGGAPLLSDTFA 360
Oy 361 AGFMWLDKLGISARMGIEVVMROVFFGAGNHLVDENFDPLPDVYLSLFFKLVGTVKYL 420
Db 361 AGFMWLDKLGISARMGIEVVMROVFFGAGNHLVDENFDPLPDVYLSLFFKLVGTVKYL 420
Oy 421 ASVQSKRRKRLRVYLHCTNTDNPRLRYKEGDLTLAIALNLHNVTKYLRPLPFSKQYDKYLL 480
Db 421 ASVQSKRRKRLRVYLHCTNTDNPRLRYKEGDLTLAIALNLHNVTKYLRPLPFSKQYDKYLL 480
Oy 481 RPLGPHGLLSKSVOLNGLTLMKAVDQDTLPRLMEKPLRGSSIGLPAFSYSPFVIRNAKVA 540
Db 481 RPLGPHGLLSKSVOLNGLTLMKAVDQDTLPRLMEKPLRGSSIGLPAFSYSPFVIRNAKVA 540
Oy 541 ACT 543
Db 541 ACT 543

RESULT 6
ABB07813
ID ABB07813 standard; protein: 543 AA.
XX
AC ABB07813:
XX
DT 03-JUL-2002 (first entry)
XX
DE human heparanase sequence.
XX
KW heparanase; catalytic; cytosolic; antiviral; antibacterial; enzyme;
KW anti-protocoon; neuroprotective; heparin; human.
XX
OS Homo sapiens.
XX
FH key Location/Qualifiers
FT Peptide 1..35
FT /note= "signal peptide"
FT Protein 36..543
FT /note= "mature protein"
XX
PN US2002034810-A1.
XX
PD 21-MAR-2002.
XX
PF 16-AUG-2001; 2001US-0930218.
XX
PR 20-SEP-2000; 2000US-0666390.
XX
PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
XX
PI Goldsmith O, Pecker I, Vlodavsky I, Michal I, Zcharia E.
XX
DR WPI: 2002-338926/37.
```

```
XX Nucleic acid encoding avian and reptile heparanase polypeptide is
PT useful to treat various heparin-related disorders and the signal
PT peptide is useful in production of membrane-targeted or secreted
PT recombinant proteins
XX
PS Disclosure: Fig 1a: 39pp: English.
XX
CC The invention relates to an isolated avian and reptile nucleic acid,
CC encoding a polypeptide with heparanase catalytic activity. The signal
CC peptide of the nucleic acid can be used to express membrane-associated or
CC secreted proteins in heterologous expression systems. The encoded
CC polypeptides can be used to prevent tumor angiogenesis, metastasis and
CC invasion, and to intervene with pathologies associated with impaired
CC heparin-binding growth factors, cellular responses to heparin-binding
CC growth factors and cytokines, cell interaction with plasma lipoproteins,
CC cellular susceptibility to viral, protozoa and bacterial infections or
CC disintegration of neurodegenerative plaques. The present sequence
CC represents a human heparanase protein sequence used in similarity
CC studies.
XX
SQ Sequence 543 AA:
XX
Query Match 100.0% Score 2842: DB 23: Length 543:
Best Local Similarity 100.0%: Pred. No. 1.3e-273:
Matches 543: Conservative 0: Mismatches 0: Indels 0: Gaps 0:
Oy 1 MLRSKRALPPPLMLLLGLPLGSLPGALPPRAQADVDLDFFTOEPLHLVSPSFLSVT 60
Db 1 MLRSKRALPPPLMLLLGLPLGSLPGALPPRAQADVDLDFFTOEPLHLVSPSFLSVT 60
Oy 61 IDANLATDPRLILLGSPKRLTLARGLSPAYLRFSGTKTDFLIPDKKESTFEERSYWS 120
Db 61 IDANLATDPRLILLGSPKRLTLARGLSPAYLRFSGTKTDFLIPDKKESTFEERSYWS 120
Oy 121 QVNODICKYGSIPRVEEKLRLKSTFKNAKLYGPDVGOPRRKTAAMKLSFLKAGCEVIDSVTHNYLL 180
Db 121 QVNODICKYGSIPRVEEKLRLKSTFKNAKLYGPDVGOPRRKTAAMKLSFLKAGCEVIDSVTHNYLL 180
Oy 181 GLDLIFGLNALRLTADLQMNSSNAQLLDYCSSKGYNISWELGNEPNSFLKKAADIFINGS 240
Db 181 GLDLIFGLNALRLTADLQMNSSNAQLLDYCSSKGYNISWELGNEPNSFLKKAADIFINGS 240
Oy 241 QLGEDYIOLHLKLRKSTFKNAKLYGPDVGOPRRKTAAMKLSFLKAGCEVIDSVTHNYLL 300
Db 241 QLGEDYIOLHLKLRKSTFKNAKLYGPDVGOPRRKTAAMKLSFLKAGCEVIDSVTHNYLL 300
Oy 301 NGRTATREDPLNPVDLDFISSVOKVFOVESTRPCKKVMGLGETSSAYGGAPLLSDTFA 360
Db 301 NGRTATREDPLNPVDLDFISSVOKVFOVESTRPCKKVMGLGETSSAYGGAPLLSDTFA 360
Oy 361 AGFMWLDKLGISARMGIEVVMROVFFGAGNHLVDENFDPLPDVYLSLFFKLVGTVKYL 420
Db 361 AGFMWLDKLGISARMGIEVVMROVFFGAGNHLVDENFDPLPDVYLSLFFKLVGTVKYL 420
Oy 421 ASVQSKRRKRLRVYLHCTNTDNPRLRYKEGDLTLAIALNLHNVTKYLRPLPFSKQYDKYLL 480
Db 421 ASVQSKRRKRLRVYLHCTNTDNPRLRYKEGDLTLAIALNLHNVTKYLRPLPFSKQYDKYLL 480
Oy 481 RPLGPHGLLSKSVOLNGLTLMKAVDQDTLPRLMEKPLRGSSIGLPAFSYSPFVIRNAKVA 540
Db 481 RPLGPHGLLSKSVOLNGLTLMKAVDQDTLPRLMEKPLRGSSIGLPAFSYSPFVIRNAKVA 540
Oy 541 ACT 543
Db 541 ACT 543

RESULT 7
AA02346
ID AA02346 standard; protein: 592 AA.
XX
AC AA02346:
```


XX 09-JUL-1999 (first entry)
 XX
 DE A human heparanase protein.
 XX
 KW Heparanase: hpa: modulator; heparin-binding growth factor;
 KW cellular response; cytokine; cell interaction; plasma lipoprotein;
 KW cellular susceptibility; infection; disintegration;
 KW neurodegenerative plaque; wound healing; angiogenesis; restenosis;
 KW atherosclerosis; inflammation; neurodegenerative disease; neutralise;
 KW plasma heparin; micrometastasis; autoimmune lesion; renal failure.
 XX
 OS Homo sapiens.
 XX
 PN WO9911798-A1.
 XX
 PD 11-MAR-1999.
 XX
 PF 31-AUG-1998: 98WO-US17954.
 XX
 PR 02-JUL-1998: 98US-0109386.
 XX 02-SEP-1997: 97US-0922170.
 XX
 PA (FRIE/) FRIEDMAN M M.
 PA (HADA-) HADAST MEDICAL RES SERVICES & DEV.
 PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
 XX
 PI Feinstein E, Pecker I, Vlodavsky I;
 XX
 DR WPI: 1999-302255/25.
 DR N-PSDB: AAX35650.
 XX
 PT New human polynucleotide useful for treating angiogenesis,
 PT restenosis, and inflammation
 XX
 PS Claim 6: Page 65-66; 63pp: English.
 XX
 CC The specification describes a polypeptide having heparanase (hpa)
 CC activity. The recombinant protein is used as a modulator of
 CC heparin-binding growth factors, cellular responses to heparin-binding
 CC growth factors and cytokines, cell interaction with plasma lipoproteins,
 CC cellular susceptibility to viral, protozoal and bacterial infections
 CC or disintegration of neurodegenerative plaques. Heparanase may be
 CC useful for conditions such as wound healing, angiogenesis, restenosis,
 CC atherosclerosis, inflammation, neurodegenerative diseases, and viral
 CC infections. Mammalian heparanase can be used to neutralize plasma
 CC heparin, and anti-heparanase antibodies may be applied for
 CC immunodetection and diagnosis of micrometastases, autoimmune lesions,
 CC and renal failure in biopsy specimens, plasma samples, and body fluids.
 CC The present sequence represents human heparanase.
 XX
 SO Sequence 592 AA:

Query Match 100.0%; Score 2842; DB 20; Length 592;
 Best Local Similarity 100.0%; Pred. NO. 1.5e-273;
 Matches 543; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MLRSKPAALPPMLLLGLGFLSPGALPRPAQADVDVDFPTEPLHLVSPSLSYT 60
 DB 50 MLRSKPAALPPMLLLGLGFLSPGALPRPAQADVDVDFPTEPLHLVSPSLSYT 109
 QY 61 IDANLATDPRFLILGSPKLTARGLSPAYLRFSGTKTDFLFFDPKKESTFEERSYWS 120
 DB 110 IDANLATDPRFLILGSPKLTARGLSPAYLRFSGTKTDFLFFDPKKESTFEERSYWS 169
 QY 121 QVWODICKGSIIPDVEEKRLLEMPYQEOULLREHYOKKFNSTYSRSSVDVLYTFRANC 180
 DB 170 QVWODICKGSIIPDVEEKRLLEMPYQEOULLREHYOKKFNSTYSRSSVDVLYTFRANC 229
 QY 181 GDLPLTGLNALRLTADLQWSSNAOLLDDYCSSKGYNISWELGNEPNSFLKKADITFINS 240
 DB 230 GDLPLTGLNALRLTADLQWSSNAOLLDDYCSSKGYNISWELGNEPNSFLKKADITFINS 289

QY 241 QLGEDYIQLHLKLRKSTFKNAKLYGPDVGOPRRKRTAKMLKSPFKAGGEVIDSVTHHHYTL 300
 DB 290 QLGEDYIQLHLKLRKSTFKNAKLYGPDVGOPRRKRTAKMLKSPFKAGGEVIDSVTHHHYTL 349
 QY 301 NGRTATREDPLNDPVI.DIFISSYQKVFQVESTRPCKKWLGETSSAYGGAPLSDTFA 360
 DB 350 NGRTATREDPLNDPVI.DIFISSYQKVFQVESTRPCKKWLGETSSAYGGAPLSDTFA 409
 QY 361 AGFMWLDKGLSARMGIEVVMROVFFGACNHYLVDENDPLPDYWL.SLFLKLVGTRVLM 420
 DB 410 AGFMWLDKGLSARMGIEVVMROVFFGACNHYLVDENDPLPDYWL.SLFLKLVGTRVLM 469
 QY 421 ASYQSKRRRLRYVLTCTNDNPRYKGGDTLVAJNHNVTXYLR.PYPSNKNQVOKYLL 480
 DB 470 ASYQSKRRRLRYVLTCTNDNPRYKGGDTLVAJNHNVTXYLR.PYPSNKNQVOKYLL 529
 QY 481 RPLGPHGLLSKSYVOLNGLTLKAVDDOTLPLMEKPLRPSSJGLPAFYSYFFVIRNAKVA 540
 DB 530 RPLGPHGLLSKSYVOLNGLTLKAVDDOTLPLMEKPLRPSSJGLPAFYSYFFVIRNAKVA 589
 QY 541 ACI 543
 DB 590 ACI 592

RESULT 8
 ID AAB08850 standard; Protein: 592 AA.
 AC AAB08850;
 DT 15-JAN-2001 (first entry)
 XX
 DE Amino acid sequence of a human heparanase polypeptide.
 XX
 KW Human: heparanase: gene therapy; tumour; inflammation; autoimmunity;
 KW heparin-binding growth factor; cytokine; neurodegenerative plaque;
 KW wound healing; infection; burn; angiogenesis; restenosis;
 KW atherosclerosis; inflammation; neurodegenerative disease;
 KW Gerstmann-Straussler Syndrome; Creutzfeldt-Jakob disease.
 OS Homo sapiens.
 XX
 PN WO200052178-A1.
 XX
 PD 08-SEP-2000.
 XX
 PF 14-FEB-2000: 2000WO-US03542.
 XX
 PR 01-MAR-1999: 99US-0258892.
 XX
 PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
 PA (HADA-) HADAST MEDICAL RES SERVICES & DEV.
 PA (FRIE/) FRIEDMAN M M.
 PI Pecker I, Vlodavsky I, Feinstein E;
 XX
 DR WPI: 2000-579289/54.
 DR N-PSDB: AAA75053.
 XX
 PT New polynucleotides encoding a polypeptide having heparanase activity,
 PT useful in wound healing and in gene therapy, particularly in treating
 PT tumour, inflammation, autoimmunity, neurodegenerative diseases
 XX
 PS Claim 22: Page 122-123; 152pp: English.
 XX
 CC The present sequence represents a human protein with heparanase catalytic
 CC activity. The heparanase (hpa) polynucleotide is useful in gene therapy,
 CC particularly in treating tumour, inflammation or autoimmunity.
 CC Particularly, the polynucleotide is useful in modulating the
 CC bioavailability of heparin-binding growth factors, cellular responses
 CC to heparin-binding growth factors (e.g. bFGF) and cytokines
 CC (e.g. interleukin (IL)-8), cell interaction with plasma lipoproteins,

CC cellular susceptibility to certain viral and some bacterial and protozoa
CC infections, or disintegration of neurodegenerative plaques. The
CC polynucleotide is also useful in wound healing (e.g. thermal, chemical
CC or radiation burns), and in the treatment of angiogenesis, restenosis,
CC atherosclerosis, inflammation, neurodegenerative diseases (Gerstmann-
CC Strausler Syndrome or Creutzfeldt-Jakob disease), and some viral,
CC bacterial or protozoa infections.

XX Sequence 592 AA:

Query Match 100.0%; Score 2842; DB 21; Length 592;
Best Local Similarity 100.0%; Pred. No. 1,5e-273;
Matches 543; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 MLRSKPALPPMLLLGLPLGSPGALPRPAQADVDLDFFTOEPLHLVSPSLSVT 60
DB 50 MLRSKPALPPMLLLGLPLGSPGALPRPAQADVDLDFFTOEPLHLVSPSLSVT 109
OY 61 IDANLATOPRFLILGSPKRLTLAGLSPAYLRFGCTKTDPLIFDPKKESTFEERSYQMS 120
DB 110 IDANLATOPRFLILGSPKRLTLAGLSPAYLRFGCTKTDPLIFDPKKESTFEERSYQMS 169
OY 121 QVNODICKYGSIPDVEEKLRLLEMPYOEOLLRHNYOKKFKNSTYSRSSVDLYTFPANC 180
DB 170 QVNODICKYGSIPDVEEKLRLLEMPYOEOLLRHNYOKKFKNSTYSRSSVDLYTFPANC 229
OY 181 GDLIFGALNALLRTADLQWSSNAQLLDYCSSKGYNISWELGNEPNSFLKADIFINCS 240
DB 230 GDLIFGALNALLRTADLQWSSNAQLLDYCSSKGYNISWELGNEPNSFLKADIFINCS 289
OY 241 QLGEDYIQLHKLLRKSTFKNAKLYGPDVGQPRRKAKMLSKLAKGCEYIDSVTHHHYLL 300
DB 290 QLGEDYIQLHKLLRKSTFKNAKLYGPDVGQPRRKAKMLSKLAKGCEYIDSVTHHHYLL 349
OY 301 NGRTATREDFLNPVDLDFISSVOKVFOVESTPRGKKVWLGETSSAYGCGAPLLSDTFA 360
DB 350 NGRTATREDFLNPVDLDFISSVOKVFOVESTPRGKKVWLGETSSAYGCGAPLLSDTFA 409
OY 361 AGFMWLDKLGLSARMGIEVVMROVFFGAGNHLVDENFDPLPDYMLSLFFKLVGTXVLM 420
DB 410 AGFMWLDKLGLSARMGIEVVMROVFFGAGNHLVDENFDPLPDYMLSLFFKLVGTXVLM 469
OY 421 ASVQSKRRKRLRVYLACTNTDNPRIKEGDLTLAYAINLHVTKYLRPLPYFSKNOVDKYL 480
DB 470 ASVQSKRRKRLRVYLACTNTDNPRIKEGDLTLAYAINLHVTKYLRPLPYFSKNOVDKYL 529
OY 481 RPLGPHGLSKSVOLNGLTLKKWDDOTLPLMEKPLRGSSSLGLPAFSTSFVIRNAKVA 540
DB 530 RPLGPHGLSKSVOLNGLTLKKWDDOTLPLMEKPLRGSSSLGLPAFSTSFVIRNAKVA 589
OY 541 AC1 543
DB 590 AC1 592

RESULT 9
AAV17082
ID AAV17082 standard; Protein: 543 AA.
AC AAV17082:
XX 21-JUL-1999 (first entry)
DE Human heparanase enzyme.
XX
KM Heparanase: endoglucuronidase; heparan sulfate proteoglycan; enzyme;
KM metastasis; angiogenesis; wound healing; angioplasty-induced restenosis;
KM arteriosclerosis; atherosclerosis; inflammation; tissue development;
KM human; HSPG.
XX
OS Homo sapiens.
XX
PN WO9921975-A1.

XX 06-MAY-1999.
PD
XX
XX 28-OCT-1998; 98WO-AU00898.
PF
XX
XX 09-DEC-1997; 97AU-0000812.
PR
XX 28-OCT-1997; 97AU-0000062.
PR
XX
XX (AUSU) UNIV AUSTRALIAN NAT.
PA
XX
XX Freeman CG, Hamdorf BJ, Hulett MD, Parish CR;
PI
XX WPI: 1999-312956/26.
DR
XX N-PSDB: AAX37259.
DR

Polynucleotides encoding mammalian endoglucuronidases, especially
heparanases, useful to promote wound healing

PS Claim 6: Page 69-73; 112pp: English.

CC The invention relates to nucleic acid sequences that encode heparanase
CC enzymes having endoglucuronidase activity. Recombinant heparanases are
CC capable of removing the HS side chain from heparan sulfate proteoglycan
CC (HSPG). Sulfated oligosaccharides, sulfonates or HSPG can be used to
CC inhibit heparanase, this is useful for treatment of a physiological or
CC medical condition associated with elevated heparanase activity, such as
CC metastasis, angiogenesis, wound healing, angioplasty-induced restenosis,
CC arteriosclerosis, atherosclerosis and inflammation. The human, murine and
CC rat heparanases can be used to enhance wound healing, especially
CC associated with tissue development and repair. The conditions mentioned
CC above can be diagnosed using specific antibodies, and also using primers
CC and probes specific for the heparanase polynucleotides. Other uses of the
CC heparanases include sequencing sulfated molecules such as HSPG. The
CC present sequence represents a human heparanase.

SO Sequence 543 AA:

Query Match 99.9%; Score 2838; DB 20; Length 543;
Best Local Similarity 99.8%; Pred. No. 3.3e-273;
Matches 542; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1 MLRSKPALPPMLLLGLPLGSPGALPRPAQADVDLDFFTOEPLHLVSPSLSVT 60
DB 1 MLRSKPALPPMLLLGLPLGSPGALPRPAQADVDLDFFTOEPLHLVSPSLSVT 60
OY 61 IDANLATOPRFLILGSPKRLTLAGLSPAYLRFGCTKTDPLIFDPKKESTFEERSYQMS 120
DB 61 IDANLATOPRFLILGSPKRLTLAGLSPAYLRFGCTKTDPLIFDPKKESTFEERSYQMS 120
OY 121 QVNODICKYGSIPDVEEKLRLLEMPYOEOLLRHNYOKKFKNSTYSRSSVDLYTFPANC 180
DB 121 QVNODICKYGSIPDVEEKLRLLEMPYOEOLLRHNYOKKFKNSTYSRSSVDLYTFPANC 180
OY 181 GDLIFGALNALLRTADLQWSSNAQLLDYCSSKGYNISWELGNEPNSFLKADIFINCS 240
DB 181 GDLIFGALNALLRTADLQWSSNAQLLDYCSSKGYNISWELGNEPNSFLKADIFINCS 240
OY 241 QLGEDYIQLHKLLRKSTFKNAKLYGPDVGQPRRKAKMLSKLAKGCEYIDSVTHHHYLL 300
DB 241 QLGEDYIQLHKLLRKSTFKNAKLYGPDVGQPRRKAKMLSKLAKGCEYIDSVTHHHYLL 300
OY 301 NGRTATREDFLNPVDLDFISSVOKVFOVESTPRGKKVWLGETSSAYGCGAPLLSDTFA 360
DB 301 NGRTATREDFLNPVDLDFISSVOKVFOVESTPRGKKVWLGETSSAYGCGAPLLSDTFA 360
OY 361 AGFMWLDKLGLSARMGIEVVMROVFFGAGNHLVDENFDPLPDYMLSLFFKLVGTXVLM 420
DB 361 AGFMWLDKLGLSARMGIEVVMROVFFGAGNHLVDENFDPLPDYMLSLFFKLVGTXVLM 420
OY 421 ASVQSKRRKRLRVYLACTNTDNPRIKEGDLTLAYAINLHVTKYLRPLPYFSKNOVDKYL 480
DB 421 ASVQSKRRKRLRVYLACTNTDNPRIKEGDLTLAYAINLHVTKYLRPLPYFSKNOVDKYL 480

```

OY 481 RPLGPHGLSKSVOLNGLTLKMYDDOTLPLPMEKPLRPGSSGLGPAFSYSFVYIRNAKVA 540
    |||
Db 481 RPLGPHGLSKSVOLNGLTLKMYDDOTLPLPMEKPLRPGSSGLGPAFSYSFVYIRNAKVA 540
OY 541 AC1 543
    |||
Db 541 AC1 543

RESULT 10
AAB86206
ID AAB86206 standard; Protein: 543 AA.
XX
AC AAB86206;
XX
DT 24-AUG-2001 (first entry)
XX
DE Human heparanase inhibitor protein.
XX
KW Heparanase; inhibitor; cardiac insufficiency; cardiast; nephrotropic;
KW hepatotropic; veterinary medicine; congestive heart failure; dyspnoea;
KW primary cardiomyopathy; peripheral odema; pulmonary congestion;
KW hepatic congestion; hydrothorax; ascite; nocturia; human.
XX
OS Homo sapiens.
XX
PN DEJ9955803-AJ.
XX
PD 23-MAY-2001.
XX
PF 19-NOV-1999; 99DE-1055803.
XX
PR 19-NOV-1999; 99DE-1055803.
XX
PA (KNOL ) KNOLL AG.
PI Herr D, Hahn A, Laux V;
XX
DR WPI: 2001-368371/39.
DR N-PSDB: AAH20940.
XX
PT Treatment or prevention of cardiac insufficiency and related
PT conditions, e.g. pulmonary congestion and dyspnoea, comprises
PT administration of heparanase inhibitor
XX
PS Disclosure: Page 11-13; 16pp; German.
XX
CC This invention describes a novel heparanase inhibitor which can be used
CC for the treatment or prevention of cardiac insufficiency and associated
CC indications, symptoms and/or malfunctions. The heparanase inhibitor of
CC the invention has cardiast, nephrotropic and hepatotropic activity. The
CC products of the invention can be used in human and veterinary medicine,
CC for the treatment or prevention of congestive heart failure e.g. primary
CC cardiomyopathy. Associated conditions treated or prevented with the
CC inhibitor are especially peripheral odemas, pulmonary and hepatic
CC congestion, dyspnoea, hydrothorax and ascites. Renal problems, e.g.
CC nocturia can also be treated. This sequence represents the human
CC heparanase protein described in the method of the invention.
XX
SQ Sequence 543 AA:

Query Match 99.9%; Score 2838; DB 22; Length 543;
Best Local Similarity 99.8%; Pred. No. 3.3e-273;
Matches 542; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```

```

OY 121 QVNDICKYGSIPPEVEEKRLPEPYOEOLLEREHYOKKFNKSTYSRSSVDVLYTFRANCS 180
    |||
Db 121 QVNDICKYGSIPPEVEEKRLPEPYOEOLLEREHYOKKFNKSTYSRSSVDVLYTFRANCS 180
OY 181 GLDLIFGLNALLRTADLQNNSSNAQLLDYCSSKGYNISWELGNEPNSFLKADIFJNGS 240
    |||
Db 181 GLDLIFGLNALLRTADLQNNSSNAQLLDYCSSKGYNISWELGNEPNSFLKADIFJNGS 240
OY 241 QLGEDYIQLHKLKSTFNNAKLYGPDVQOPRRKTKAKMLKSPFKAGEVIDSTWHHHYTL 300
    |||
Db 241 QLGEDYIQLHKLKSTFNNAKLYGPDVQOPRRKTKAKMLKSPFKAGEVIDSTWHHHYTL 300
OY 301 NGRTATREDFLNPVDLDFITSSQKVFQVVESTRPCKKWLGETSSAYGCGAPLISDTFA 360
    |||
Db 301 NGRTATREDFLNPVDLDFITSSQKVFQVVESTRPCKKWLGETSSAYGCGAPLISDTFA 360
OY 361 AGFMWLDKLGLSARMGIEVVMROVFFGAGNYHLVDENFDPPLDPYWLSTLFFKKLYGTRVLM 420
    |||
Db 361 AGFMWLDKLGLSARMGIEVVMROVFFGAGNYHLVDENFDPPLDPYWLSTLFFKKLYGTRVLM 420
OY 421 ASVQSKRRKRLRYLHCTNTDNPRYEGDLTLALNLHVTYKTLRLPYPSKQVDKYL 480
    |||
Db 421 ASVQSKRRKRLRYLHCTNTDNPRYEGDLTLALNLHVTYKTLRLPYPSKQVDKYL 480
OY 481 RPLGPHGLSKSVOLNGLTLKMYDDOTLPLPMEKPLRPGSSGLGPAFSYSFVYIRNAKVA 540
    |||
Db 481 RPLGPHGLSKSVOLNGLTLKMYDDOTLPLPMEKPLRPGSSGLGPAFSYSFVYIRNAKVA 540
OY 541 AC1 543
    |||
Db 541 AC1 543

```

```

RESULT 11
AAV30124
ID AAV30124 standard; Protein: 588 AA.
XX
AC AAV30124;
XX
DT 14-OCT-1999 (first entry)
XX
DE A human protein with heparanase activity.
XX
KW Human; heparanase; heparan sulfate; trauma; autoimmune disease;
KW skin disease; cardiovascular disease; nervous system disease;
KW Alzheimer's disease; cancer; cancer metastasis; angiogenesis;
KW inflammation; arthritis.
XX
OS Homo sapiens.
XX
PN WO9940207-A1.
XX
PD 12-AUG-1999.
XX
PF 05-FEB-1999; 99WO-EP00777.
XX
PR 09-FEB-1999; 98GB-0002725.
XX
PA (NOVS ) NOVARTIS-ERFINDUNGEN VERW GES MBH.
PI Nakajima M, Toyoshima M;
XX
DR WPI: 1999-494300/41.
DR N-PSDB: AAX8671.
XX
PT New heparanase polypeptide useful for treating autoimmune diseases,
PT skin diseases, cardiovascular diseases and nervous system diseases
PT including Alzheimer's disease
XX
PS Claim 3; Page 29-31; 40pp; English.
XX
CC The present sequence represents a polypeptide with human heparanase
CC biological activity. Antagonists and inhibitors of the protein prevent

```

CC it from degrading the extracellular matrix and releasing heparan sulfate
 CC from the extracellular matrix surface. The heparanase protein or the
 CC anti-heparanase antibody are used in pharmaceutical compositions for
 CC treating warm blooded animals suffering from a disease resulting from
 CC shortage or lack of the heparanase protein, or from excessive activity
 CC or over-expression of the heparanase protein, respectively. The
 CC heparanase protein is used in treating diseases such as trauma,
 CC autoimmune disease, skin diseases, cardiovascular diseases and nervous
 CC system diseases including Alzheimer's disease resulting from shortage or
 CC lack of polypeptide. The anti-heparanase antibody is used in treating
 CC the diseases like cancer, cancer metastasis, angiogenesis and
 CC inflammation including arthritis resulting from excessive activity or
 CC over expression of heparanase protein. The anti-heparanase antibody can
 CC be used to detect the presence or absence of polypeptide and its
 CC concentration.

SO Sequence 588 AA:

Query Match 99.98: Score 2838: DB 20: Length 588:
 Best Local Similarity 99.88: Pred. No. 3.8e-273:
 Matches 542: Conservative 1: Mismatches 0: Indels 0: Gaps 0:

OY 1 MLRSKPALPPMLLLGLGPGALPPPAOAOVDVLDFTFOEPHLVSPFLSVT 60
 DB 46 MLRSKPALPPMLLLGLGPGALPPPAOAOVDVLDFTFOEPHLVSPFLSVT 105

OY 61 IDANLATDPRFLLILGSPKLTARGLSPAYLRFGGTKTDFLJFDPKKESTFEERSYWG 120
 DB 106 IDANLATDPRFLLILGSPKLTARGLSPAYLRFGGTKTDFLJFDPKKESTFEERSYWG 165

OY 121 QVNODICKYGSIPPDVEEKLRLMPYOEOLLLREHYOKKKNSTYSSSDVLYTPANC 180
 DB 166 QVNODICKYGSIPPDVEEKLRLMPYOEOLLLREHYOKKKNSTYSSSDVLYTPANC 225

OY 181 GLDLIFGLNLLPTADLQWNSNAQLLDYCSSKGYNISWELGNEPSPFLKKADIFING 240
 DB 226 GLDLIFGLNLLPTADLQWNSNAQLLDYCSSKGYNISWELGNEPSPFLKKADIFING 285

OY 241 QLGEDYIQLHKLRLKSTFKNAKLYGPVGOGRKRTAKMLKSFLLAGEVVIDSVTHNYL 300
 DB 286 QLGEDYIQLHKLRLKSTFKNAKLYGPVGOGRKRTAKMLKSFLLAGEVVIDSVTHNYL 345

OY 301 NGRTATREDPLNPVDLFISSVOKVQVVESTTRPKKWWLGETSSAYGGAPLLSTFA 360
 DB 346 NGRTATREDPLNPVDLFISSVOKVQVVESTTRPKKWWLGETSSAYGGAPLLSTFA 405

OY 361 AGFAMLLKLGISARNGIEVWVROVFGAGNYHLVDENDDLPDYLWLSLFLKKGTVYLM 420
 DB 406 AGFAMLLKLGISARNGIEVWVROVFGAGNYHLVDENDDLPDYLWLSLFLKKGTVYLM 465

OY 421 ASVOGSKRRKRLVYLHCTNTDNPRYKGGDLTLVAJNLHNTKYLRLPYPSNKOVDKYL 480
 DB 466 ASVOGSKRRKRLVYLHCTNTDNPRYKGGDLTLVAJNLHNTKYLRLPYPSNKOVDKYL 525

OY 481 RPLGPHGLSKSVOLNGLTLKAVDQTLPLMEKPLRPGSSLGIPARSYSFFVIRNAKVA 540
 DB 526 RPLGPHGLSKSVOLNGLTLKAVDQTLPLMEKPLRPGSSLGIPARSYSFFVIRNAKVA 585

OY 541 ACI 543
 DB 586 ACI 588

RESULT 12
 AAB88361
 ID AAB88361 standard: Protein: 543 AA.

XX AAB88361:

XX 23-MAY-2001 (first entry)

XX Human membrane or secretory protein clone PSEC0090.

DE

KW Human: secretory protein; membrane protein; vaccine; gene therapy;
 KW rheumatoid arthritis; diabetes.

XX Homo sapiens.

XX EP1067182-A2.

XX 10-JAN-2001.

XX 07-JUL-2000: 2000EP-0114090.

XX 08-JUL-1999: 99JP-0194179.

XX 11-JAN-2000: 2000JP-0118175.

XX 02-MAY-2000: 2000JP-0183766.

XX (HELI-) HELIX RES INST.

PI Ota T, Isogai T, Nishikawa T, Kawai Y, Sugiyama T, Hayashi K.

DR WPI: 2001-093989/11.

DR N-PSDB: AAF93788.

PS Claim 1: SEQ ID 90: 609pp + CD ROM: English.

XX This invention relates to nucleic acid sequences AAF93744 - AAF93916

CC which encode human secretory or membrane proteins represented by

CC AAB88317 - AAB88419. Included in the invention are primers

CC AAF93917 - AAF94295 and AAF62232 - AAF62235 which are used to isolate the

CC cDNA sequences of the invention. The invention also includes methods for

CC the production of antibodies directed against the proteins, and cDNA

CC sequences, which can be used in vaccines. The polynucleotide sequences

CC can be used in gene therapy. The polynucleotide sequences and the

CC proteins they encode may be used in the prevention, treatment and

CC diagnosis of diseases associated with inappropriate secretory

CC protein/membrane protein expression. The nucleic acids and complementary

CC sequences may also be used as DNA probes in diagnostic assays

CC (e.g. polymerase chain reactions (PCR)) to detect and quantitate the

CC presence of similar nucleic acid sequences in samples. They may also be

CC used to study the expression and function of secretory proteins/membrane

CC polypeptides and their role in metabolism. The polypeptides may be used

CC as antigens in the production of antibodies against them and in assays to

CC identify modulators (agonists and antagonists) of expression and

CC activity. The antibodies and antagonists may also be used as therapeutic

CC agents to down regulate expression and activity. The antibodies may also

CC be used as diagnostic agents for detecting the presence of the

CC polypeptides in samples (e.g. by enzyme linked immunosorbent assay

CC (ELISA). Examples of diseases which may be treated include rheumatoid

CC arthritis and diabetes.

SO Sequence 543 AA:

Query Match 99.48: Score 2826: DB 22: Length 543:
 Best Local Similarity 99.48: Pred. No. 5.2e-272:
 Matches 540: Conservative 2: Mismatches 1: Indels 0: Gaps 0:

OY 1 MLRSKPALPPMLLLGLGPGALPPPAOAOVDVLDFTFOEPHLVSPFLSVT 60

DB 1 MLRSKPALPPMLLLGLGPGALPPPAOAOVDVLDFTFOEPHLVSPFLSVT 60

OY 61 IDANLATDPRFLLILGSPKLTARGLSPAYLRFGGTKTDFLJFDPKKESTFEERSYWG 120

DB 61 IDANLATDPRFLLILGSPKLTARGLSPAYLRFGGTKTDFLJFDPKKESTFEERSYWG 120

OY 121 QVNODICKYGSIPPDVEEKLRLMPYOEOLLLREHYOKKKNSTYSSSDVLYTPANC 180

DB 121 QVNODICKYGSIPPDVEEKLRLMPYOEOLLLREHYOKKKNSTYSSSDVLYTPANC 180

OY 181 GLDLIFGLNLLPTADLQWNSNAQLLDYCSSKGYNISWELGNEPSPFLKKADIFING 240

DB 181 GLDLIFGLNLLPTADLQWNSNAQLLDYCSSKGYNISWELGNEPSPFLKKADIFING 240

```

OY 241 QIACEDYIOLHKLRLKSTFKNAKLYGPDVCGPRKRTAKMLKSFLLKAGGEVIDSTVHHYYL 300
    |||||
DB 241 QIACEDYIOLHKLRLKSTFKNAKLYGPDVCGPRKRTAKMLKSFLLKAGGEVIDSTVHHYYL 300
OY 301 NGRTATREDFLNPVDLIDFISVQKVFQVVESTRPCKKWLGETSSAYGGAPLLSDTFA 360
    |||||
DB 301 NGRTATREDFLNPVDLIDFISVQKVFQVVESTRPCKKWLGETSSAHGCGAPLLSDTFA 360
OY 361 AGFMWLDKGLSARMGIEVVMKQVFFGAGNYHLVDENFDPLPDYWLSLFFKKLVGTRVLM 420
    |||||
DB 361 AGFMWLDKGLSARMGIEVVMKQVFFGAGNYHLVDENFDPLPDYWLSLFFKKLVGTRVLM 420
OY 421 ASVOGSKRRRLRYLHCTNTDNPYKGGDLTLAIINLHVNTKYLRLPYPSNKQOVOKYLL 480
    |||||
DB 421 ASVOGSKRRRLRYLHCTNTDNPYKGGDLTLAIINLHVNTKYLRLPYPSNKQOVOKYLL 480
OY 481 RPLGPHGLLSKSVOLNGLTLKMYDDOTLPLMEKPLRPSSSLGLPAFVSFFVIIRAKVA 540
    |||||
DB 481 RPLGPHGLLSKSVOLNGLTLKMYDDOTLPLMEKPLRPSSSLGLPAFVSFFVIIRAKVA 540
OY 541 AC1 543
    |||
DB 541 AC1 543

RESULT 13
AAV34173
ID AAV34173 standard; Protein: 530 AA.
AC AAV34173;
XX
DT 15-NOV-1999 (first entry)
DE Human pre-proheparanase protein sequence.
XX
KW Human; pre-proheparanase; platelet; wound healing; angiogenesis blocker;
KW inflammation; psoriasis; diabetic retinopathy; solid tumour; arthritis;
KW heparin degradation; anticoagulant neutralisation; asthma; CDS disease;
KW inflammatory disease; vascular restenosis; atherosclerosis; diagnosis;
KW tumour growth; fibroproliferative disorder; neurodegenerative disease;
KW therapy.
XX
OS Homo sapiens.
XX
PN WO9943830-A2.
XX
PD 02-SEP-1999.
XX
PF 18-FEB-1999; 99MO-US01489.
XX
PR 26-MAR-1998; 98US-0079401.
PR 24-FEB-1998; 98US-0075706.
XX
PA (PHAA ) PHARMACIA & UPJOHN CO.
XX
PI Fairbanks MB, Heinrikson RL, Mildner AM;
XX
DR WPI: 1999-540598/45.
DR N-PSDB: AAC11236.
XX
PT New isolated platelet heparanase polypeptides, used to develop
XX products for, e.g. wound healing and blocking angiogenesis
XX
PS Claim 12: Fig 7: 57pp: English.
XX
CC This sequence is the human pre-proheparanase of the invention. This
CC sequence was isolated from human platelets. The heparanase can be used
CC for identifying agents which alter heparanase activity. The heparanase
CC can be used for wound healing or for blocking angiogenesis or
CC inflammation. It can be used for treating e.g. psoriasis, diabetic
CC retinopathy or solid tumours, or for the degradation of heparin and the
CC neutralisation of heparin's anticoagulant properties during surgery.

```

```

CC Inhibitors of heparanase activity can be used in the treatment of
CC arthritis, asthma, and other inflammatory diseases, vascular restenosis,
CC atherosclerosis, tumour growth and progression, fibroproliferative
CC disorders, and central nervous system (CNS) and neurodegenerative
CC diseases. The products can also be used for detection and diagnosis. The
CC purified heparanase, both recombinantly produced human heparanase and
CC heparanase isolated from human platelet activity, allows for the
CC convenient selection of compounds having anti-heparanase activity,
CC i.e. inhibitors of heparanase activity, by measuring inhibition of
CC heparanase activity. Inhibition of heparanase activity can be measured by
CC blocking heparanase-mediated release of radioactive fragments from in
CC vivo radiolabelled (HSPG)/heparin.
XX
SQ Sequence 530 AA:
XX
Query Match 97.3%; Score 2764; DB 20; Length 530;
Best Local Similarity 99.4%; Pred. No. 7,4e-266;
Matches 527; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
OY 14 MLLLGPLGLPSPGALPPAODVVDLDFEFOEPLHVSFSLSTIDANLATDPRFLI 73
    |||||
DB 1 MLLLGPLGLPSPGALPPAODVVDLDFEFOEPLHVSFSLSTIDANLATDPRFLI 60
OY 74 LIGSPKRLTARGLSPAYLRFSGTKTDPLIPPKKESTFEERSYMOQVNOIDCKYGSIP 133
    |||||
DB 61 LIGSPKRLTARGLSPAYLRFSGTKTDPLIPPKKESTFEERSYMOQVNOIDCKYGSIP 120
OY 134 PVEEKLRLMPYOEOLLRHNYOKKFNKSTYSRSSVDVLYFPANCSDGLIFGLNALLR 193
    |||||
DB 121 PVEEKLRLMPYOEOLLRHNYOKKFNKSTYSRSSVDVLYFPANCSDGLIFGLNALLR 180
OY 194 TADLQWSSNAOILLDYCSSKGYNISWELGNPNSTFKADIFINGSOIGEDYIOLHKL 253
    |||||
DB 181 TADLQWSSNAOILLDYCSSKGYNISWELGNPNSTFKADIFINGSOIGEDYIOLHKL 240
OY 254 RKSTFKNAKLYGPDVCGPRKRTAKMLKSFLLKAGGEVIDSTVHHYYLNGRTATREDFLNP 313
    |||||
DB 241 RKSTFKNAKLYGPDVCGPRKRTAKMLKSFLLKAGGEVIDSTVHHYYLNGRTATREDFLNP 300
OY 314 DYLDIFISSVQKVFQVVESTRPCKKWLGETSSAYGGAPLLSDTFAAGFMWLDKGLSA 373
    |||||
DB 301 DYLDIFISSVQKVFQVVESTRPCKKWLGETSSAYGGAPLLSDTFAAGFMWLDKGLSA 360
OY 374 RMGIEVVMKQVFFGAGNYHLVDENFDPLPDYWLSLFFKKLVGTRVLMASVOGSKRRRLRY 433
    |||||
DB 361 RMGIEVVMKQVFFGAGNYHLVDENFDPLPDYWLSLFFKKLVGTRVLMASVOGSKRRRLRY 420
OY 434 YLHCTNTDNPYKGGDLTLAIINLHVNTKYLRLPYPSNKQOVOKYLLRPLGPHGLLSKV 493
    |||||
DB 421 YLHCTNTDNPYKGGDLTLAIINLHVNTKYLRLPYPSNKQOVOKYLLRPLGPHGLLSKV 480
OY 494 QNLGLTLKMYDDOTLPLMEKPLRPSSSLGLPAFVSFFVIIRAKVAACI 543
    |||||
DB 481 QNLGLTLKMYDDOTLPLMEKPLRPSSSLGLPAFVSFFVIIRAKVAACI 530

RESULT 14
AAV17083
ID AAV17083 standard; Protein: 532 AA.
XX
AC AAV17083;
XX
DT 21-JUL-1999 (first entry)
XX
DE Seq ID No: 15 of WO9921975.
XX
XX
KW Heparanase; endoglyuronidase; heparan sulfate proteoglycan; enzyme;
KW metastasis; angiogenesis; wound healing; angioplasty-induced restenosis;
KW arteriosclerosis; atherosclerosis; inflammation; tissue development;
KW human; HSPG.
XX
OS Homo sapiens.
XX

```

PN W09921975-A1.
XX
PD 06-MAY-1999.
XX
PF 28-OCT-1998: 98MO-AU00898.
XX
PR 09-DEC-1997: 97AU-0000812.
PR 28-OCT-1997: 97AU-0000062.
XX
PA (AUSU) UNIV AUSTRALIAN NAT.
XX
PI Freeman CG, Hamdorf BJ, Hulett MD, Parish CR;
XX
XX WPI: 1999-312956/26.
DR N-PSDB: AAX37260.
XX
PT Polynucleotides encoding mammalian endoglucuronidases, especially
PT heparanases, useful to promote wound healing
PS
PS Claim 6: Page 76-79; 112pp: English.
XX
XX The invention relates to nucleic acid sequences that encode heparanase
CC enzymes having endoglucuronidase activity. Recombinant heparanases are
CC capable of removing the HS side chain from heparan sulfate proteoglycan
CC (HSPG). Sulfated oligosaccharides, sulphates or HSPG can be used to
CC inhibit heparanase, this is useful for treatment of a physiological or
CC medical condition associated with elevated heparanase activity, such as
CC metastasis, angiogenesis, wound healing, angioplasty-induced restenosis,
CC arteriosclerosis, atherosclerosis and inflammation. The human, murine and
CC rat heparanases can be used to enhance wound healing, especially
CC associated with tissue development and repair. The conditions mentioned
CC above can be diagnosed using specific antibodies, and also using primers
CC and probes specific for the heparanase polynucleotides. Other uses of the
CC heparanases include sequencing sulfated molecules such as HSPG.
XX
SO Sequence 532 AA:

Query Match 96.3%; Score 2737; DB 20; Length 532;
Best Local Similarity 99.8%; Pred. No. 3.6e-263;
Matches 522; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1 MLRSKRALPPMLLLGLPGLSRGALPPRAQADVDVDFFTOEPLHLVSPSFLSVT 60
DB 1 MLRSKRALPPMLLLGLPGLSRGALPPRAQADVDVDFFTOEPLHLVSPSFLSVT 60
OY 61 IDANLATDPRFLILGSPKRLTARGLSPAYLRFSGTGTDFLPPPKKESTFEERSYQMS 120
DB 61 IDANLATDPRFLILGSPKRLTARGLSPAYLRFSGTGTDFLPPPKKESTFEERSYQMS 120
OY 121 QVNODICKYGSIPDVEEKLRLMPYOEQLLREHYOKKFKNSTYSRSSVDVLYTFANCS 180
DB 121 QVNODICKYGSIPDVEEKLRLMPYOEQLLREHYOKKFKNSTYSRSSVDVLYTFANCS 180
OY 181 GUDLFGNALRLTADLQWNSNMAQLLDYCSSKGYNISWELGNEPNPFLKKADLFIINGS 240
DB 181 GUDLFGNALRLTADLQWNSNMAQLLDYCSSKGYNISWELGNEPNPFLKKADLFIINGS 240
OY 241 QLGEDYIOLHLKLRKSTFKNAKLYGPDVGOPRRKTAAMKLSFKAGCEVDSVTNNHYL 300
DB 241 QLGEDYIOLHLKLRKSTFKNAKLYGPDVGOPRRKTAAMKLSFKAGCEVDSVTNNHYL 300
OY 301 NGRTATREDFLNPVDLDFISSVQKVFQVESTPRGKVMUGETSSAYGGAPLLSDTFA 360
DB 301 NGRTATREDFLNPVDLDFISSVQKVFQVESTPRGKVMUGETSSAYGGAPLLSDTFA 360
OY 361 AGFMILDLKLGLSARMGIEVMQVFFGAGNHLVDENFDPLPDYVLSLFFKLVSTKYL 420
DB 361 AGFMILDLKLGLSARMGIEVMQVFFGAGNHLVDENFDPLPDYVLSLFFKLVSTKYL 420
OY 421 ASVQSSKRRKRLVLYLACTNTDNPARYKEGDLTYAINLNNVKKYLRAPPFSKKQYDKYL 480
DB 421 ASVQSSKRRKRLVLYLACTNTDNPARYKEGDLTYAINLNNVKKYLRAPPFSKKQYDKYL 480

OY 481 RPLGPHGLSKSVQNLGTLTKMVDQTLPLPMEXPLRPGSSLG 523
DB 481 RPLGPHGLSKSVQNLGTLTKMVDQTLPLPMEXPLRPGSSLG 523

RESULT 15
ABB07815
ID ABB07815 standard; protein: 527 AA.
XX
AC ABB07815;
XX
DT 03-JUL-2002 (first entry)
XX
XX Chicken signal peptide/human heparanase chimeric protein sequence.
DE
DE Heparanase; catalytic; cytosolic; antiviral; antibacterial; enzyme;
KW anti-protozoan; neuroprotective; heparin; chicken; human; chimeric.
XX
XX Synthetic.
OS Gallus gallus.
OS Homo sapiens.
XX
XX Key location/Qualifiers
FT Peptide 1..19
FT /note= "chicken heparanase signal peptide"
FT Protein 20..527
FT /note= "human heparanase mature protein"
XX
PN US2002034810-A1.
XX
XX 21-MAR-2002.
PD
PD 16-AUG-2001; 2001US-0930218.
PF
PF 20-SEP-2000; 2000US-0666390.
PR
PR (INST-) INSIGHT STRATEGY & MARKETING LTD.
PA Goldsmith O, Pecker I, Vlodavsky I, Michal I, Zcharja E;
XX WPI: 2002-338926/37.
XX N-PSDB: ABL40753.
DR
DR Nucleic acid encoding avian and reptile heparanase polypeptide is
PT useful to treat various heparin-related disorders and the signal
PT peptide is useful in production of membrane-targeted or secreted
PT recombinant proteins
XX
PS Disclosure: Page 26-28; 39pp: English.
XX
XX The invention relates to an isolated avian and reptile nucleic acid,
CC encoding a polypeptide with heparanase catalytic activity. The signal
CC peptide of the nucleic acid can be used to express membrane-associated or
CC secreted proteins in heterologous expression systems. The encoded
CC polypeptides can be used to prevent tumor angiogenesis, metastasis and
CC invasion, and to intervene with pathologies associated with impaired
CC heparin-binding growth factors, cellular responses to heparin-binding
CC growth factors and cytokines, cell interaction with plasma lipoproteins,
CC cellular susceptibility to viral, protozoa and bacterial infections or
CC disintegration of neurodegenerative plaques. The present sequence
CC represents a chicken signal peptide/human heparanase chimeric protein
CC sequence.
XX
SO Sequence 527 AA:

Query Match 94.1%; Score 2673.5; DB 23; Length 527;
Best Local Similarity 96.8%; Pred. No. 7.6e-257;
Matches 514; Conservative 4; Mismatches 4; Indels 9; Gaps 1;

OY 13 LMLLLGLPLGSLPGALPPRAQADVDVDFFTOEPLHLVSPSFLSVTIDANLATDPRFL 72
DB 6 LTVLL-----AVPRRTADVDVDFFTOEPLHLVSPSFLSVTIDANLATDPRFL 56

OY	73	ILCSPKRLTJLARGISPLVJLAFEGSTKIDFLIDFKKSTSEERSYUOSQVONODICXGSI	132
Db	57	ILJGSPKRLTJLARGISPLVJLAFEGSTKIDFLIDFKKSTSEERSYUOSQVONODICXGSI	116
OY	133	PPDVEEKRLJEMPYOEOLLRJENHOKFKKNSTYSRSSVDVLYTFANCSGLJDLJFGLNALI	192
Db	117	PPDVEEKRLJEMPYOEOLLRJENHOKFKKNSTYSRSSVDVLYTFANCSGLJDLJFGLNALI	176
OY	193	RTADJLONHNSNAQJLLDDYCSSKGINISWELGNENSTLKKADJFINGSQJGEDYIQJHLK	252
Db	177	RTADJLONHNSNAQJLLDDYCSSKGINISWELGNENSTLKKADJFINGSQJGEDYIQJHLK	236
OY	253	LRSSTFKNAKJLYGPDVOCPRKTKMKLKSFLKACGEYIDSTYMHNYJLNGRTATREDFLN	312
Db	237	LRSSTFKNAKJLYGPDVOCPRKTKMKLKSFLKACGEYIDSTYMHNYJLNGRTATREDFLN	296
OY	313	PDVDJLDFISSVOKVFOVVESTRPGKKVYLDETSAYGGAPJLLSDTFPAAGFMJLMDKJLS	372
Db	297	PDVDJLDFISSVOKVFOVVESTRPGKKVYLDETSAYGGAPJLLSDTFPAAGFMJLMDKJLS	356
OY	373	ARMGJEVVMROVFPFGAGYHLYDEBNPRLPDYMLSLFKJLYCSTKYVLAWSQOSKRKRLR	432
Db	357	ARMGJEVVMROVFPFGAGYHLYDEBNPRLPDYMLSLFKJLYCSTKYVLAWSQOSKRKRLR	416
OY	433	VYLLHCTNTDNRYREGDILYLAJNLJAHVJTYLRLRYPFSSKQYQDKYLLRPLGCHGLSKS	492
Db	417	VYLLHCTNTDNRYREGDILYLAJNLJAHVJTYLRLRYPFSSKQYQDKYLLRPLGCHGLSKS	476
OY	493	VOLNGLJTLKXNDJOTLPPJLMEKPLRPPSSJGLPASFYSFVIRAKVAAJCI	543
Db	477	VOLNGLJTLKXNDJOTLPPJLMEKPLRPPSSJGLPASFYSFVIRAKVAAJCI	527

Search completed: November 20, 2002, 11:36:11
Job time : 40 secs

=> dis his

(FILE 'HOME' ENTERED AT 13:53:38 ON 21 NOV 2002)

FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS' ENTERED AT 13:54:35 ON 21 NOV 2002

L1	406 S PECKER I?/AU OR VLODASKY I?/AU OR FRIEDMAN Y?/AU OR PERETS T?
L2	60 S L1 AND HEPARANASE
L3	12 S L1 AND (HEPARANASE (10N) ANTIBOD?)
L4	9 DUP REM L3 (3 DUPLICATES REMOVED)
L5	79 S (HEPARANASE (10N) ANTIBOD?)
L6	70 S L5 NOT L4
L7	18 S L6 AND PD<19970902
L8	7 DUP REM L7 (11 DUPLICATES REMOVED)

WEST**Create A Case**

Select?	Database	Query	Plural	Op	Thesaurus	Set Name
<input checked="" type="checkbox"/>	USPT	(5968822)[PN]	YES	OR		L1
<input checked="" type="checkbox"/>	USPT,PGPB,JPAB,EPAB,DWPI	(pecker)[in] or (vlodasky)[in] or (friedman)[in] or (perets)[in]	YES	OR		L2
<input checked="" type="checkbox"/>	USPT,PGPB,JPAB,EPAB,DWPI	L2 and heparanase	YES	OR		L3
<input checked="" type="checkbox"/>	USPT,PGPB,JPAB,EPAB,DWPI	antibod\$4and heparanase	YES	OR		L4
<input checked="" type="checkbox"/>	USPT,PGPB,JPAB,EPAB,DWPI	L4 and @ad<19970902	YES	OR		L5
<input checked="" type="checkbox"/>	USPT,PGPB,JPAB,EPAB,DWPI	antibod\$4 near heparanase	YES	OR		L6
<input checked="" type="checkbox"/>	USPT,PGPB,JPAB,EPAB,DWPI	L6 and @ad<19970902	YES	OR		L7

Please enter the case name: **Rules for naming Cases**

- Case names can only contain alphanumeric characters including underscore (_).
- Any other special characters or punctuation characters will be automatically removed prior to saving the case.
- All white space characters will be replaced by an underscore.

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1644axd

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08 "Ask CAS" for self-help around the clock
NEWS	3	Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	4	Apr 09 ZDB will be removed from STN
NEWS	5	Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS	6	Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS	7	Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS	8	Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS	9	Jun 03 New e-mail delivery for search results now available
NEWS	10	Jun 10 MEDLINE Reload
NEWS	11	Jun 10 PCTFULL has been reloaded
NEWS	12	Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS	13	Jul 22 USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS	14	Jul 29 Enhanced polymer searching in REGISTRY
NEWS	15	Jul 30 NETFIRST to be removed from STN
NEWS	16	Aug 08 CANCERLIT reload
NEWS	17	Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	18	Aug 08 NTIS has been reloaded and enhanced
NEWS	19	Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	20	Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS	21	Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS	22	Aug 26 Sequence searching in REGISTRY enhanced
NEWS	23	Sep 03 JAPIO has been reloaded and enhanced
NEWS	24	Sep 16 Experimental properties added to the REGISTRY file
NEWS	25	Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS	26	Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS	27	Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS	28	Oct 21 EVENTLINE has been reloaded
NEWS	29	Oct 24 BEILSTEIN adds new search fields
NEWS	30	Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	31	Oct 25 MEDLINE SDI run of October 8, 2002
NEWS	32	Nov 18 DKILIT has been renamed APOLLIT
NEWS EXPRESS		October 14 CURRENT WINDOWS VERSION IS V6.01, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:53:38 ON 21 NOV 2002

=> file medline caplus embase biosis		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'MEDLINE' ENTERED AT 13:54:35 ON 21 NOV 2002

FILE 'CAPLUS' ENTERED AT 13:54:35 ON 21 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 13:54:35 ON 21 NOV 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 13:54:35 ON 21 NOV 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

=> s pecker I?/au or vlodasky I?/au or friedman Y?/au or Perets T?/au
L1 406 PECKER I?/AU OR VLODASKY I?/AU OR FRIEDMAN Y?/AU OR PERETS T?/AU

=> s l1 and heparanase
L2 60 L1 AND HEPARANASE

=> s l1 and (heparanase (10N) antibod?)
MISSING OPERATOR 'EPARANASE (10N'
The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l1 and (heparanase (10N) antibod?)
MISSING OPERATOR 'EPARANASE (10N'
The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l1 and (heparanase (10N) antibod?)
MISSING OPERATOR 'EPARANASE (10N'
The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s (heparanase (10N) antibod?)
MISSING OPERATOR 'EPARANASE (10N'
The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s (heparanase (10N) antibod?)
MISSING OPERATOR 'EPARANASE (10N'
The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l1 and (heparanase (10N) antibod?)
L3 12 L1 AND (HEPARANASE (10N) ANTIBOD?)

=> dup rem l3

PROCESSING COMPLETED FOR L3
L4 9 DUP REM L3 (3 DUPLICATES REMOVED)

=> dis l4 1-9 ibib abs

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:429402 CAPLUS

DOCUMENT NUMBER: 137:5014

TITLE: Monoclonal anti-**heparanase**
antibodies for treating conditions related to
heparan sulfate proteoglycan-associated growth factor,
chemokine, cytokine or degradative enzyme
INVENTOR(S): Peretz, Tuvia; Miron, Daphna; Shlomi, Yinon;
Pecker, Iris; Ayal-HersHKovitz, Maty;
Vlodavsky, Isreal; Friedmann, Yael

PATENT ASSIGNEE(S): Israel

SOURCE: U.S. Pat. Appl. Publ., 11 pp., Cont.-in-part of U.S.
Ser. No. 71,618, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 15

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002068061	A1	20020606	US 1998-186200	19981104
US 5968822	A	19991019	US 1997-922170	19970902
WO 2000025817	A1	20000511	WO 1999-US25451	19991028
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1126878	A1	20010829	EP 1999-956781	19991028
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
AU 751170	B2	20020808	AU 2000-13314	19991028
NO 2001002190	A	20010612	NO 2001-2190	20010503
PRIORITY APPLN. INFO.:			US 1997-922170	A2 19970902
			US 1998-71618	B2 19980501
			US 1998-186200	A 19981104
			WO 1999-US25451	W 19991028

AB Monoclonal **antibodies**, neutralizing **antibodies**, humanized **antibodies** specific to **heparanase** protein or an immunogenic portion thereof are disclosed. These **antibodies** are useful for inhibiting **heparanase** activity and for treating conditions assocd. with altered function of a HSPG-assocd. biol. effector mol., e.g. growth factor, chemokine, cytokine, or degradative enzyme. The condition is angiogenesis, cell proliferation, tumor cell proliferation, invasion of circulating tumor cell, metastasis, inflammatory disorders and autoimmune diseases.

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:131509 CAPLUS

DOCUMENT NUMBER: 136:195300

TITLE: Genetically modified cells and methods for expressing recombinant human heparanase and methods of its purification

INVENTOR(S): Ayal-HersHKovitz, Maty; Moskowitz, Haim; Miron,

Daphna; Gilboa, Ayelet; Mimon, Madelene; Ben-Artzi,
 Hanna; Yacoby-Zeevi, Oron; **Pecker, Iris**;
 Peleg, Yoav; Schlomi, Yinon
 PATENT ASSIGNEE(S): Insight Strategy & Marketing Ltd., Israel
 SOURCE: U.S., 66 pp., Cont.-in-part of U.S. Ser. No. 71,618,
 abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 15
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6348344	B1	20020219	US 1999-260038	19990302
US 5968822	A	19991019	US 1997-922170	19970902
US 6177545	B1	20010123	US 1998-71739	19980501
CA 2329142	AA	19991111	CA 1999-2329142	19990429
WO 9957244	A1	19991111	WO 1999-US9256	19990429
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG AU 9937705 A1 19991123 AU 1999-37705 19990429 EP 1076689 A1 20010221 EP 1999-920135 19990429 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI JP 2002513560 T2 20020514 JP 2000-547200 19990429 US 6475763 B1 20021105 US 2000-487716 20000119 US 6426209 B1 20020730 US 2000-635923 20000810 NO 2000005100 A 20001228 NO 2000-5100 20001010 PRIORITY APPLN. INFO.: US 1997-922170 A2 19970902 US 1998-71618 B2 19980501 US 1998-71739 A2 19980501 US 1999-260038 A 19990302 WO 1999-US9256 W 19990429 US 2000-487716 A1 20000119 AB Bacterial, yeast, and animal cells and methods for overexpressing recombinant heparanase in cellular systems, methods of purifying recombinant heparanase therefrom and modified heparanase species which serve as precursors for generating highly active heparanase by proteolysis are provided. Thus, cloning of human heparanase cDNA into baculovirus-infected High 5 and Sf21 cells yielded 0.44 and 0.16 mg enzyme/mL, resp. Enzyme purifn. is achieved by cation-exchange chromatog. on Source-S or affinity chromatog. with anti-native heparanase antibodies . Highly active partially proteolytically cleaved forms of heparanase were identified. This led to the construction of recombinant heparanase contg. (1) an enterokinase cleavage site (Ser-Gln-Val-Asn-Gln) leading to cleavage between residues 119 and 120, or (2) a cathepsin L cleavage site leading to cleavage between residues 157 and 158. REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2001:12473 CAPLUS DOCUMENT NUMBER: 134:96257 TITLE: Protein and cDNA sequences of a novel human heparanase gene hnhp1 and its splicing variants				

INVENTOR(S) : **Pecker, Iris**; Michal, Israel; Itzhaki, Hanan
 PATENT ASSIGNEE(S) : Insight Strategy & Marketing Ltd., Israel
 SOURCE : PCT Int. Appl., 67 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000643	A2	20010104	WO 2000-IL358	20000619
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG EP 1212341 A1 20020612 EP 2000-937164 20000619 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL NO 2001005526 A 20011218 NO 2001-5526 20011112 PRIORITY APPLN. INFO.: US 1999-140801P P 19990625 WO 2000-IL358 W 20000619				

AB The invention provides protein and cDNA sequences of a novel human heparanase gene *hnhp1* and two variants resulted from alternative splicing. The longest clone is 2060 nucleotide long and it contains an open reading frame of 1776 nucleotides, which encodes a polypeptide of 592 amino acids, with a calcd. mol. wt. of 66.5 kDa. The two shorter forms contain an in frame deletion as a result of alternative splicing, one is 162 nucleotides (nt473-634) corresponding to amino acids 150-203, and one is 336 nucleotides (nt473-808) corresponding to amino acids 150-261. The *hnhp1* gene is mapped to chromosome 10, next to the marker SHGC-57721. The tissue distribution of *hnhp1* transcripts is detd. The invention also relates to constructing *hnhp1* gene expression vector to produce recombinant proteins in mammalian cells, which may have **heparanase** or other glycosyl hydrolase activity, its **antibodies**, and antisense oligonucleotide and ribozymes for gene modulation and therapeutic use.

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:57239 CAPLUS
 DOCUMENT NUMBER: 134:128217
 TITLE: Heparanase specific molecular probes and their use in research and medical applications
 INVENTOR(S) : **Pecker, Iris**; Vlodavsky, Israel;
Friedman, Yael; Perets, Tuvia
 PATENT ASSIGNEE(S) : Insight Strategy & Marketing Ltd., Israel
 SOURCE : U.S., 41 pp., Cont.-in-part of U.S. 5,968,822.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 15
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6177545	B1	20010123	US 1998-71739	19980501
US 5968822	A	19991019	US 1997-922170	19970902

US 6348344	B1	20020219	US 1999-260038	19990302
WO 9957153	A1	19991111	WO 1999-US9255	19990429

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9938706	A1	19991123	AU 1999-38706	19990429
EP 1073682	A1	20010207	EP 1999-921513	19990429

R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, IE, FI

JP 2002512533	T2	20020423	JP 1999-555528	19990429
US 2002114801	A1	20020822	US 1999-322977	19990601
NO 9906229	A	20000224	NO 1999-6229	19991215
US 6475763	B1	20021105	US 2000-487716	20000119
US 6426209	B1	20020730	US 2000-635923	20000810
US 2002004585	A1	20020110	US 2001-759207	20010116
US 2002102619	A1	20020801	US 2001-944602	20010904

PRIORITY APPLN. INFO.: US 1997-922170 A2 19970902
US 1998-71618 B2 19980501
US 1998-71739 A2 19980501
US 1999-260038 A1 19990302
WO 1999-US9255 W 19990429
US 1999-322977 A1 19990601
US 2000-487716 A1 20000119
US 2001-759207 A1 20010116

AB A variety of heparanase specific mol. probes which can be used for research and medical applications including diagnosis and therapy. Specific applications include the use of a heparanase specific mol. probe for detection of the presence, absence or level of heparanase expression; the use of a heparanase specific mol. probe for therapy of a condition assocd. with expression of heparanase; the use of a heparanase specific mol. probe for quantification of heparanase in a body fluid; the use of a heparanase specific mol. probe for targeted drug delivery; and the use of a heparanase specific mol. probe as a therapeutic agent.

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:314574 CAPLUS

DOCUMENT NUMBER: 132:333392

TITLE: **Heparanase activity neutralizing anti-heparanase monoclonal antibody**

INVENTOR(S): Peretz, Tuvia; Miron, Daphna; Shlomi, Yinon; **Pecker, Iris**; Ayal-HersHKovitz, Maty; **Friedman, Yael**; Vlodavsky, Israel

PATENT ASSIGNEE(S): Insight Strategy & Marketing Ltd., Israel; Hadasit Medical Research Services & Development Ltd.; Friedman, Mark M.

SOURCE: PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 15

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000025817	A1	20000511	WO 1999-US25451	19991028

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,

JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
 MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
 TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 2002068061 A1 20020606 US 1998-186200 19981104
 EP 1126878 A1 20010829 EP 1999-956781 19991028
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 AU 751170 B2 20020808 AU 2000-13314 19991028
 NO 2001002190 A 20010612 NO 2001-2190 20010503
 PRIORITY APPLN. INFO.: US 1998-186200 A 19981104
 US 1997-922170 A2 19970902
 US 1998-71618 B2 19980501
 WO 1999-US25451 W 19991028

AB A monoclonal **antibody** elicited by a **heparanase** protein
 or an immunogenic portion thereof, the monoclonal **antibody**
 specifically inhibits **heparanase** activity. The
heparanase-specific monoclonal **antibody** may be human or
 humanized **antibody** and is useful for treating conditions assocd.
 with altered function of a heparan sulfate proteoglycan-assocd. biol.
 effector mol. such as growth factor, chemokine, cytokine and degradative
 enzyme. The condition is selected from the group consisting of
 angiogenesis, cell proliferation, tumor, metastasis, inflammatory
 disorders and autoimmune conditions.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:53938 CAPLUS

DOCUMENT NUMBER: 132:102821

TITLE: Method of screening for potential anti-metastatic and
 anti-inflammatory agents using mammalian heparanase as
 a probe

INVENTOR(S): Ben-Artzi, Hanna; Ayal-Hershkovitz, Maty; Vlodavsky,
 Israel; **Pecker, Iris**; Peleg, Yoav; Miron,
 Daphna

PATENT ASSIGNEE(S): Insight Strategy & Marketing Ltd., Israel; Hadasit
 Medical Research Services & Development Ltd.;
 Friedman, Mark M.

SOURCE: PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 15

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000003036	A1	20000120	WO 1999-US15643	19990712
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,			
	DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,			
	JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,			
	MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,			
	TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,			
	MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,			
	ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,			
	CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6190875	B1	20010220	US 1998-113168	19980710
CA 2335382	AA	20000120	CA 1999-2335382	19990712
AU 9948697	A1	20000201	AU 1999-48697	19990712

EP 1097241 A1 20010509 EP 1999-932382 19990712
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
JP 2002520029 T2 20020709 JP 2000-559256 19990712
NO 2001000136 A 20010309 NO 2001-136 20010109
PRIORITY APPLN. INFO.: US 1998-113168 A 19980710
US 1997-922170 A2 19970902
US 1998-109386 B2 19980702
WO 1999-US15643 W 19990712

AB Qual. and quant. methods are provided for testing an agent for its potential at inhibiting glycosidase catalytic activity, the methods including interacting a glycosidase enzyme with a glycosidase substrate in a presence of the agent and qual. or quant. evaluating an effect of the agent on the catalytic activity of the glycosidase enzyme toward the glycosidase substrate. Preferably the glycosidase enzyme is a heparanase enzyme and the glycosidase substrate is, resp., a heparanase substrate.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 9 MEDLINE DUPLICATE 1

ACCESSION NUMBER: 2001009022 MEDLINE

DOCUMENT NUMBER: 20476203 PubMed ID: 11021821

TITLE: Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis.

AUTHOR: Friedmann Y; Vlodavsky I; Aingorn H; Aviv A; Peretz T; Pecker I; Pappo O

CORPORATE SOURCE: Departments of Oncology and Pathology, Hadassah-Hebrew University Hospital, Jerusalem, and InSight Ltd., Rabin Science Park, Rehovot, Israel.

SOURCE: AMERICAN JOURNAL OF PATHOLOGY, (2000 Oct) 157 (4) 1167-75. Journal code: 0370502. ISSN: 0002-9440.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals

ENTRY MONTH: 200010

ENTRY DATE: Entered STN: 20010322
Last Updated on STN: 20010322
Entered Medline: 20001025

AB The human heparanase gene, an endo-beta-glucuronidase that cleaves heparan sulfate at specific intrachain sites, has recently been cloned and shown to function in tumor progression and metastatic spread. Antisense digoxigenin-labeled **heparanase** RNA probe and monoclonal anti-human **heparanase antibodies** were used to examine the expression of the **heparanase** gene and protein in normal, dysplastic, and neoplastic human colonic mucosa. To our knowledge, this is the first systematic study of heparanase expression in human colon cancer. Both the heparanase gene and protein were expressed at early stages of neoplasia, already at the stage of adenoma, but were practically not detected in the adjacent normal-looking colon epithelium. Gradually increasing expression of heparanase was evident as the cells progressed from severe dysplasia through well-differentiated to poorly differentiated colon carcinoma. Deeply invading colon carcinoma cells showed the highest levels of the heparanase mRNA and protein associated with expression of both the gene and enzyme by adjacent desmoplastic stromal fibroblasts. A high expression was also found in colon carcinoma metastases to lung, liver, and lymph nodes, as well as in the accompanying stromal fibroblasts. Moreover, extracts derived from tumor tissue expressed much higher levels of the heparanase protein and activity as compared to the normal colon tissue. In all specimens, the heparanase gene and protein exhibited the same pattern of expression. These results suggest a role of heparanase in colon cancer progression and may have both prognostic and therapeutic applications.

L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:723147 CAPLUS
DOCUMENT NUMBER: 131:332967
TITLE: Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same
INVENTOR(S): Ben-Artzi, Hanna; Ayal-HersHKovitz, Maty; Yacoby-Zeevi, Oron; **Pecker, Iris**; Peleg, Yoav; Shlomi, Yinon
PATENT ASSIGNEE(S): Insight Strategy & Marketing Ltd., Israel; Friedman, Mark, M.
SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 15
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9957244	A1	19991111	WO 1999-US9256	19990429
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6348344	B1	20020219	US 1999-260038	19990302
CA 2329142	AA	19991111	CA 1999-2329142	19990429
AU 9937705	A1	19991123	AU 1999-37705	19990429
EP 1076689	A1	20010221	EP 1999-920135	19990429
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2002513560	T2	20020514	JP 2000-547200	19990429
NO 2000005100	A	20001228	NO 2000-5100	20001010

PRIORITY APPLN. INFO.:

US 1998-71618	A	19980501
US 1999-260038	A	19990302
US 1997-922170	A2	19970902
US 1998-71739	A2	19980501
WO 1999-US9256	W	19990429

AB Bacterial, yeast and animal cells and methods for overexpressing recombinant heparanase in cellular systems, methods of purifying recombinant heparanase therefrom and modified heparanase species which serve as precursors for generating highly active heparanase by proteolysis. Heparanase is a glycosylated enzyme involved in catabolism of certain glycosaminoglycans, in tumor cell invasion and metastasis, and possibly in angiogenesis. It has potential therapeutic applications for viral infection, neurodegenerative diseases, restenosis, and atherosclerosis. A signal peptide was incorporated for effective protein secretion in yeast and bacteria and insect and mammalian cells. Protein secretion is achieved by induction by thrombin and calcium ionophores and immune complexes and antigens and mitogens. This work describes prodn. of heparanase on a biotechnol. scale of at least half a liter growth medium by affinity purifn. This large scale propagation of animal cells is described in a Spinner-basket bioreactor. The heparanase enzyme is activated by digestion with a protease such as cathepsin L or trypsin at appropriate pH. A correctly folded catalytically active heparanase is generated.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:723067 CAPLUS

DOCUMENT NUMBER: 131:350261

TITLE: Heparanase specific molecular probes and their use in research and medical applications

INVENTOR(S): Pecker, Iris; Vlodavsky, Israel;

Friedman, Yael; Perets, Tuvia

PATENT ASSIGNEE(S): Insight Strategy & Marketing Ltd., Israel; Hadasit

Medical Research Services & Development Ltd.;

Friedman, Mark, M.

SOURCE: PCT Int. Appl., 90 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 15

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9957153	A1	19991111	WO 1999-US9255	19990429
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6177545	B1	20010123	US 1998-71739	19980501
AU 9938706	A1	19991123	AU 1999-38706	19990429
EP 1073682	A1	20010207	EP 1999-921513	19990429
R:	AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, IE, FI			
JP 2002512533	T2	20020423	JP 1999-555528	19990429
NO 9906229	A	20000224	NO 1999-6229	19991215

PRIORITY APPLN. INFO.:

US 1998-71739 A 19980501
US 1997-922170 A2 19970902
WO 1999-US9255 W 19990429

AB A variety of heparanase specific mol. probes which can be used for research and medical applications including diagnosis and therapy. Specific applications include the use of a heparanase specific mol. probe for detection of the presence, absence or level of heparanase expression; the use of a heparanase specific mol. probe for therapy of a condition assocd. with expression of heparanase; the use of a heparanase specific mol. probe for quantification of heparanase in a body fluid; the use of a heparanase specific mol. probe for targeted drug delivery; and the use of a heparanase specific mol. probe as a therapeutic agent.

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s (heparanase (10N) antibod?)

L5 79 (HEPARANASE (10N) ANTIBOD?)

=> s l5 not l4

L6 70 L5 NOT L4

=> s l6 and PD<19970902

'19970902' NOT A VALID FIELD CODE

3 FILES SEARCHED...

L7 18 L6 AND PD<19970902

=> dup rem l7

PROCESSING COMPLETED FOR L7

=> dis l8 1-7 ibib abs

L8 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 1
 ACCESSION NUMBER: 1997:763245 CAPLUS
 DOCUMENT NUMBER: 128:47265
 TITLE: Major colocalization of the extracellular-matrix degradative enzymes heparanase and gelatinase in tertiary granules of human neutrophils
 AUTHOR(S): Mollinedo, Faustino; Nakajima, Motowo; Llorens, Ana; Barbosa, Enrique; Callejo, Sagrario; Gajate, Consuelo; Fabra, Angels
 CORPORATE SOURCE: Facultad de Medicina, Laboratory of Signal Transduction and Leucocyte Biology, Instituto de Biologia y Genetica Molecular, Consejo Superior de Investigaciones Cientificas-Universidad de Valladolid, Valladolid, E-47005, Spain
 SOURCE: Biochemical Journal (1997), 327(3), 917-923
 CODEN: BIJOAK; ISSN: 0264-6021
 PUBLISHER: Portland Press Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The expression of cell-surface adhesion proteins and the release of extracellular-matrix degradative enzymes constitute crucial processes for the attachment of neutrophils to the endothelium and for the subsequent extravasation of these cells through the endothelial layer. We have analyzed in resting human neutrophils the subcellular localization of heparanase, a heparan-sulfate-degrading endoglycosidase that can degrade basement-membrane components, thereby facilitating neutrophil passage into the tissue during an inflammatory reaction. By subcellular fractionation of postnuclear supernatants from resting human neutrophils on continuous gradients, we have found that heparanase activity was mainly located in gelatinase-contg. tertiary granules. Using a specific **antibody**, the 96-kDa **heparanase** protein was further located in the gelatinase-rich subcellular fractions. Following immunoblotting and immunopptn. anal. in the distinct subcellular fractions, we also found colocalization of heparanase and Mol (CD11b/CD18), a leukocyte integrin involved in the attachment of neutrophils to the endothelium, in the fractions enriched in gelatinase-contg. tertiary granules. Treatment of human neutrophils with tumor necrosis factor or granulocyte/macrophage colony-stimulating factor induced an increase in the CD11b/CD18 cell-surface expression, as well as the release of both gelatinase (matrix metalloproteinase-9) and heparanase, but not of other granule markers, indicating a major co-localization of gelatinase, heparanase and CD11b/CD18 in the same organelle. Furthermore, confocal laser scanning microscopy using specific **antibodies** against gelatinase and **heparanase** revealed a major co-localization of both enzymes in intracellular cytoplasmic granules. The major localization of heparanase and CD11b/CD18 in the gelatinase-contg. tertiary granule supports the notion that mobilization of this organelle can regulate extravasation on human neutrophils.

L8 ANSWER 2 OF 7 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.DUPLICATE 2
 ACCESSION NUMBER: 97266746 EMBASE
 DOCUMENT NUMBER: 1997266746
 TITLE: Subendothelial retention of lipoprotein (a). Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix.
 AUTHOR: Pillarisetti S.; Paka L.; Obunike J.C.; Berglund L.; Goldberg I.J.
 CORPORATE SOURCE: Dr. S. Pillarisetti, Department of Medicine, Columbia University, College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032, United States.

ps42@columbia.edu
SOURCE: Journal of Clinical Investigation, (1997) 100/4
(867-874).
Refs: 59
ISSN: 0021-9738 CODEN: JCINAO
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 005 General Pathology and Pathological Anatomy
LANGUAGE: English
SUMMARY LANGUAGE: English

AB Vessel wall subendothelial extracellular matrix, a dense mesh formed of collagens, fibronectin, laminin, and proteoglycans, has important roles in lipid and lipoprotein retention and cell adhesion. In atherosclerosis, vessel wall heparan sulfate proteoglycans (HSPG) are decreased and we therefore tested whether selective loss of HSPG affects lipoprotein retention. A matrix synthesized by aortic endothelial cells and a commercially available matrix (Matrigel; Becton Dickinson Inc., Rutherford, NJ) were used. Treatment of matrix with heparinase/heparitinase (1 U/ml each) increased LDL binding by .apprx. 1.5-fold. Binding of lipoprotein (a) [Lp(a)] to both subendothelial matrix and Matrigel.RTM. increased 2-10-fold when the HSPG were removed by heparinase treatment. Incubation of endothelial cells with oxidized LDL (OxLDL) or lysolecithin resulted in decreased matrix proteoglycans and increased Lp(a) retention by matrix. The effect of OxLDL or lysolecithin on endothelial PG was abolished in the presence of HDL. The decrease in matrix HSPG was associated with production of a heparanase-like activity by OxLDL-stimulated endothelial cells. To test whether removal of HSPG exposes fibronectin, a candidate Lp(a) binding protein in the matrix, antifibronectin antibodies were used. The increased Lp(a) binding after HSPG removal was inhibited 60% by antifibronectin antibodies. Similarly, the increased Lp(a) binding to matrix from OxLDL-treated endothelial cells was inhibited by antifibronectin **antibodies**. We hypothesize that atherogenic lipoproteins stimulate endothelial cell production of **heparanase**. This enzyme reduces HSPG which in turn promotes Lp(a) retention.

L8 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 3
ACCESSION NUMBER: 1997:194122 CAPLUS
DOCUMENT NUMBER: 126:262494
TITLE: Human prostate carcinoma cells produce extracellular heparanase
AUTHOR(S): Kosir, Mary Ann; Quinn, Christiane C. V.; Zukowski, Kim L.; Grignon, David J.; Ledbetter, Steven
CORPORATE SOURCE: VA Medical Center, Surgical Service, Detroit, MI, 48201, USA
SOURCE: Journal of Surgical Research (1997), 67(1), 98-105
CODEN: JSGRA2; ISSN: 0022-4804
PUBLISHER: Academic
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The degrdn. of heparan sulfate proteoglycan (HSPG) in basement membranes (BM) has been previously suggested to be accomplished by an endoglycosidase activity called heparanase which has not been isolated outside of platelets. HSPG degrdn. by heparanase has been assocd. with tumor cell invasion, angiogenesis, and growth factor function. In this study, we identify heparanase activity biochem. and immunol. in malignant human prostate carcinoma cells (PC-3M), linking platelet heparanase probes with the tumor heparanase activity obsd. Concd. conditioned medium from PC-3M cells was analyzed by a heparin-Sepharose affinity column. Three peaks eluted with 0.15, 0.35, and 0.5 M NaCl. Each peak was analyzed by incubation with 3H-labeled heparin as well as [3H]HSPG from EHS tumor BM. The 0.5 M peak material degraded [3H]-heparin by 17.2%, with little addnl. degrdn. by the other peaks in comparison to the conditioned medium from

which they were obtained. Likewise, the same amt. of the 0.5 M peak accounted for the majority of degrdn. (30.8%) of 3H-labeled HSPG. Interestingly, for the same amt. of 0.5 M peak material, significantly more HSPG was degraded than heparin under the same conditions. In addn., carrageenan-.lambda., an inhibitor of glycanase, completely inhibited the degrdn. of heparin and heparan sulfate proteoglycan by the 0.5 M peak. Using **antibody** to the N-terminus domain of platelet **heparanase**, a 60-kDa protein was identified by immunoblot in 0.5 M peak material. Addnl., immunohistochem. staining of human prostate carcinoma specimens showed granular staining at or near the cell membrane and near the luminal surface using **antibody** to the N-terminus and C-terminus domains of platelet **heparanase**. In summary, human prostate carcinoma cells show heparanase activity in conditioned medium that degrades heparin and BM HSPG and is detected by **antibody** to platelet **heparanase**. In addn., the membrane-assocd. staining in tissue sections of prostate cancer strongly correlates with the biochem. and immunol. detection in conditioned medium of human PC-3M cells.

L8 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 4
 ACCESSION NUMBER: 1994:627556 CAPLUS
 DOCUMENT NUMBER: 121:227556
 TITLE: immunoselection of GRP94/endoplasmin from a KNRK cell-specific .lambda.gt11 library using **antibodies** directed against a putative **heparanase** amino-terminal peptide
 AUTHOR(S): De Vouge, Michael W.; Yamazaki, Amy; Bennett, Steffany A.L.; Chen, Jia Hua; Shwed, Philip S.; Couture, Chantal; Birnboim, H. Chaim
 CORPORATE SOURCE: Ottawa Reg. Cancer Cent., Ottawa, ON, K1H 8L6, Can.
 SOURCE: International Journal of Cancer (1994), 56(2), 286-94
 CODEN: IJCNAW; ISSN: 0020-7136
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Induction of an invasive phenotype by metastatic tumor cells results in part from inappropriate expression of extracellular matrix-degrading enzymes normally involved in embryonic morphogenesis, tissue remodelling, angiogenesis and wound healing. Such enzymes include endoglycosidases that degrade heparan sulfate (HS) in endothelial basement membrane, as well as better characterized proteases. Heparanase, an endo-.beta.-D-glucuronidase initially detected in B16 melanoma cells, has been described as a Mr 96,000 glycoprotein with pI of 5.2, and has been immunolocalized to the cell surface and cytoplasm. We have utilized a polyacrylamide-gel-based HS degrdn. assay to demonstrate that KNRK, a rat kidney fibroblast cell line transformed by v-K-ras, exhibits HS-degrading activity similar to that of B16F10 mouse melanoma cells. To immunoselect heparanase-expressing clones from a KNRK-cell-specific .lambda.gt11 cDNA library, we have also prepd. a rabbit anti-serum directed against a putative amino-terminal peptide of B16F10 cellular heparanase. Lysogens from one clone expressed a .beta.-galactosidase fusion protein whose staining with peptide anti-serum was inhibited by competition with excess peptide. Dideoxy-mediated sequencing of the insert termini of this recombinant revealed that it represents a rat homolog of Mr 94,000 glucose-regulated protein (GRP94/endoplasmin), a mol. chaperone that contains the exact amino-terminal sequence previously attributed to heparanase. Our results call into question the specificity of this peptide sequence, as well as previous immunolocalization studies of heparanase carried out using such anti-sera.

L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1992:190176 CAPLUS
 DOCUMENT NUMBER: 116:190176
 TITLE: **Antibodies**, kits, and methods for

immunochemical localization of **heparanase** in mouse and human melanomas, and characterization of melanoma heparanase

INVENTOR(S): Nicolson, Garth L.; Nakajima, Motowo; Jin, Li
 PATENT ASSIGNEE(S): University of Texas System, USA
 SOURCE: PCT Int. Appl., 82 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9119197	A1	19911212	WO 1991-US3832	19910530 <--
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
AU 9182317	A1	19911231	AU 1991-82317	19910530 <--
AU 641269	B2	19930916		
EP 532695	A1	19930324	EP 1991-913555	19910530 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05509403	T2	19931222	JP 1991-512410	19910530 <--
PRIORITY APPLN. INFO.:			US 1990-530869	19900531
			WO 1991-US3832	19910530

AB **Antibodies** to a glycosaminoglycan endoglycosidase (esp. **heparanase**), as well as kits and methods employing the **antibodies**, are disclosed. **Antibodies** against an N-terminal **heparanase** peptide are produced. These antibodies are used for the detection of heparan sulfate endoglycosidase in human and murine tumors. Purifn. of melanoma heparanase is described. A hemocyanin-coupled **heparanase**-derived peptide was used as an immunogen for **antibody** prodn. Also described is prepn. and reactivity of various substrates (e.g. desulfated or desulfated and acetylated heparan sulfate) with melanoma heparanase. The anti-**heparanase antibodies** of the invention stained metastatic melanoma cells, but did not stain surrounding tissue.

L8 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 5

ACCESSION NUMBER: 1990:529983 CAPLUS

DOCUMENT NUMBER: 113:129983

TITLE: Immunochemical localization of heparanase in mouse and human melanomas

AUTHOR(S): Jin, Li; Nakajima, Motowo; Nicolson, Garth L.

CORPORATE SOURCE: M. D. Anderson Cancer Cent., Univ. Texas, Houston, TX, 77030, USA

SOURCE: International Journal of Cancer (1990), 45(6), 1088-95
 CODEN: IJCNAW; ISSN: 0020-7136

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Heparanase, an endo-.beta.-D-glucuronidase, has been assocd. with melanoma metastasis. Polyclonal **antibodies** directed against the murine N-terminal **heparanase** peptide detected a Mr .apprx.97,000 protein on SDS-PAGE of mouse melanoma and human melanoma cell lysates. In an indirect immunocytochem. study, human A375-SM and mouse B16-BL6 melanoma cells were stained with the anti-**heparanase antibodies**. Heparanase antigen was localized in the cytoplasm of permeabilized melanoma cells as well as at the cell surface of unpermeabilized cells. Immunohistochem. staining of frozen sections from syngeneic mouse lungs contg. micrometastases of B16-BL6 melanoma demonstrated heparanase localized in metastatic melanoma cells. Similar studies using frozen sections of malignant melanomas resected from patients indicated that heparanase is localized in invading melanoma cells. These studies suggest that (a) the N-terminus of the heparanase

mol. in mouse and human is antigenically related; (b) heparanase antigens are localized at the cell surface and in the cytoplasm of metastatic human and mouse melanoma cells; and (c) heparanase antigens are enriched in invasive and metastatic murine and human melanomas in vivo.

L8 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 6
ACCESSION NUMBER: 1987:117981 CAPLUS
DOCUMENT NUMBER: 106:117981
TITLE: Soluble antigen induces T lymphocytes to secrete an endoglycosidase that degrades the heparan sulfate moiety of subendothelial extracellular matrix
AUTHOR(S): Fridman, Rafael; Lider, Ofer; Naparstek, Yaakov; Fuks, Zvi; Vlodavsky, Israel; Cohen, Irun R.
CORPORATE SOURCE: Dep. Radiat., Hadassah Univ. Hosp., Jerusalem, 91120, Israel
SOURCE: Journal of Cellular Physiology (1987), 130(1), 85-92
CODEN: JCELLX; ISSN: 0021-9541
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The antigen-mediated induction of heparanase, an endoglycosidase capable of degrading heparan sulfate from the subendothelial extracellular matrix (ECM), was investigated in a rat T lymphocyte cell line reactive against the basic protein (BP) of myelin. It was found that nonactivated T lymphocytes could be induced to express heparanase activity following exposure to sol. but not to ECM-bound BP. The induction of heparanase was immunolog. specific and independent of the presence of syngeneic or allogeneic antigen-presenting cells (APC). However, anti-IA **antibodies** inhibited **heparanase** expression. Sol. BP induced secretion of heparanase into the culture medium within minutes, despite inhibition of protein synthesis. Cell lysates of T lymphocytes contained heparanase activity. Thus, T lymphocytes secrete a preformed heparanase following exposure to specific antigen.

=> dis his

(FILE 'HOME' ENTERED AT 13:53:38 ON 21 NOV 2002)

FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS' ENTERED AT 13:54:35 ON 21 NOV 2002

L1 406 S PECKER I?/AU OR VLODASKY I?/AU OR FRIEDMAN Y?/AU OR PERETS T?
L2 60 S L1 AND HEPARANASE
L3 12 S L1 AND (HEPARANASE (10N) ANTIBOD?)
L4 9 DUP REM L3 (3 DUPLICATES REMOVED)
L5 79 S (HEPARANASE (10N) ANTIBOD?)
L6 70 S L5 NOT L4
L7 18 S L6 AND PD<19970902
L8 7 DUP REM L7 (11 DUPLICATES REMOVED)